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Abstract 
Traditionally, medicine has been conducted using a diagnostic procedure followed by 
an appropriate therapy and monitored were possible. On the whole, these steps have 
happened independently of each other. In recent years however many have started 
to question this independent approach and have asked whether technologies that 
seek to combine diagnostics and therapies would be more beneficial at treating 
diseases. This new medical discipline has been termed theranostics. The aim of this 
project was to design and synthesise a novel theranostic nanoparticle, using a micelle 
forming amphiphilic carbohydrate, with the overall hypothesis of determining whether 
using a nanomedicine that can simultaneously image and treat would improve the 
effectiveness of a cancer treatment. 
Super paramagnetic iron oxide nanoparticles (IONPs) have gained considerable 
attention as an MRI contrast agent due to their unique magnetic properties and 
relatively inoffensive toxicity profile. Before IONPs may be used in a biological 
environment they must overcome several challenges, including being stable to 
aggregation and organ targeting. In this project a modified chitosan amphiphilic 
polymer was used to successfully formulate IONPs into colloidal stable aqueous 
dispersions using two different methods which produced blackberry nanoparticles 
and raspberry nanoparticles. The raspberry nanoparticles were extensively 
characterised in vitro and in vivo and were found to be highly effective as an MRI 
imaging probe for the liver and spleen. Following this, they were tested for their cancer 
imaging properties in an in vivo mouse tumour model. The drug loading capacity of 
the raspberry nanoparticles was investigated using lomustine, paclitaxel and 
methotrexate, however no effective drug encapsulation was determined in this 
project. Overall, a highly effective MRI probe was engineered and characterised, 
although its future success will be determined by its activity towards a disease target.   
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NaCl    sodium chloride 
NaI    sodium iodide  
NaOH    sodium hydroxide 
nm    nanometre 
NMP    N-Methyl-2-pyrrolidone    
ns    nanoseconds  
OC    degrees Celsius  
Oe    oersted    
PBMA    Poly(isobutylene-alt-maleic anhydride) 
PBS    phosphate buffer saline 
PCL    poly(capro-lactone) 
PdI    polydispersity index 
PEG    poly(ethylene glycol) 
PEO    poly(ethylene oxide)  
PFP    perfluoropentane 
PGC    palmitoylated glycol chitosan 
pH    molar concentration of hydrogen ions 
ppm    parts per million 
PPO    poly(propylene oxide) 
PTX    paclitaxel 
PVA    polyvinyl acetate 
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r1    longitudinal relaxivity  
r2    transverse relaxivity 
rcf    relative centrifugal force    
RF    radio frequency  
s    seconds 
s.d.    standard deviation 
SDS    sodium dodecyl sulfate 
SQUID    super quantum interference device  
T    tesla or temperature  
T1    longitudinal relaxation time 
t1/2    half-life 
T2    transverse relaxation time 
Tc    Curie temperature 
TCL    thermally cross-linked 
TE    echo time 
TEM    transmission electron microscopy 
TI    inversion time 
TPES    D-α-tocopheryl polyethylene glycol 1000 succinate 
TP-LENK   leucine-enkephalin 
TR    repetition time 
UV/Vis    ultra violet/visible spectroscopy  
v/v    volume/volume 
XRD    x-ray diffraction 
δ    delta or solubility parameter 
ΔE    change in energy 
ΔG    change in Gibbs free energy  
ΔH    change in enthalpy  
ΔS    change in entropy 
λ    wavelength 
χ    Flory-Huggins parameter 
ћ     Planck unit   
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1.1 Thesis Motivations   
The aim of this project was to design and create a theranostic nanoparticle to test the 
hypothesis that using a nanomedicine that can simultaneously be imaged and used 
as a therapy will improve the effectiveness of a cancer treatment. Nanotechnology is 
a rapidly advancing discipline and it is now possible to create structures with more 
than one application and function. These kinds of multi-functional nanoparticles look 
particularly interesting in the field of medicine. Traditionally, medicine has been 
conducted using a diagnostic procedure to assess a pathological condition, followed 
by an appropriate therapy and then monitored where possible. On the whole, these 
steps are applied independently of each other. In recent years however, many have 
started to question this independent approach and have asked whether technologies 
that seek to combine diagnosis and therapy would be more beneficial at treating 
diseases.1 This has become an increasingly interesting area and treatments that 
combine both diagnostics and therapies have been termed theranostics.2 
Theranostics is a relatively new area of science with some remarkable applications. 
A typical example of this can be explained as follows; a patient visits their doctor and 
after a consultation and a diagnostic procedure a tumour is detected. Their oncologist 
may make a decision to treat them with an appropriate drug based on general 
information about patients calculated from population averages (i.e. this 
chemotherapeutic drug has had an effect in 25% of cases). If the medication does 
not work after a period of time, the medication may be switched.3 Of course treating 
a patient in this way is not desirable as it leads to a loss of time, adverse side effects, 
increased costs of treatment and patient dissatisfaction. In many circumstances, the 
reason why it has not worked is because not all diseases are the same and not all 
patients are the same. In fact, in recent years a rather complex picture has emerged 
where genetic variation in diseases and patients significantly contributes to the 
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response of a drug.4 In light of this, it would seem that the future of medicine could 
rely heavily on the effective diagnosis of patients and diseases during every stage of 
their treatment. Creating treatments that fuse diagnostics and therapeutics together 
is at the centre of this new movement towards the personalisation of medicine.    
There are many strategies for combining diagnostics and therapies, however two 
have gained considerable popularity; companion diagnostics and nanotheranostics. 
Companion diagnostics is the term given to a diagnostic procedure that when 
performed can predict whether a person will benefit from a particular treatment.5,6 This 
type of technology has become more prevalent with the development of more specific 
drugs. The first commercial companion diagnostic was the HercepTestTM, an 
immunohistochemical assay that could predict whether a cancer would be responsive 
to the chemotherapeutic HerceptinTM.7 Since its release in 1998, HerceptinTM has 
become a gold standard therapeutic as it is highly active against cancers that 
overexpress the HER2 receptor. It is widely believed however, that because only 15-
20% of breast cancers over express the HER2 receptor, without the HercepTestTM 
the development of HerceptinTM may well have been discontinued in early clinical 
trials for lack of efficacy in large populations.7,8 Designing medical treatments by 
carefully diagnosing the specific biology of a disease and then providing an 
appropriate treatment specific to the patients’ needs has led to a new approach in 
healthcare that has been termed personalised medicines.9 With the advances in 
biomedical technology the personalization of medicine is set to radically alter the 
landscape of healthcare over the coming years.  
More recently, theranostics has come to encompass a branch of nanotechnology 
whereby nanoparticles are developed to simultaneously provide imaging and 
therapeutic effects.10 These types of structures have been termed nanotheranostics.11 
Combining therapeutic and diagnostic elements into a single nanoparticle allows for 
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disease visualisation, treatment and real time monitoring of treatment progress. The 
issue can be illustrated as follows; when a patient presents them-selves with a 
disease they will be given a therapeutic based on general information about patients 
calculated from population averages. As explained previously, patients and diseases 
can be highly variable and there is a chance that the given medicine will have no 
effect. Usually a patient will have to wait until the end of a treatment to determine 
whether the medicine has been successful and this can lead to a loss of time, adverse 
side effects and patient dissatisfaction. By combining the therapeutic with an imaging 
agent, it can quickly be determined if the administered drug is reaching the diseased 
site by performing a simple diagnostic procedure. This extra information will improve 
the overall efficiency of disease treatment. It can be misleading to group both the 
companion diagnostic and the nanotheranostic strategies together under the single 
term “theranostics”, as they are both unique approaches each with their own 
individual advantages. However both strategies are united by their desire to combine 
the disciplines of diagnosis and therapy to improve the overall healthcare of a patient.  
This project will focus on nanotheranostics as their clinical relevance has generally 
been less explored compared to its companion diagnostic counterpart. The 
hypothesis is that using a theranostic nanoparticle will improve the treatment of a 
disease compared to the separate use of its individual components (diagnostic and 
therapeutic). A scientific investigation into this prediction can be conducted by at first, 
designing and synthesising a suitable theranostic nanoparticle and then by evaluating 
its potential using in vitro and in vivo models. This project will aim to synthesise a 
theranostic nanoparticle by harnessing the MRI potential of superparamagnetic iron 
oxide nanoparticles and combining them with a therapeutic drug. The overall 
nanostructure will be held together within a micelle forming amphiphilic carbohydrate 
based polymer. The overall aim will be a biologically suitable MRI agent with cytotoxic 
effects against tumours.  
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1.2 Iron Oxide Nanoparticles as Magnetic 
Resonance Imaging Contrast agents    
 
1.2.1 Magnetic resonance imaging  
Magnetic resonance imaging (MRI) is a powerful imaging technique used to produce 
detailed anatomical images of organs and tissues within the body.12 MRI specifically 
allows for the three-dimensional mapping of the hydrogen nuclei (or protons) in any 
given sample. As water is comprised of one oxygen nuclei coupled to two hydrogen 
nuclei it is responsible for the majority of an MRI signal. As the density and distribution 
of water molecules differs within each tissue type, MRI allows for the in vivo imaging 
of tissues and organs within a patient. The powerful imaging capability of MRI has led 
this technique to become common practice in modern hospitals. Strong super 
conducting magnets between 1.5 – 3.0 Tesla (T) are used to generate the strong 
magnetic fields needed for this particular technique.13 MRI has the ability to provide 
anatomical information in any part of the body where there is difference in water 
concentration. Significantly, the concentration of water can change with disease or 
injury and this has led MRI to become commonly used in medical diagnostics. A 
number of other diagnostic techniques are available, these are summarised in Table 
1.2.1.1.14 Compared to its counterparts MRI is a technique with good spatial 
resolution and excellent tissue penetration. Another advantage is that MRI is the only 
deep tissue imaging technique that uses non-ionising radiation. Positron emission 
tomography (PET) usually uses radio isotopes that decay and release 511-keV 
positrons which have enough energy to damage biological structures. Low doses 
usually mean PET is relatively safe for patients, however technicians in nuclear 
medicine facilities can often receive more harmful levels of positron exposure.15,16 
Recently, a long term clinical study by Matthews et al has found that the radiation 
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used in a diagnostic X-Ray/CT procedure is likely to slightly increase the patient’s risk 
of getting cancer in the future.17 As MRI is considered the safest of the in vivo deep 
tissue imaging techniques it is often preferred in general situations.      
 
1.2.2 The fundamentals of MRI 
The MRI signal arises from the interaction of a proton with an external magnetic field. 
The phenomenon is founded in the quantum mechanical principle that sub-atomic 
particles possess spin.12 Each spinning proton is associated with a magnetic dipole 
moment. In many atoms the spins of the protons are paired, annulling their effect and 
ultimately giving no overall dipole moment. Commonly known atoms include 12C and 
16O. Other atoms, including hydrogen nuclei (1H), do contain unpaired spinning 
protons and as a result they possess an overall dipole moment resulting in some 
impressive magnetic characteristics that can be exploited by MRI. In the absence of 
a magnetic field these dipole moments are randomly orientated. However when 
placed in the presence of an external magnetic field (B0) the majority of these protons 
will seek to align their dipoles in the direction of B0. The ratio of protons that align their 
dipoles with B0 is governed by the Boltzmann distribution. A radiofrequency (RF) 
Table 1.2.1.1. A comparison of various imaging modalities.  
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pulse can then be applied to the sample, in turn exciting some protons into a new 
dipole orientation, offset from that of B0. As the spinning protons relax back to their 
natural thermal equilibrium, determined by T1 and T2 relaxation, they produce a 
change in the magnetic field that can be measured by a receiver coil. The change in 
magnetism induced from a single proton relaxing back from one spin orientation to 
another is exceedingly small but fortuitously for medical science there are a large 
number of protons in biological samples (6.6 x1019 per mL of water) which overall give 
enough of an effect to be measured.18 This process is illustrated in 1.2.2.1.     
 
 
Figure 1.2.2.1. The physics of MRI. Principally all hydrogen nuclei or protons 
have an associated dipole moment; denoted by blue arrows in the schematic. (a); 
In the absence of a magnetic field the protons have randomly orientated magnetic 
dipole moments. (b); In the presence of an external magnetic field (B0), the 
protons will seek to align their dipole moments with B0, overall this creates a net 
magnetization in the direction of B0. (c); A radio frequency (RF) pulse can be used 
to knock the proton’s dipole moments out of alignment with B0. (d); The spinning 
nuclei relax back to their original alignment and in doing so produce a change in 
voltage in the receiver coil that can be measured. 
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Understanding the mechanism of how the protons relax back to thermal equilibrium 
is an important principle of MRI. In 1946 Felix Bloch attempted to describe the origin 
of an MRI signal.19 His mathematical interpretations are commonly known as the 
Bloch equations and they have provided the standard model for understanding the 
nature of an MRI signal to this day. The assumption is made that any proton in a 
sample can be represented by a single vector (m) precessing around the direction of 
an external magnetic field.20 The rate of precession is determined by the Larmor 
frequency. Since m is a vector in space it can be resolved into 3 components mx, my 
and mz. mx and my are known as the transverse components and mz is known as the 
longitudinal component. Using a radiofrequency pulse the dipole moment of the 
proton can be knocked out of alignment with the external magnetic field (B0). The 
proton will then seek to re-establish its alignment with B0 and will do so by precessing 
around the longitudinal axis at the Larmor frequency as shown in Figure 1.2.2.2.c. 
This type of relaxation mechanism creates a change in net magnetism in both the 
transverse and longitudinal components. Understanding these mechanisms is 
important as MRI can make measurements in either component which can ultimately 
give very different effects. 
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When the net magnetisation of relaxing protons is measured relative to the 
longitudinal axis it is termed T1 relaxation or longitudinal relaxation or spin-lattice 
relaxation. At equilibrium there is an overall net magnetisation in the longitudinal 
component as the majority of the dipoles are aligned with the magnetic field. After a 
RF pulse, the dipoles are flipped, overall reducing the net magnetization in the 
longitudinal component. As the dipoles of the protons relax back to their thermal 
equilibrium over a period of time the net magnetisation in the longitudinal component 
Figure 1.2.2.2. A mathematical interpretation of spinning nuclei in a magnetic 
field; (a), a representation of the 3-dimensional space of a proton: The z-axis is 
the longitudinal axis (green) and is always in the direction of the magnetic field 
(B0). The x and y plane is the transverse plane (yellow) and is always 
perpendicular to B0; (b), the proton is represented as a vector (m); (c), the 
relaxation pathway of a protons’ dipole moment over a period of time (t1-t6) 
following a 90O-radiofrequency pulse. 
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increases until it is restored.21 The restoration of the net magnetisation can be 
modelled as a simple exponential with T1 as the first order rate constant (Mz = M0(1-
e-t/T1)).22 This process usually takes several seconds and is illustrated in Figure 
1.2.2.3. The energy associated with T1 relaxation is lost into the surrounding 
environment which has led to the common synonym spin-lattice relaxation.  
 
 
When the net magnetisation of relaxing protons is measured in the transverse plane 
it is termed T2 relaxation or transverse relaxation or spin-spin relaxation. At 
equilibrium the precession of the protons is random overall creating no net 
magnetisation in the transverse plane. After a RF pulse, the dipole moments of the 
protons are flipped into the transverse plane. This results in the net magnetisation 
that was in longitudinal axis now being transferred into the transverse plane. As the 
protons precess at the Larmor frequency small magnetic inhomogeneities cause the 
Figure 1.2.2.3. The origin of T1 relaxation; (a), hydrogen nuclei relaxing back to 
the equilibrium following a 180O radiofrequency pulse over several seconds; (b), 
the net magnetisation (green) plotted as a function of time in the longitudinal axis.   
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protons to precess at slightly different rates “de-phase”, in turn reducing the net 
magnetisation in the transverse plane.21 This can be modelled as a simple 
exponential decay with T2 as the first order rate constant (Mx,y = M0.e-t/T2)).23 T2 
relaxation is usually much faster than T1 relaxation and usually takes 10s of 
milliseconds and is illustrated in Figure 1.2.2.4. Magnetic inconsistences in the 
surrounding environment can change the T1 and T2 relaxations and overall give rise 
to contrast in an MR image and lead to the differentiation between different types of 
tissues and organs.   
 
 
 
 
Figure 1.2.2.4. The origin of T2 relaxation; (a), hydrogen nuclei relaxing back to 
the equilibrium following a radiofrequency pulse over several milliseconds; (b), 
the net magnetisation (yellow) plotted as a function of time in the transverse axis.   
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1.2.3  Contrast agents 
MRI can distinguish between tissue types as different tissue types contain different 
amounts of water. This said however, it can often be difficult to distinguish between 
healthy and unhealthy sites in the same tissue.24 Contrast agents work by significantly 
changing the T1 and T2 relaxation times of the hydrogen nuclei in their vicinity, thus 
altering the MRI signal and allowing the protons to be differentiated more clearly in 
an MRI image. Currently, the majority of clinically available contrast agents affect the 
T1 signal and are called positive contrast agents due to the distinctive image 
brightening of the tissue in their vicinity (hyperintense contrast). These positive 
contrast agents are predominately made up of gadolinium chelates and the chemical 
structures of the commercially available products are shown in Figure 1.2.3.1.25 
Gadolinium (Gd3+) is used owed to its high abundance of unpaired electrons in the 4f 
electron orbital and slow electron relaxation rate giving it greater magnetic properties 
compared to other atoms. For T1 relaxation to occur the gadolinium ion must exhibit 
field fluctuations near to the Larmor frequency which is achieved by the gadolinium 
ion rotating, colliding, bonding and diffusing with the surrounding environment in a 
phenomenon known as Brownian motion.26 As a water molecule approaches and co-
ordinately binds to a fluctuating gadolinium ion it can undergo a magnetic interaction 
that gives rise to inner sphere relaxation. Gadolinium ions can also magnetically 
interact with water molecules via a dipole-dipole interaction and this is known as outer 
sphere relaxation. As the interaction and the physical movement of a gadolinium ion 
has such an effect on relaxation, scientists have found that they can control T1 
relaxivity effects by using various chelates that differ in size, molecular weight, 
hydrophobicity, number of hydrogen bonding donors/acceptors and co-ordination 
number.27 Also, the distribution of the gadolinium species within the body can 
somewhat be controlled by the nature of the chelating agent used. The main 
complication with using gadolinium is that it is extremely toxic in its free form and so 
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these products are characteristically based around a gadolinium ion complexed to 
strong chelators.28 By shielding the gadolinium from the biological environment its 
toxicity can be reduced. Nevertheless, these complexes are entropically unfavourable 
and strong thermodynamic driving forces are able to pull these complexes apart 
releasing free gadolinium into the body.29 In recent years there has been an 
association made between free gadolinium and the debilitating disease nephrogenic 
systemic fibrosis.30 The disease was first recognised in 1997 in patients with impaired 
renal function and typically causes hardening of the connective tissue throughout the 
body. Although gadolinium based contrast agents do raise safety concerns, for many, 
the risks are worth taking. Gadolinium based contrast agents are also limited by their 
non-specificity to a target, quick removal by renal elimination and a short window for 
contrast enhancement.31 It is for these reasons that new MRI contrast agents need to 
be developed. 
 
 
Figure 1.2.3.1. The chemical structure of the commercially available T1 
gadolinium chelate contrast agents.   
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The next class of contrast agents are the super paramagnetic iron oxide nanoparticle 
(IONP) contrast agents.32 The magnetic properties of IONPs enable it to affect T1 and 
T2 relaxation times on the surrounding protons. IONP research is predominately 
focused on their effect at decreasing the T2 relaxation times of protons. When the 
IONPs are placed in a magnetic field they become magnetised. These magnetic 
nanoparticles induce pockets of magnetic disruption into the system known as in-field 
inhomogeneities.33 The inhomogeneities in the field cause the precession of the 
protons to de-phase at a much faster rate, in turn decreasing T2 relaxation time. 
IONPs can also act as a T1 contrast agent as the iron ions themselves have several 
Figure 1.2.3.2. The origin of T1 contrast; (a), schematic illustration of a 
gadolinium contrast agent interacting with water molecules to induce T1 
relaxation; (b), an example of the effect a T1 contrast agent has on the 
magnetisation over time. The T1 relaxation time is decreased providing contrast 
to protons in the vicinity of the contrast agent.  
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unpaired electrons (5 and 4 unpaired electrons for Fe3+ and Fe2+, respectively) making 
them paramagnetic in nature. This gives the IONP’s surface bound iron ions the ability 
to induce inner and outer sphere relaxation, albeit to a lesser extent that gadolinium.34 
The type and extent of contrast is predominantly determined by the size of the IONP.35 
Larger IONPs have larger magnetic fields and therefore, introduce larger 
inhomogeneities into the system. This increases T2 relaxation and makes T2 contrast 
the more dominant effect over T1 contrast. Smaller IONPs have smaller magnetic 
fields and therefore introduce less inhomogeneities into the system, additionally in 
relation to size, water molecules are able to diffuse between smaller IONPs at a much 
faster rate. Overall, both effects create a system that experiences less 
inhomogeneities. This reduces the T2 contrast effect for smaller IONPs, in some 
cases it is reduced to such an extent it makes T1 contrast the dominant effect. 
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Figure 1.2.3.3. The origin of T2 contrast; (a), water molecules in the presence on 
an external magnetic field; (b), IONPs introducing local magnetic field 
inhomogeneities; (c), example of the effect a T2 contrast agent has on the 
magnetisation over time. The T2 relaxation time is decreased providing contrast 
to protons in the vicinity of the contrast agent.  
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Commercially available products have primarily focused on using IONPs as a T2 
contrast agent.36 IONP contrast agents are characteristically called negative contrast 
agents due to the distinctive image darkening of the tissue in their vicinity 
(hypointense contrast). These agents work by accumulating in healthy tissue and 
darkening its MRI signal enabling easier detection of the damaged or diseased tissue. 
There have been 6 licensed commercially available IONP products in the market 
Figure 1.2.3.4. The effects of IONP size on contrast capability; (a), increase in IONP 
size increases the overall magnetization of the magnetic nanoparticle; (b), Smaller 
IONPs have smaller magnetic fields and therefore introduce less inhomogeneities 
into the system, also, in relation to size, water molecules are able to diffuse between 
smaller IONPs at a much faster rate. Overall, creating a system that experiences 
less inhomogeneities. (c), Larger IONPs have larger magnetic fields and therefore 
introduce larger inhomogeneities into the system.  
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including; Feridex IV® (a.k.a. EndoremTM), Resovist®, Sinerem® (a.k.a. Combidex®), 
Ferumoxytol®, Lumirem® (a.k.a. GastroMARK®) and Abdoscan®.37 All the products 
have a core made from IONP crystals, however each are formulated with their own 
unique polymers and have varying hydrodynamic sizes, therefore yielding products 
with distinctive in vivo pharmacokinetic characteristics. The majority of these 
compounds (Feridex IV®, Resovist® and Sineren®) were all primarily used to provide 
contrast in large organs of the lymphatic system (liver, spleen, lymph nodes, bone 
marrow). Prior to the time of writing this thesis, 3 of the products have been 
discontinued; Feridex IV® in 2009, Sinerem® in 2007 and Abdoscan® in 2000.38 
Resovist® is only available in Japan and the USA. Ferumoxytol® is licensed for use 
as an anaemia medication only, however it has been reported that this formulation is 
used off-label as an MRI contrast agent.39 Lumirem® is still currently licenced for 
providing contrast in the GI tract following oral administration. A table summarising 
the current status of contrast agents can be found in Table 1.2.3.1. Generally, the 
intravenously administered lymphatic IONP contrast products have now been 
discontinued. After a number of years in clinical use, companies ceased production 
of their IONP contrast agents largely attributing their withdrawal to the lack of demand 
in the market. The discontinuation of lymphatic IONP contrast agents was due to a 
number of factors: Firstly, a major reason for their withdrawal was highlighted in a 
pinnacle study on Sinerem®, reported by the EMA.40 The EMA found that using 
Sinerem® gave no significant benefits in sensitivity and failed to confirm non-inferiority 
with regards to specificity. Overall clinicians were finding that these products were not 
sensitive or specific enough to consistently and reliably detect cancer as often as they 
should. Secondly, it is reported that clinicians and radiographers were finding that 
they could use gadolinium agents and other imaging techniques to provide better 
detection of liver lesions when compared to IONPs.41 Lastly, a minor consideration 
was that although findings from many studies conclude that IONP contrast agents 
have an agreeable safety profile, individual case studies reveal that patients did not 
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relish large volumes of black liquid being intravenously administered which inevitably 
led to patient dissatisfaction.42 Essentially, these points combined, largely left IONPs 
without a market. Their manufacture was no longer economically viable and so their 
production was discontinued. Although the clinical utility of the first generation of 
IONP contrast agents was not demonstrated, IONPs do have remarkable magnetic 
properties and low toxicities, leading many to still believe that the material has a 
promising future in medicine. The key to using IONPs as a contrast agent will largely 
revolve around engineering particles that are specific in function and nature and that 
have a greater contrasting ability. 
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Table 1.2.3.1. Current status of commercially available contrast agents.  
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1.2.4 Superparamagnetic iron oxide nanoparticles  
Nanoparticles offer a great platform from which to build a biological device. They have 
controllable sizes ranging from a few nanometres to many hundreds of nanometres. 
As a result, they have comparable sizes to proteins, viruses, enzymes and other 
biological nanostructures.18 The iron oxide family is probably the most popular family 
of nanoparticles to emerge in recent years. Out of the 16 types of iron oxide, 
Magnetite (Fe3O4) holds perhaps the most promising potential in biomedicine.43 In its 
bulk form magnetite is somewhat uninteresting, but when its particle size is reduced 
to only a few nanometres it takes on some rather remarkable magnetic 
characteristics. These magnetic properties allow iron oxide nanoparticles (IONPs) to 
be used for MRI contrast imaging, hyperthermia treatment and magnetic targeting.18 
In addition to this, they are widely regarded as non-toxic and have already been 
approved by the FDA and EMA for use in MRI contrast applications and anaemia 
treatment.44,45 
Magnetite’s magnetic properties may be explained by looking into the material’s 
structure. Magnetite has a cubic spinel structure with a general formula that can be 
written as (Fe3+)tet(Fe3+Fe2+)octO4. A single unit cell consists of oxygen atoms found in 
a ‘face centred cubic’ arrangement.46 This arrangement creates interstitial octahedral 
sites (2/3) and interstitial tetrahedral sites (1/3).47 Half of the Fe3+ ions occupy the 
tetrahedral sites, while the Fe2+ ions and the remaining half of the Fe3+ ions occupy 
the octahedral sites.48,49 The nuclei spins of the Fe3+ ions in the octahedral sites are 
aligned antiparallel to the Fe3+ ions in the tetrahedral sites, therefore contributing no 
effect to the overall net magnetisation, however, the nuclear spins of the Fe2+ ions are 
aligned parallel to the electron spins of the Fe3+ ions found in the tetrahedral sites 
thus, giving magnetite an overall net magnetic dipole.49 This overall structure gives 
magnetite ferrimagnetic properties. 
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IONPs are interesting because of their unique magnetic properties. All compounds 
may be divided into 5 distinctive groups of magnetic materials largely governed by 
their atomic structure and arrangement:50 1. Diamagnetism is a phenomenon 
exhibited by all materials that possess paired electrons and is typically characterised 
by the material being slightly repelled by an external magnetic field. Diamagnetism is 
a weak force and is only observed if the material has no other competing magnetic 
properties; 2. Paramagnetism is a phenomenon exhibited by an atomic or molecular 
species that possess unpaired electrons and this gives the material an overall dipole 
moment. Paramagnetic materials are usually characterised by their slight positive 
magnetisation in the presence of an external magnetic field. The next three 
classifications of materials are observed when atoms are arranged in ordered 
structures termed crystal lattices: 3. Ferromagnetism arises when paramagnetic 
nuclei in ordered structures undergo long-range ordering and arrange their spins in a 
single direction giving the material an overall net magnetisation. Ferromagnetic 
materials are highly magnetic; 4. Antiferromagnetism is exhibited when paramagnetic 
Figure 1.2.4.1. The structure of IONPs; (a), Macro image of magnetite iron oxide 
nanoparticles (IONPs); (b), A schematic representation of the crystal structure of 
magnetite.49 
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nuclei in ordered structures are arranged in equal and opposite directions cancelling 
out any contributions from their magnetic dipoles. A perfect antiferromagnetic material 
should have no overall net magnetisation, however small lattice defects usually result 
in these materials being weakly magnetic and often exhibit small paramagnetic or 
ferrimagnetic behaviour; 5. Ferrimagnetism is found when paramagnetic nuclei in 
ordered materials are arranged in opposite directions where the nuclei are not equal 
in dipole moment. This usually is observed for more complex crystal structures and 
results in a strong overall net magnetisation. The characterisation of all materials is 
usually determined by how they react in the presence on an external magnetic field. 
Measuring the magnetism of a material while cycling between positive and negative 
external magnetic fields usually results in a plot that is unique to each magnetic 
classification. These plots are termed M-H curves or hysteresis loops and are 
summarised in Figure 1.2.4.2.18     
 
 
47 
 
 
 
 
Magnetite is a ferrimagnetic material. To reduce the internal energy in the bulk 
material, magnetite establishes small regions of uniform magnetisation termed 
domains which are often 10s of nanometres in diameter.51 When the size of a 
magnetite particle falls below a threshold value it enters a single-domain state as it is 
Figure 1.2.4.2. The origin of magnetism; (a), A schematic representation of the 
nuclei spin ordering that gives rise to the main types of magnetic material. Typical 
M-H curves for; (b), diamagnetic materials; (c), paramagnetic materials; (d), ferro-
/ferri- magnetic materials and; (e), superparamagnetic materials.     
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too small to set up multiple domains. This critical limit varies depending on source but 
is usually considered to be below 20 nm for magnetite.52 When a particle of magnetite 
is reduced to below this critical value it behaves rather differently and is said to be 
Superparamagnetic. Superparamagnetic materials become magnetized in the 
presence of an external magnetic field however, unlike ferromagnetic and 
ferrimagnetic materials, superparamagnetic materials do not retain any magnetisation 
when the external magnetic field is removed. Superparamagnetic materials give 
distinct sigmoidal M-H curves, an example is given in Figure 1.2.4.2.e. The overall 
bulk properties resemble that of paramagnetic materials, the key differences being 
that they are highly ordered at the molecular level and usually have much greater 
magnetic moments. Gadolinium,53 nickel54 and cobalt55 have also been used to make 
magnetic nanoparticles due to their paramagnetic atomic nuclei, however their use in 
medicine is somewhat limited due to their associated toxicities in humans. Iron oxide 
on the other hand is generally considered safe and non-toxic which therefore makes 
it an extremely promising nano-material for biomedical applications. 
1.2.5 Engineering superparamagnetic iron oxide nanoparticles for biomedical 
applications 
IONPs hold a high level of interest in the scientific community, as a result a 
considerable amount of attention has been devoted to the development of this 
material. Many methods for IONP synthesis exist each with their own unique 
advantages and shortcomings:  
Chemical co-precipitation is by far the most popular way of synthesising IONPs. This 
method is a well-studied technique, relatively straight forward and can be performed 
at minimal cost.56 The method is based on the precipitation of IONPs from Fe3+ and 
Fe2+ salts via the addition of a base.57 The overall reaction may be written as: Fe2+ + 
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2Fe3+ + 8OH- → Fe3O4 + 4H2O.56 Although chemical co-precipitation is a widely used 
method it does have shortcomings. Firstly, nanoparticles made using chemical co-
precipitation are extremely sensitive to their reaction conditions including; ionic 
strength, pH of the reaction, presence of oxygen, injection rates, presence of salts 
and counter ions, temperature and concentration of the alkali agent. This often leads 
to relatively polydisperse samples. A polydisperse sample could lead to batch to batch 
variation in stability, magnetism and biodistribution. Secondly, IONPs made via 
chemical co-precipitation tend to form large polydisperse aggregates which lead to 
sedimentation. Finally, naked magnetite nanoparticles made using chemical co-
precipitation readily oxidise into a less magnetic form called maghemite, often with a 
loss of magnetisation, however this can be reduced by keeping the IONPs in an inert 
environment.58  
High temperature thermal decomposition is a method that has considerably increased 
in popularity in recent years. This non-aqueous method utilises organometallic 
compounds, high boiling point organic solvents and long chained fatty acids to yield 
IONPs with highly controllable sizes and narrow size distributions.59 The main 
drawback with these IONPs is that they are hydrophobic and can only be dispersed 
in organic solvents, therefore they are unsuitable for biological applications without 
further modification.  
Hydrothermal synthesis is a process whereby IONPs are produced in aqueous 
conditions at high temperature and pressure using autoclaves and microwave 
reactors.60 This technique can also be performed using organic solvents where it is 
referred to as solvothermal synthesis. Both strategies are known to produce IONPs 
with high crystallinity and recent publications have reported the synthesis of particles 
with varying shapes and morphologies including; rods, rings, and hollow 
nanoparticles.61   
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Sol-gel synthesis is a technique widely used to produce metal oxides and is 
commonly employed for the development of ceramics.62 The ‘sol’ is a colloidal 
suspension of precursor reagents. In IONP synthesis this usually involves iron 
alkoxides or iron salts (chlorides, nitrates and acetates). The ‘gel’ is formed by the 
addition of gelators, catalysts and reagents. These additives form a gel like reaction 
mixture creating an integrated network between the precursors and gelators. This 
network plays a key role in influencing the type of structures formed and can be 
heavily influenced by temperature, pH, concentration of reagents, salts and 
solvents.24 Heat treatment or high vacuum conditions are then used to remove the 
solvent yielding the final crystal product.  
Sonochemical synthesis is a method that produces IONPs in the presence of high 
energy sounds waves (>20 mHz), a process more commonly known as sonication.63 
The negative and positive pressures of these high energy waves generate 
microbubbles. These microbubbles are thermodynamically unstable and as a result 
implode in a phenomenon known as cavitation.64 The imploding nanoparticle releases 
energy into the environment as heat. This localised heating or ‘hot spot’ can be used 
to facilitate processes where large amounts of energy are needed in small volumes.65 
This technique is frequently used in; chemical reactions, homogenation, mixing, 
cleaning and drug encapsulation. Sonochemical synthesis has been used to produce 
naked and functionalised IONPs. The energies involved in sonication are usually 
large enough to force species together that have a high activation energy for mixing. 
The major drawback is that the high energies used can often damage delicate 
molecules and biologics. This however, can be reduced by using cooling systems 
such as an ice bath.  
Microbial synthesis is a remarkable process that exploits biological organisms to 
synthesise near perfect IONPs.66 Thermoanaerobacter ethanolicus and Shewanella 
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loihica are two strains of bacteria that have been shown to reproducibly produce 
IONPs under anaerobic conditions. The main drawback with microbial synthesis was 
the small scale of IONP production, however recently Moon et al, have been seeking 
to address this issue by using large scale fermentation processes.67  
The most widely used IONP synthesis methods have been discussed, however many 
more methods exist including; polyol synthesis, microwave synthesis, electron beam 
lithography, gas-phase deposition, flow reactors, electrochemical synthesis, nano-
reactors and supercritical fluid synthesis. In depth reviews of each of these synthesis 
processes may be found in recent publications by Reddy et al and Wu et al.68,69 
Considerable effort has been placed into synthesising IONPs, however the methods 
discussed rarely make IONPs that are suitable for biomedical applications. Due to 
their small size, bare or naked IONPs have large surface energies and to reduce this 
effect IONPs have a tendency to agglomerate.58 These aggregates are often several 
microns in size which sediment under their own gravitational mass. In this aggregated 
state IONPs are largely unsuitable for biomedical applications.58 IONPs synthesised 
using organic solvents are usually functionalised with long chained fatty acids making 
these particles extremely hydrophobic and again not suitable for biomedical 
applications.70  
Traditionally, polymers have been used to overcome many of the challenges faced 
with the delivery of IONPs.24 Polymers provide stabilisation via two key mechanisms; 
firstly, steric stabilisation which is founded in the quantum mechanical principle that 
clouds of electrons cannot occupy the same space (Pauli’s exclusion principle).71 The 
resulting effect is that large bulky molecules tend to repel each other and act as a 
barrier against agglomeration; secondly, electrostatic stabilisation which originates 
from the electronic repulsion experienced by two species of the same charge.72 As a 
result, introducing highly charged polymers onto the surface of nanoparticles 
52 
 
promotes colloidal stabilisation. Polymers may promote colloidal stabilisation by a 
single or combined effect (Figure 1.2.5.1). Many hundreds of polymers have been 
used to stabilise IONPs, though the most common include; polyethylene glycol (PEG), 
polyvinyl acetate (PVA), dextran (and its derivative carboxymethyl dextran) and 
chitosan, with dextran being the most widely used in the first generation of IONP 
contrast agents (Figure 1.2.5.2). Additional, the nature of polymer not only provides 
stabilisation but also determines properties such as size, morphology, charge and 
has a large impact on the resulting pharmacokinetic profile.     
 
 
 
 
Figure 1.2.5.1. Steric stabilisation and electrostatic stabilisation. 
   
Figure 1.2.5.2. Structure of common IONP stabilising polymers: (a), 
polyethylene glycol (PEG); (b), polyvinyl acetate (PVA); (c), chitosan and (d), 
dextran    
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Research has shown, that as an IONP enters the body it is exposed to a rich 
environment of proteins that bind to the material and label it as “foreign”, a process 
known as opsonisation.73 The tagged material is then taken up by phagocytic cells 
(macrophages and monocytes) where they are processed and broken down.74 This 
process makes it very difficult to engineer long circulating nanoparticles for medical 
treatment. The key advantage of using IONPs is due to their favourable toxicity profile 
in humans, however iron is also a valuable mineral vital for healthy human function.74 
As a result, the body is extremely good at scavenging IONPs and recycling them to 
obtain the valuable iron mineral where it is stored in ferritin to later be used in the 
production of haemoglobin in red blood cell synthesis.74,75 The body has an efficient 
and effective clearance system for IONPs making engineering long surviving IONPs 
very difficult. The blood half-life of these compounds varies considerably depending 
on the nature of the nanoparticle species, however one key aspect that scientists can 
easily control is the selection of polymer.76 A common example is given by the stealth 
polymer polyethylene glycol (PEG). A PEGylated IONP was created under the trade 
name Clariscan®. It has widely been reported that Clariscan® has an increased blood 
half-life compared to its dextran counterparts, however it did not reach the clinic and 
was discontinued in the late development stages.32 It should also be considered, that 
it may not be appropriate for a diagnostic nanoparticle to have too long a circulation 
time. Ideally, a diagnostic agent should be cleared from the body as soon as the 
imaging procedure is performed, although this may not be true for a theranostic 
nanoparticle. Another major factor that is believed to play a role in the 
pharmacokinetics and biodistribution of IONPs is the effect of hydrodynamic size. 
Classically, clinical IONP contrast agents which had a mean hydrodynamic diameter 
<50 nm where categorised as ultra-small superparamagnetic iron oxide contrast 
agents (such as Clariscan® and Combidex®).77 The general size trend is that larger 
IONPs have shorter blood half-lives as they are more quickly taken up by the 
macrophage rich organs whereas, the ultra-small IONPs have longer circulation times 
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and better tissue penetration. The importance of size is debated, but what is generally 
accepted is that nanoparticles larger than 200 nm are usually filtered out by the liver 
and spleen, whereas particles smaller than 6 nm are usually quickly excreted 
renally.78 Of course, these values are not absolute and do vary depending on the 
nature of the nanoparticle. Overall, it seems that quite a complex picture is emerging 
where IONP synthesis technique and the polymer stabiliser all have a crucial impact 
on the resulting contrast agent.  
  
55 
 
1.3 Polymer Micelles as Delivery Vectors 
for Biomedical Applications     
 
1.3.1 Amphiphilic polymers as drug carriers  
Polymeric micelles have been widely used in industrial processes and commercial 
products over the years. Micelles are formed from the aggregation of amphiphiles and 
provide a particularly useful strategy for the delivery of medicines in biomedical 
applications. An amphiphile is a species that is composed of both a hydrophilic region, 
termed the head group and a hydrophobic region, termed the tail group.79 When an 
amphiphile is placed in an aqueous environment it will seek to minimise the high 
energy interactions between its hydrophobic moieties and the surrounding water 
molecules. Consequently, this causes the amphiphiles to rearrange to form a 
secondary structure which shields the hydrophobic moieties from the surrounding 
aqueous environment.80 Several secondary structures exist and their architecture is 
usually determined by the amphiphile geometry. In 1976, Israelachvili described the 
relationship between the amphiphile and its secondary structure mathematically and 
summarised it using the critical packing parameter (CPP).81    
𝐶𝑃𝑃 =
𝑉
𝑎0.𝑙𝑐
    (1.3.1.1) 
Where: 𝒍𝒄, is the length of hydrocarbon chain. 𝒗, the volume of the hydrocarbon chain 
and 𝒂0, the area of the head group. CPP values allow for the prediction of a secondary 
structure from the geometry of a specific amphiphile: values of approximately 1 give 
planar bilayer secondary structures; a CPP between 0.5-1 forms bilayer vesicles 
commonly known as liposomes, a CPP of 0.3-0.5 produces cylindrical nanofibers and 
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a CPP of less than 0.3 tends to create micelles. An example of these structures can 
be found in Figure 1.3.1.1.82  
 
 
Micelles are typically used as industrial solubilizers and cleaning agents, however 
they have become particular interesting for medical applications.83,84 Overall micelle 
structures are stable in aqueous conditions while still maintaining a hydrophobic core 
making them promising vectors for the delivery of challenging medicines, mostly 
hydrophobic drug molecules.85 The delivery of hydrophobic drugs poses a 
Figure 1.3.1.1. The origin of amphiphilic nanoparticles; (a), chemical structure of 
the common amphiphile sodium dodecyl sulphate highlighting the hydrophobic tail 
group and hydrophilic head group; (b), Geometric structure of an amphiphile 
modelled by Israelachvili’s crystal packing parameter (CPP); (c), table summarising 
the relationship between CPP and aqueous secondary structure.  
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considerable challenge for formulation scientists as they are incredibly hard to deliver 
via traditional solid oral dosage forms or by intravenous injection. In recent years, 
industrial techniques such as high-throughput screening (HTS) have led to the 
development pipeline being dominated by highly hydrophobic new chemical entities.86 
These potential drugs usually have promising in vitro results but are often let down 
by their poor aqueous solubility leading to a poor bioavailability in a patient.87 Micelles 
have gained considerable attention as aqueous vectors for hydrophobic drugs, 
especially for the delivery of poorly soluble anticancer drugs.88 Despite a large focus 
on micelle technology no commercial products are available, yet. However, a number 
of promising potential candidates are in clinical trials and they are summarised in 
Table 1.3.1.1.89   
 
 
At very low concentrations amphiphiles have an affinity for liquid-air or liquid-solid 
interfaces in an attempt to minimise their unfavourable interactions with the water. 
When amphiphile concentrations become large enough, the interfaces become 
saturated and the amphiphiles begin to agglomerate within the aqueous solution to 
form micelles.90 The concentration at which this phenomenon is observed is known 
Table 1.3.1.1. Current status of some promising commercial micelle products. 
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as the critical micelle concentration (CMC).90 The CMC is considered one of the most 
important features of a micelle and is associated with structural stability. The lower 
the CMC value the less polymer is needed to create the micellar structure. Low CMC 
amphiphiles are favoured for biomedical applications as they are less sensitive to 
changes in concentration, this is especially significant in pharmacology where dilution 
with the blood or stomach contents could result in the deaggregation of micelles held 
together by weaker forces, resulting in the premature release and precipitation of the 
drug contents.85 Research has found that large polymeric amphiphiles often have a 
CMC several orders of magnitude lower than their small molecular counterparts. 
These larger polymer amphiphiles can also be composed of more biocompatible 
materials like carbohydrates or PEGylated species. Furthermore, small molecule 
amphiphiles can be associated with toxicities as the amphiphiles can interact with 
biological membranes and disrupt their function.91 Polymeric amphiphiles used for 
formulation and delivery applications are often considered in terms such as 
biocompatible or non-biocompatible. These terms are often derived from the ability of 
a polymer to be able to successfully deliver an agent (therapeutic or diagnostic) 
without inducing significant negative responses (toxic, thrombogenic, immunogenic 
or carcinogenic effects).92 Of course, one must always consider the contextual 
application of a polymeric material, as a single polymer may be applicable in one 
circumstance but may not be suitable in another. For example, a particular polymer 
may have virtually no side effects when used orally but may have significantly larger 
side effects when administered intravenously. Therefore, polymers may only truly be 
regarded as biocompatible with regards to a specific application. This has led to the 
contemporary scientific understanding of biocompatibility to be defined as “the ability 
of a material to perform with an appropriate host response in a specific application”.93  
Various polymer amphiphiles have been reported and they can be categorised into 
groups depending on their chemical structure (Figure 1.3.2).85 These polymers 
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include repeating units of hydrophilic and hydrophobic segments that give rise to their 
amphiphilic characteristics. The orders and proportions of hydrophilic and 
hydrophobic segments can usually be controlled to yield micelles with the appropriate 
thermodynamic properties for stability, drug loading and pharmacokinetic profile.                          
 
 
 
1.3.2 Amphiphile interactions 
There is a large volume of publications describing micelle formation, mostly due to 
the large resources of the detergent industries that sought to understand the 
underlying mechanisms of their amphiphiles in order to maximise efficiency and 
profits. The traditional way of understanding the self-assembly of amphiphiles can be 
described thermodynamically using the Gibbs-Helmholtz equation:  
∆𝐺𝑚 = ∆𝐻𝑚 − 𝑇∆𝑆𝑚    (1.3.2.1) 
Where: ∆𝐺𝑚, is the change in Gibbs free energy for micellisation; ∆𝐻𝑚, the enthalpy 
change for micellisation; T, temperature and ∆𝑆𝑚, the entropy change for 
micellisation. Micellisation is driven by the minimisation of ∆𝐺𝑚. The enthalpy change 
for micellisation is made up of two competing factors: Firstly, upon micellisation there 
Figure 1.3.1.2. Main structural types of micelle forming amphiphile polymers. 
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is a favourable solvent interaction which arises from increased number of hydrogen 
bonding between water molecules. The second, but competing component is that 
large, bulky, often charged head groups have to be bought into close proximity to one 
another during micelle formation and this is an unfavourable interaction. These two 
competing enthalpy contributions largely cancel each other out, making ∆𝐻𝑚 not 
significant in the process of micellisation. As a result, this leaves entropy as the major 
driving factor behind micellisation. At first this may seem surprising as the entropy 
change associated with the aggregation of colloidal stable particles is usually an 
unfavourable process, however it is the entropy change of the solvent that drives the 
micellisation process.79 This favourable change in entropy is associated with the 
hydrophobic effect.81 To solubilise an amphiphile in an aqueous environment water 
molecules must organise them-selves into highly structured arrays that promote 
hydrogen bonding but reduce interaction with the hydrophobic tail group. This 
arrangement forms “lattice like cages” termed iceberg arrays.90 This structuring is 
remarkably effective in stabilising hydrophobic moieties, however are highly 
unfavoured entropically. Micellisation reduces the need for these iceberg arrays, 
freeing water molecules and allowing them to adopt their more favoured disordered 
arrangements, in turn giving a large increase in entropy.94 It is not too much of a jump 
to appreciate that an increase in the size of the hydrophobic tail group would increase 
the iceberg arrays around the amphiphile resulting in a more favourable entropy gain 
upon micellisation. As micelle formation would be more favourable with a larger 
hydrophobic moiety, it would result in less amphiphile needed to undergo micellisation 
or in other words, a reduction in CMC. This effect was first published by Traube in 
1891 and he proposed that small changes in hydrophobic moieties have considerable 
impacts on the activity of an amphiphile.90 It could be imagined that all amphiphile 
chemists would simply just increase the hydrophobic potions of their polymers 
indefinitely to obtain favourable activities. However if the hydrophobic portion 
becomes disproportionally large, it will result in precipitation making the amphiphile 
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largely redundant for aqueous applications. These effects have been extensively 
studied in the detergent industry, where amphiphile chemists attempt to maximise 
hydrophobicity while maintaining adequate stability in aqueous environments. In 
these industries small changes in chemical structure can have large financial 
implications.    
The structural nature of micelles have made them particularly interesting as vectors 
to transport poorly water soluble materials. This has overwhelmingly led to their 
success as detergents, mainly due to their ability of removing poorly soluble materials 
like grease, fats and oils.84 For a number years now, biomedicine has also looked into 
using micelles as delivery vectors for hydrophobic drugs, which also suffer from poor 
solubility in water, usually leading to poor bioavailability.95 For a material to be 
incorporated into the core of a micelle there has to be a favourable interaction. When 
any material is placed into an aqueous solution with an amphiphile it primarily has 
three fates: Firstly, it may have a favourable interaction with the water molecules and 
simply form an aqueous suspension of drug independent of the amphiphile. Secondly, 
it may undergo an unfavourable interaction with the water molecules and a favourable 
interaction with the amphiphile, resulting in micellisation or, lastly, it could have an 
unfavourable interaction with the water molecules and an unfavourable interaction 
with the amphiphile, overall resulting in material precipitation. It can therefore be 
assumed that a key driving force behind drug encapsulated micellisation is the 
favourable interaction between the drug and the amphiphile. Interestingly, this has 
been modelled by the Flory-Huggins theory.85,96 The interaction between a polymer 
and a drug species is given by the Flory-Huggins parameter 𝜒 and is typically 
considered a measure of compatibility between a polymer and a drug species.  
𝜒 =  
(𝛿𝑑𝑟𝑢𝑔−𝛿𝑝𝑜𝑙𝑦𝑚𝑒𝑟)
2
𝑉𝑑𝑟𝑢𝑔
𝑅𝑇
           (1.3.2.2) 
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Where: 𝜒 is the Flory-Huggins parameter; 𝛿𝑑𝑟𝑢𝑔, is the solubility parameter of the 
drug; 𝛿𝑝𝑜𝑙𝑦𝑚𝑒𝑟, is the solubility parameter of the polymer; 𝑉𝑑𝑟𝑢𝑔, is volume of drug, 𝑅, 
is the ideal gas constant and 𝑇, the temperature.  
𝛿𝑑𝑟𝑢𝑔 is the Hilderbrand-Scatchard solubility parameter and is defined by: 
𝛿 =  
√∆𝐸𝑣𝑎𝑝
𝑉
    (1.3.2.3) 
Where: ∆𝐸𝑣𝑎𝑝, is the energy change for evaporation and V, is the volume of solvent. 
Interaction is maximised between the drug and polymer when 𝜒 is minimised. Values 
<0.5 are generally considered favourable and will most likely result in a positive 
amphiphile-drug interaction. Overall this can be summarised in an assumption that 
“like interacts with like”, or in other words drugs that are similar in nature to the 
hydrophobic core of a micelle will probably be easier to load and have higher drug 
encapsulation efficiencies.97 In summary, the main driving force behind micellisation 
is the entropy driven hydrophobic effect, where hydrophobic moieties of an 
amphiphile will seek to minimise interactions with the water molecules and create a 
hydrophobic core, aligning its hydrophilic regions towards the aqueous environment. 
If a species is similar enough in nature to the hydrophobic core, then the micelle may 
act as a delivery vector for that particular species.   
1.3.3 N-palmitoyl,N-monomethyl-N,N-dimethyl-N,N,N-trimethyl-6-O-
glycolchitosan (GCPQ) 
The amphiphilic polymer selected for this project was a chitosan based polymer 
named N-palmitoyl,N-monomethyl-N,N-dimethyl-N,N,N-trimethyl-6-O-glycolchitosan 
(GCPQ).98 Chitosan, α (1-4) 2-amino β-D glucan, is a heterogeneous polymer 
produced by the deacetylation of chitin, of which, is an abundant material produced 
by an array of living organisms making it one of the most abundant natural polymers 
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on the planet.99 This hydrophilic polymer is widely considered to have an inoffensive 
toxicity profile making it particularly interesting for biomedical applications.100 In 
addition to this, chitosan also contains amino and hydroxyl side groups that allow for 
additional functionalization meaning polymer chemists can manipulate the properties 
of this polymer giving chitosan some truly remarkable characteristics.101 As a result, 
chitosan has been used in a number of areas in science including; tissue engineering, 
gene delivery, wound dressing and hydrogel technologies.102 Our group, has used 
chitosan as a platform to synthesise a particularly interesting amphiphile named 
GCPQ, a relatively non-toxic polymer which has been shown to enhance the delivery 
and bioavailability of a number of drug molecules.98 GCPQ consists of a glucosamine 
sugar backbone where, a fraction of the amine groups have been functionalised with 
either a long chained hydrophobic pendant group or a quaternary ammonium cation. 
Functionalisation in this way creates an amphiphilic polymer which exhibits some 
interesting properties.  
 
 
Upon addition to water the polymer self-assembles into nano-sized micelles usually 
between 20-40 nm in diameter as determined by electron microscopy.103 The GCPQ 
micelles are considered suitably stable and have a CMC in the µM range when 
Figure 1.3.3.1. N-palmitoyl,N-monomethyl-N,N-dimethyl-N,N,N-trimethyl-6-O-
glycolchitosan (GCPQ). 
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measured by isothermal calorimetry. The hypothesis behind micelle formation is that 
the long chained hydrophobic pendant groups rearrange to form an inner hydrophobic 
core, whilst the positively charged sugar backbone faces outwards towards the 
aqueous environment shielding the core. The polymer has an IC50 of 1.28 mg/mL 
against the A431 cell line which compares favourably with other cationic polymers 
including; poly-l-lysine (0.007 mg/ml) and poly-l-ornithine (0.004 mg/ml) against the 
same cell line.103 Furthermore, when measured for haemolytic activity, 
polyoxyethylene (20) sorbitan a common amphiphile, gave around 80% haemolysis 
at a concentration of 1 mg/mL, were as GCPQ gave no haemolysis at the same 
concentration and only 20% haemolysis at a concentration of 10 mg/mL.79 
Characteristically, GCPQ micelles appear to have rather favourable properties and 
so they have been employed in a number of drug transport applications. GCPQ has 
been used to encapsulate cyclosporine A, a poorly water soluble cyclic peptide used 
as an immunosuppressant.104 The GCPQ nanoparticle formulation has been shown 
to increase the bioavailability by 3-fold and the CMAX by 5-fold against cyclosporine 
alone in water. In addition to this, GCPQ has also been loaded with leucine-
enkephalin (TP-LENK) a pro-drug used for the treatment of chronic pain.105,106 The 
study showed that the GCPQ micelle did not cross the blood brain barrier but did 
facilitate the delivery of the peptide to the brain, improving the pharmacokinetic 
activity and sustaining its pharmacological effect. It is likely that this is a result of the 
micelle protecting the peptide from plasma degradation and promoting blood brain 
barrier (BBB) adhesion. Furthermore, at a sufficiently large doses the GCPQ-LENK 
nanoparticles could also be delivered via the oral route. A particularly interesting 
result as peptides are often quickly degraded in the gastrointestinal tract. In a study 
by Lalatsa et al, they found that GCPQ did not accumulate in the liver following 
intravenous administration. This is quite a significant result for a polymeric 
nanoparticle, as it may be evidence that GCPQ has a stealth effect allowing it evade 
the immune system. Intravenously administrated IONPs have primarily been used as 
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imaging agents for the lymphatic system and therefore it can be hypothesised that a 
GCPQ micellar IONP may not share the same fate and possibly lead to new 
modalities for imaging and diagnostics. Overall, GCPQ is an interesting amphiphile 
and may provide a good strategy to facilitate IONP and drug delivery.     
1.3.4 Polymer micelles as vectors for iron oxide nanoparticles  
This project will use the amphiphilic polymer GCPQ as the scaffold to engineer the 
proposed nanotheranostic. It is therefore worth reviewing the literature to evaluate 
strategies that have already been attempted in this area. The earliest known IONP 
micelle was published was in 2003 by Euliss et al.107 Aqueous stability was provided 
to hydrophobic IONPs using a peptide based polymer known as polypeptide(EG)-
(asp). No function for these particles was investigated, however it was the first 
evidence to show that IONPs could be encapsulated within micellar architecture.   
Ai et al, used a common micelle forming polymer named poly(capro-lactone)-b-
poly(ethylene glycol) (PCL-PEG).108 In their study they were able to synthesis IONPs 
with a high degree of control and subsequently encapsulated them within their PCL-
PEG micelles. In this study, they found that by increasing the size of the IONP core 
they could increase the T2 contrast of their nanoparticles. Cheng et al went a step 
further and produced a targeted IONP micelle by conjugating folic acid to the end of 
the PCL-PEG polymer, yielding PCL-PEG-Folate.109 They did form an IONP micelle 
and they could accurately control the size of the nanoparticle by altering the molecular 
weight of the PCL polymer. They subsequently tested their particles in an in vivo, 
flank tumour, mouse model and found that their folate targeted micelles did 
accumulate at the site of the tumour to a larger extend than the non-targeted micelles. 
Pӧselt et al used a branched ethylene imine PCL-PEG (PEI-PCL-PEG) to synthesise 
nanoparticles with a high degree of control over micelle size and IONP loading.35 They 
took the opportunity to investigate the relationship between particle size and relaxivity 
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and surprisingly found their results had been predicted by the computer simulations 
of Gillis et al, who attempted to model IONP aggregation and its effects on T2 
relaxation a decade earlier.110 PCL-PEG is widely considered non-toxic, while the 
outer PEG corona can act as a stealth coating, shielding the nanoparticle form the 
immune system and prolonging residence time.111 PCL-PEG is a good micelle forming 
polymer, however alternative polymers and strategies should also be investigated.  
Li et al, created polymeric micelles composed of 2,2,3,4,4,4-hexafluorobutyl 
methacrylate - methoxy poly(ethylene glycol) monomethacrylate (HFMA-g-PEGMA) 
and encapsulated hydrophobic IONPs to yield “magnetomicelles”.112 They employed 
an emulsification method using hexane and probe sonication to formulate their 
structures and then removed the organic solvent using a stream of N2. Cyctoxicity 
studies demonstrated a cell viability of over 90% at a concentration of 250 μg/mL in 
a Hela cell line, suggesting average cytocompatibility. In an in vivo mouse model 
study they found that the majority of their nanoparticles quickly accumulated in the 
liver and spleen significantly reducing their T2 MRI signal.    
Su et al, synthesised a unique “star like” amphiphile by conjugating β-cyclodextrins to 
a branched dextran polymer that had been modified with stearic acid.113 Adding the 
β-cyclodextrins reduced the CMC of their polymers by 10-fold, making them more 
stable for biomedical applications. They then used their star micelles as a platform to 
encapsulate IONPs and then went on to produce a nanotheranostic by incorporating 
doxorubicin into the nanoparticles structure.     
Paquet et al used sodium dodecyl sulfate (SDS) to make their IONP micelles, an 
amphiphile widely found in detergents.114 They could control the size of their IONP 
micelles with high precision and made particles ranging between 40-200 nm. The 
main drawback with these simple amphiphiles is that they may result in toxicity issues 
if used for biomedical applications due to their interaction with biological membranes.  
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Choo et al synthesised an interesting polymer using Poly(isobutylene-alt-maleic 
anhydride) (PBMA) as the main backbone and then decorated it with hydrophobic 
pendant groups made from 1-dodecylamine and fluoresceinamine.115 Upon addition 
to water it formed micelles and the author was successfully able to load these 
structures with IONPs using an emulsification technique. They were able to strictly 
control IONP loading and were able to model the relationship between magnetic 
saturation and relaxivity in simple aqueous environments.  
Lin et el, have recently engineered an IONP loaded within a chitosan polymer.116 
Chitosan is not an amphiphile, however the structures produced do resemble micelle 
like nano-spheres. As chitosan is not an amphiphile, the group had to use the 
crosslinking agent ethylenediaminetetraacetic acid (EDTA) to hold the nanoparticle 
together in aqueous conditions. Crosslinking is often an effective strategy for 
stabilising nanoparticles. However, such cross-linked nanoparticles may become too 
stable and not be efficiently broken down by biological clearance mechanisms. The 
nanoparticles synthesised had a large effect on T2 contrast and did produce a 
contrast effect at a tumour site in an in vivo mouse model.116     
As discussed a variety of IONP micelles have been engineered using a number of 
amphiphiles and strategies and they are summarised in Table 1.3.4.1.117-119 The 
micelle nanoparticles produced have been shown to be relatively magnetic and 
produce good T2 contrast in vitro testing. This said, there is a lack of truly novel 
polymers, with the majority relying on PEG and hydrocarbon chains. This produces 
micellar species that are limited in properties such as surface composition and 
surface charge. These properties are considered important as the nanoparticle will 
interact with its environment using these surface characteristics. Also, it is of the 
author’s opinion that the translation from the bench to in vivo investigation is relatively 
weak and clinical relevance has largely not been explored. Interestingly, none of the 
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particles discussed above have been tested for stability in biologically relevant media. 
This is often a key experiment for amphiphilic systems as charge screening from 
electrolytes, protein adsorption and pH can all have destabilising effects on polymeric 
nanoparticles. It is predicted that the positively charged, carbohydrate based polymer 
GCPQ will generate some novel applications in this area, while also providing a 
platform to further build a nanotheranostic.  
   
 
 
  
Table 1.3.4.1. A summary of published IONP micelles. 
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1.4 Nanotheranostics: Drug Delivery with 
Iron Oxide Nanoparticles      
 
1.4.1 Engineering drug loaded iron oxide nanoparticles    
The hydrophobic core of a micelle is not limited to the encapsulation of a single entity, 
but can incorporate any number of species as long as they are compatible. This 
allows for the design of quite exotic nanoparticle species that could have more than 
one function. Multifunctional nanoparticles which comprise both an imaging element 
and a drug payload are termed nanotheranostics. In recent years, a large number of 
publications have emerged where groups have engineered nanotheranostics using a 
variety of different strategies. The majority of the nanoparticles published have mainly 
been engineered for the treatment of cancer. This is because cancer is not only widely 
considered an important disease target for scientists today, but also because 
nanoparticles have a proven track record in this field. IONPs are widely used when 
engineering nanotheranostic platforms as they have a favourable toxicity profile 
compared to other nanomaterials and they can also be used for several applications 
including localised magnetic heating (hyperthermia) and selective accumulation via 
the use of an external magnetic field (magnetic guidance). Many hundreds of drug 
loaded IONP based nanotheranostics have been developed and a small number of 
the most cited examples can be found in Table 1.4.1.1.120-132  
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Overwhelmingly the majority of the nanotheranostics have been designed around 
incorporating IONPs with doxorubicin. This is most likely due to the fact that 
doxorubicin has already been formulated into a commercially available nanoparticle 
product, Doxil®. Although many nanotheranostics have been synthesised their 
translation into in vivo studies has been relatively low, leading to the biological 
relevance of many of these nanotheranostics remaining unexplored.     
 
 
             
Table 1.4.1.1. A summary of some of the most widely cited IONP and drug 
nanotheranostics. Hundreds more have been published showing the true scale 
and interest in this area.  
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1.4.2 In vivo studies using nanotheranostics   
There have been a small number of recent publications where a nanotheranostic has 
been tested in vivo. These studies are highly valued as they are the first to illustrate 
how these species could be used to treat disease.   
In an impressive study by Maeng et al, they synthesised a new vesicle forming 
polymer composed of poly(ethylene oxide)-trimellitic anhydride chloride-folate (PEO-
TMA-FA) and loaded it with IONPs and doxorubicin.133 Their nanoparticles had an 
average diameter of 88 nm and contained 2.1 mg/mL of doxorubicin. Their dissolution 
results suggested that the rate of doxorubicin release was much larger in acidic 
conditions than in neutral conditions. This could be advantageous as the tumour 
environment is often slightly acidic, therefore the toxic payload would be preferentially 
released at the disease site minimising off target side effects. An MRI studied 
confirmed that the nanoparticle was accumulating in the liver and this led them in 
develop an in vivo liver tumour study using VX2-implanted rabbits. When studied for 
tumour efficiency the nanotheranostic group gave a decreased tumour volume when 
compared to the free doxorubicin control group. This is a good example that shows 
the effectiveness of a dual imaging and therapeutic nanoparticle.  
Wang et al, used a PEGylated dextran to encapsulated IONPs and doxorubicin 
forming structures roughly 116 nm in diameter.128 They tested their nanotheranostic 
in an in vivo tumour model and monitored their distribution via MRI. It was found that 
after 15 min the nanotheranostic had accumulated in the liver and tumour site 
reducing their signal by 84.4% and 42.7%, respectively. As the nanotheranostic did 
accumulate in the tumour tissue they decided to conduct an anti-tumour study. It was 
found that after 21 days the tumour volume in the nanotheranostic group was half that 
of the control group (49%) and impressively when an external magnetic field was 
placed at the site of the tumour its volume was one third that of the control group 
72 
 
(32%). This is strong evidence that by adding a magnetic component to a drug 
species you can markedly increase the efficiency of the treatment.    
Yu et al used their anti-biofouling polymer coated, thermally cross-linked IONPs (TCL-
IONP) to encapsulate doxorubicin.134 Their hypotheses was that their nanoparticle 
could accumulate and treat cancer purely based on size without the need to 
magnetically target. An MRI study conducted on tumour bearing mice showed that 
their nanotheranostic did accumulate at the tumour site over a 4.5 h period. An anti-
tumour efficiency study was conducted and found that the nanotheranostic group 
gave a significant reduction in tumour growth (approximately 63 % relative to the 
control). The health of the animals was monitored by weight, the control group treated 
with doxorubicin alone showed a drop in weight, however the nanotheranostic 
treatment group increased in the same manner as the non-treatment group 
suggesting they may not be suffering from as many off target side effects.  
Chen et al used a temperature responsive poly(ethyleneimine)-modified 
poly(ethylene oxide)−poly(propylene oxide)−poly(ethylene oxide) (PEO−PPO−PEO) 
block copolymer to encapsulate IONPs.135 Using this nanoparticle they were 
successfully able to encapsulate hydrophobic drugs (ibuprofen) and hydrophilic drugs 
(Eosin Y and monosialotetrahexosylganglioside(GM-1)). GM-1 is a drug that can be 
used to treat spinal cord injury. Their hypothesis was that GM-1 is a hydrophilic 
compound and upon injection into the spinal cavity the drug quickly flows away as a 
result of fluid exchange. If GM-1 could be loaded into a nanoparticle it may prolong 
the drugs residence time and improve treatment. This was tested in an in vivo model 
where their GM-1-IONPs were injected into the damaged spinal cords of living 
Sprague−Dawley rats. 4 weeks after treatment the rats were sacrificed and their 
spinal cords were analysed. They found that the group treated with the GM-1-IONPs 
displayed significant spinal cord recovery, whereas the GM-1 control group displayed 
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no significant recovery. Although the MRI experimentation was not conducted in this 
study, one could monitor the drug in the spinal cord cavity using MRI allowing for 
evaluation of GM-1 retention and therefore personalised dosing regimens.  
1.4.3 Hyperthermia treatment and magnetic targeting  
As briefly highlighted earlier in the report, IONPs are not limited to purely being an 
MRI diagnostic probe. The studies described above give clear examples of how a 
nanotheranostic (imaging and drug therapy) can be used to improve the efficiency of 
a cancer treatment and reduced the rate of tumour growth. This said however, in 
many of the examples highlighted, generally there is still a slow increase in tumour 
size throughout the experiment. Some of the most impressive data being published 
in recent years uses all the functions of IONPs to go beyond simply slowing the 
progression of the tumour, but actually causing tumour remission. These approaches 
involve: magnetic guidance and hyperthermia therapy.18 As IONP theranostics are 
magnetic by nature they can be guided and held at the site of disease via an external 
magnet, this increases nanoparticle accumulation and residence time leading to an 
increased bioavailability. Hyperthermia therapy involves the IONP theranostic being 
subjected to an alternating magnetic field used to induce nanoparticle heating. Cancer 
cells are particularly sensitive to heat and it have been found that If the cancer is 
subjected to a temperature of 42 OC for 30 min it will be destroyed, whereas the 
healthy cells will survive.18,136 In addition to this, many publications have highlighted 
a synergistic effect of having a drug present, which significantly increased the 
efficiency of the hyperthermia treatment.137 The most impressive examples of multi-
functional therapeutic nanotheranostics are evaluated here, although a 
comprehensive review has recently been published by Ulbrich et al:138  
Tietze et al, used chemical co-precipitation to synthesise IONPs and then coated 
them in lauric acid.139 This most likely created a lipid bilayer, confirmed by the 
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negative zeta potential of their particles. They could subsequently load these 
nanoparticles with mitoxantrone to yield a nanoparticle that was less than 200 nm in 
diameter. To study the therapeutic effect of these nanoparticles an, in vivo study was 
conducted using tumour bearing rabbits. The nanoparticles were injected directly into 
the tumours and an external magnetic field was used to hold the nanoparticles at the 
site of the tumour. Half of the treated animals experienced complete tumour remission 
(8 of 16) and the other half experienced a reduction in growth rate, even when the 
injected drug dose in the nanoparticle group was 10% that of the drug dose used in 
the control group. Intravenous results were not as impressive, this could be to do with 
plasma instability or poor distribution to the tumour site. Overall, this experiment 
displays the advantage of using an external magnetic field.  
Hu et al, used PVA to create IONP emulsions which were later loaded with 
doxorubicine and paclitaxel.140 This formulation was injected directly into the solid 
tumours of nude mice. It was measured that the nanoparticles were cleared from the 
site after 4 h, most likely as a result of fluid exchange. To evaluate the therapeutic 
effect, an alternating magnetic field was applied for 10 min following administration of 
the nanoparticles. Treatments were carried out every 3 days. Impressively the 
tumours went into complete remission during treatment over a 30 day period, and by 
the end of the experiment the tumours were barely visible. 
Peiris et al, developed some remarkable “nano-chains” that were composed of three 
IONPs and one doxorubicin filled liposome organised in a linear arrangement.141 The 
authors cleverly engineered the liposome portion of the nanoparticle to release the 
doxorubicin when exposed to a radio frequency of 10 kHz. Its rate of release could 
be modulated by varying the dissipation power (1-50 W). A pharmacokinetic study 
was conducted and the authors found that the doxorubicin had a blood half-life of c.a. 
26 h, which compared favourably to a commercially available liposomal formulation 
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which had a blood half-life of 18 h. The therapeutic effect of the nanoparticles was 
investigated in tumour bearing rats. The nanoparticles were intravenously injected 
followed by the application of a radio frequency pulse. After just one treatment on day 
6, a significant reduction in tumour growth rate was observed. Additionally, when a 
second treatment was applied on day 8 the development of the tumour arrested and 
did not continue to grow for the remainder of the 17 day experiment. 
Finally, another high performing IONP was engineered by Huang et al. IONP 
perfluoropentane (PFP) vapour “nanobubble” emulsions were engineered using 
temperature-sensitive Pluronic F127 and high-polarity polyacrylic acid (PEO–PPO–
PEO, F127).142 The nanobubbles were loaded with carmustine which is a toxic 
chemotherapeutic DNA alkylying agent. To test the therapeutic efficiency the 
nanobubbles were injected into tumour bearing mice and an external magnetic field 
was placed on the tumour for 30 s. MRI studies confirmed the presence of the 
nanobubbles in the tumour up to two hours after administration. Over a 13 day study, 
mice were administered with the nanobubbles and subjected to magnetic targeting 
combined with the high-intensity focused ultrasound, by the end of the experiment 
the treatment group displayed complete remission of tumour growth.   
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1.4.4   Summary and future prospects   
Over the past decade there has been an unprecedented increases in the engineering 
of nanotheranostics for biomedical applications. Due to the advances in nanoparticle 
and polymer synthesis these nanotheranostics are becoming complex systems, 
which have led to some remarkable applications. Due to their versatility, IONPs have 
been an influential component in the design of many of these nanotheranostics, most 
notably because they are widely considered as a safe material and can be used as 
an imaging probe within MRI. The clinical utility of the first generation of IONP contrast 
agents was simply not demonstrated, however this does not mean that IONP 
research is a fruitless pursuit. Magnetic materials have truly revolutionised our 
modern society and are considered a valuable material in many disciplines. Data 
storage, domestic appliances, entertainment systems, computing, particle physics 
and even planet earth all have magnetic materials at the core of their function, in fact 
it would be hard to imagine a world without magnetic materials. Medicine is not far 
behind and as this review has highlighted, there are many that still dedicate large 
resources to IONP research believing they could be beneficial in the treatment of 
many of society’s most difficult diseases. Of course, the key to using IONPs in 
biomedicine heavily depends on their polymeric architecture and therefore finding 
new polymers is of high importance. Combining IONPs with therapeutic drugs offers 
a unique opportunity to overcome many of the challenges faced with the delivery of 
medicines and it is a technology worth investigating. The aim of this project is to 
design and synthesise a novel theranostic nanoparticle, using a positively charged 
micelle forming amphiphilic carbohydrate (GCPQ), with the overall hypothesis of 
determining whether using a nanomedicine that can simultaneously image and treat 
would improve the effectiveness of a cancer treatment.          
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Chapter 2 
Design, Synthesis and Characterisation of 
an Iron Oxide Nanoparticle Formulation 
using Amphiphilic Chitosan Based 
Polymers for MRI applications  
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2.1 Introduction  
 
 
It has long been a goal for scientists to have complete synthetic control over 
nanoparticle size and shape and as a result, iron oxide nanoparticles (IONPs) have 
been prepared using a variety of methods including: chemical co-precipitation, high 
temperature thermal decomposition, sono-chemical synthesis, hydrothermal 
synthesis, sol-gel synthesis and microbial synthesis.1,2 Each method inevitably comes 
with advantages and challenges and so choosing an appropriate IONP synthesis 
method could be essential to the success of this project. By far the most conventional 
way for synthesising IONPs is via chemical coprecipitation, this well-studied method 
allows for the production of large volumes of nano-sized magnetic iron oxide particles 
at low cost and using relatively non-toxic materials.3 Chemical co-precipitation is 
based on the precipitation of IONPs from Fe3+ and Fe2+ salts in the presence of a 
base, were black IONPs are usually seen when the pH of the reaction mixture reaches 
pH 9-14.4 Although chemical coprecipitation is a widely used method it does have a 
number of shortcomings: The first main challenge is that IONPs made using chemical 
coprecipitation are extremely sensitive to their reaction conditions. This sensitivity 
often leads to relatively polydisperse products that could result in batch to batch 
variation in; levels of stability, magnetism and biodistribution. Secondly, by their 
nature nanoparticles have a high surface to volume ratio often leading to particles 
with high surface energies.5 To minimise this effect naked IONPs have a tendency to 
agglomerate which in turn leads to sedimentation, consequentially making them 
largely unsuitable for use in biological applications.5 In addition to this, magnetite 
(Fe3O4) nanoparticles can readily oxidise into maghemite (Fe2O3) unless kept in inert 
conditions, often with a loss of magnetisation and this could have an effect on the 
sensitivity of the final contrast agent. To overcome many of the challenges discussed, 
IONPs made via chemical coprecipitation are often formulated with polymers or 
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surfactants to stop agglomeration and reduce oxidation. Many examples have been 
published, however dextran, carboxymethyl dextran, poly ethylene glycol (PEG) and 
polyvinyl alcohol (PVA) are amongst the most reported with a dextran-IONP being 
one of the first iron oxide based MRI contrast agents to become commercially 
available (Feridex I.V. ®).6 
 
In more recent years, synthesis of IONPs via high temperature thermal decomposition 
has considerably gained in popularity.7 This non-aqueous method utilises 
organometallic compounds, high boiling point organic solvents and long chained fatty 
acids to yield IONPs with highly controllable sizes and narrow size distributions. One 
of the most commonly used fatty acids is oleic acid, a fatty acid that is often used in 
pharmaceutical formulations to improve the bioavailablilty of poorly soluble drugs. In 
addition to this, scientists have also been able to use this method to prepare IONPs 
with various shapes by varying the reaction conditions, altering the ratio of reagents 
and by the introduction of seeding and capping agents.8,9 Although these oleic acid 
coated iron oxide nanoparticles (IONPs) exhibit more desirable properties, their 
drawback is that they are hydrophobic and can only be dispersed in organic solvents 
making them unsuitable for biological applications without further modification.10   
 
The aim of this work was to create a multifunctional nanotheranostic using IONPs as 
the main diagnostic component. As mentioned previously formulating IONPs into a 
colloidal suspension that is suitable for in vivo MRI applications is often challenging. 
In this project it was believed that many of these complications could be overcome by 
using a chitosan based amphiphilic polymer named N-palmitoyl-N-monomethyl-N,N-
dimethyl-N,N,N-trimethyl-6-O-glycolchitosan (GCPQ). This polymer was selected as 
it has previously demonstrated to be rather effective at formulating challenging drug 
species, as well as having a reasonable toxicity profile. This chapter will explore the 
design, synthesis and formulation of a polymer-IONP formulation utilising IONPs 
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formed from the chemical coprecipitation and high temperature thermal 
decomposition processes. Chemical coprecipitation is the most widely used method 
for IONP synthesis. This method has been used for many years and so it was deemed 
a reasonable place to begin. The formation of hydrophobic IONPs made from the high 
temperature thermal decomposition was also explored as an alternative method as it 
was postulated that by talking advantage of the polymer’s ability to undergo 
micellisation it may allow for effective IONP encapsulation within the micelle’s 
hydrophobic core. To gain a deeper knowledge about nanoparticles and their 
potential for an application, comprehensive characterisation must be conducted. In a 
nanoparticle system one is usually interested in; colloidal stability, surface charge, 
size, aggregation, surface area and shape.11 Fortunately, in the last few decades the 
field of nanoscience has rapidly grown and a number of characterisation techniques 
have now been developed. This chapter will cover the characterisation of the two 
newly formed IONP formulations and will seek to evaluate their potential as an MRI 
contrast agent. 
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2.2 Materials  
Chemical  Purity  Supplier  
1,10-phenanthroline  >99.5% Sigma-Aldrich 
Acetone    
Amberlite IRA-96 
 
Sigma-Aldrich 
Ammonia hydroxide 35% v/v Fisher 
Dextrose 20% w/v Martindale 
Pharmaceuticals  
Dialysis membrane   Medicell 
Diethyl ether  >99.5% Sigma-Aldrich 
Dimercaptosuccinic acid 98% Sigma-Aldrich 
Dimethyl sulfoxide  >99.7% Sigma-Aldrich 
Diphenyl ether  >99% Alfa Aesar 
Ethanol >99.5% Fisher  
FeCl2.4H2O 98% Sigma-Aldrich 
FeCl3.6H2O >99% Sigma-Aldrich 
Glycol chitosan   WAKKO 
Hexane  >99.5% Sigma-Aldrich 
Hydrochloric acid  32% Fisher 
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Chemical  Purity  Supplier  
Hydroxylamine hydrochloride  >99% Alfa Aesar 
Methanol    
Methyl iodide >99% Sigma-Aldrich 
Nitrogen   BOC 
N-methyl-2-pyrrolidone >99% Sigma-Aldrich 
Oleic acid  >85% CRODA 
Oleyl alcohol >85% Sigma-Aldrich 
Palmitic acid N-
hydrosuccinimide 
 Toronto Research 
Chemicals  
Polystyrene size standard 
(200 nm) 
(0.2 ± 0.03) µm Sigma-Aldrich 
Polystyrene zeta standard  (-42 ± 4.2) mV Malvern 
Sodium acetate  >99% Sigma-Aldrich 
Sodium chloride  >99.8% Fisher 
Sodium hydroxide  >97% Sigma-Aldrich 
Sodium iodide  >99% Sigma-Aldrich 
Sodium oleate  97% TCI chemicals  
Toluene  >99.5% Fisher 
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2.3 Methods 
2.3.1   Synthesis of the modified chitosan amphiphilic polymer — N-palmitoyl-N-
monomethyl-N,N-dimethyl-N,N,N-trimethyl-6-O-glycolchitosan (GCPQ)  
GCPQ was synthesised as described previously.12 Briefly, glycol chitosan (5 g, Mw    
~120 kDa, WAKO) was dissolved in 4M HCl (380 ml). The solution was heated to 50 
oC and stirred for 24 h. The resulting solution was dialysed exhaustively against water 
(MWCO – 3.5 kDa) and then lyophilised to obtain degraded glycol chitosan (dGC) as 
a white fibrous solid in a yield of 46%, ~7000 Da.    
The degraded glycol chitosan (1 g) and NaHCO3 (0.75 g) were dissolved into a 
mixture of ethanol and water (24:76). Palmitic acid N-hydrosuccinimide (1.58 g, 
Toronto Research Chemicals) was dissolved in ethanol (300 mL) and was added drop 
wise. The reaction was left to stir for 72 h protected from light. Ethanol was removed 
under vacuo and then extracted using diethyl ether. The aqueous phase was dialysed 
exhaustively against water (MWCO – 3.5 kDa) and then lyophilised to obtain 
palmitoylated glycol chitosan (PGC) as a white fibrous solid. 
The palmitoylated glycol chitosan (300 mg) was dispersed in N-methyl-2-pyrrolidone 
(25 mL) and stirred vigorously overnight. Sodium hydroxide (40 mg) dissolved in 
ethanol (2mL) and sodium iodide (45 mg) dissolved in ethanol (2 mL) was added to 
the solution and the mixture was heated to 36 OC. Methyl iodide (0.45 mL) was added 
and the reaction was stirred under a N2 environment for 3 h. The product was 
precipitated using diethyl ether and left over night. The resulting precipitate was 
washed x3 with diethyl ether (50 mL) and dissolved in water (100 mL) and then was 
dialysed exhaustively against water (MWCO – 3.5 kDa). The dialysate was passed 
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through an amberlite IRA-96 column to remove iodide and then lyophilised to obtain 
GCPQ in a white fibrous solid with a total synthetic yield of 30%.   
2.3.2    Synthesis of iron oxide nanoparticles made via coprecipitation  
IONPs (Fe3O4) were made via co-precipitation using ferrous complexes and NH4OH 
as the base. Briefly, solutions of FeCl3.6H2O (0.389 M) and FeCl2.4H2O (0.195 M) 
[Fe3+: Fe2+ = 2:1] were made using deoxygenated water and mixed in a round bottom 
flask under a N2 atmosphere. 25% NH4OH was added rapidly resulting in a dark black 
precipitate forming. The reaction was allowed to proceed for 30 mins whilst vigorously 
stirring. The black precipitate was isolated with a strong magnet and washed with de-
oxygenated water until a neutral pH was obtained. De-oxygenated water was 
obtained by purging distilled H2O with a stream of N2 for several hours. The particles 
were stored wet under deoxygenated conditions.  
2.3.3    Polymer stabilised iron oxide ‘blackberry’ nanoparticles  
The GCPQ polymer stabilised IONPs were prepared via sonication. Usually, 1 mL of 
IONP (10 mg mL-1) was added to 4 mL of polymer solution. The resulting formulation 
was probe sonicated for 10 mins (2 x 5 mins, 7 micron amplitude) to yield a black 
formulation.   
2.3.4    Synthesis of iron oxide nanoparticles via high temperature thermal 
decomposition  
Iron oxide nanoparticles were synthesised in a procedure outlined by Kim et al.13 In a 
typical reaction, FeCl3.6H2O (3 g) and sodium oleate (10.2 g) were dissolved in a 
solvent mixture of: 17 mL water, 23 mL ethanol and 40 mL hexane. The resulting 
mixture was stirred for 4 h at 70 OC. After 4 h the reaction mixture was allowed to cool 
to room temperature and the hexane layer was extracted and washed x3 with distilled 
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water (30 mL). The hexane was then evaporated under vacuo to yield the iron oleate 
complex as a waxy orange oil.  
For synthesis of the iron oxide nanoparticles, iron-oleate complex (1.8 g), oleic acid 
(0.57 g) and oleyl alcohol (1.61 g) were dissolved in diphenyl ether (10 g). The 
reaction mixture was heated to 250 OC and then kept at this temperature for 20 mins 
under a N2 blanket. The mixture was then rapidly cooled to room temperature and 
acetone (50 mL) was added to precipitate out the nanoparticles. Nanoparticles were 
collected via centrifugation (3000 rcf, 10 min), the supernatant was discarded and 
replaced with acetone (40 mL), and this procedure was repeated x3. The washed 
nanoparticles were finally dispersed and stored in hexane. To obtain dry 
nanoparticles for characterisation; hexane was removed under vacuo. Acetone was 
added and the nanoparticles could be gently be collected with a spatula and dried 
overnight under vacuum. From here, the particles could be weighed and made up to 
the desired concentration in hexane or chloroform.  
2.3.5    Formulation of iron oxide polymeric ‘raspberry’ nanoparticles   
In a small vial, iron oxide nanoparticles in hexane (2 mL, 4 mg/mL) were added to a 
GCPQ solution (5 mL, 1 mg/mL). The solution was then sonicated using probe 
sonication (2 x 5 min, 7 micron amplitude, Soni Prep 150, MSE, UK) at the interface 
between the organic and aqueous phases, creating a brown emulsion. This emulsion 
was left to separate over 48 h. The aqueous layer was then extracted and any residual 
hexane was allowed to evaporate overnight. The product was frozen and lyophilised 
to obtain a dry product which rapidly dispersed when added to water (5 mL). For the 
in vivo investigations a formulation with a higher yield of iron oxide nanoparticles was 
made by increasing the IONPs and polymer concentration by a factor of 15; iron oxide 
nanoparticles in hexane (2 mL, 60 mg/mL) were added to a GCPQ solution (5 mL, 15 
mg/mL) and then processed as described above. 
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2.3.6    Ligand exchange of hydrophobic iron oxide nanoparticles with meso-2,3-
dimercaptosuccinic acid (DMSA) 
This ligand exchange protocol was followed as described previously by Palma et al.14 
Briefly, iron oxide nanoparticles (20 mg) were precipitated from hexane (1 mL) by the 
addition of ethanol and were collected via centrifugation (9000 rcf, 10 min), the 
supernatant was discarded and replaced with ethanol and this procedure was 
repeated twice. The final precipitate was re-dispersed in toluene. DMSA (36 mg) in 
DMSO (2 mL) was added to the toluene mixture and the reaction was bath sonicated 
(10 min) and left to stir at room temperature for 48 h. After 48 h a sediment was 
observed, this was collected via centrifugation (9000 rcf, 10 min), the supernatant 
was discarded and replaced with ethanol and this procedure was repeated twice. The 
final precipitate was re-dispersed in water, titrated to pH 10 using NaOH and then 
filtered through a 0.22 µm membrane.      
2.3.7    1H-Nuclear magnetic resonance  
All 1H-NMR experiments were recorded on Brüker AMX 400 MHz spectrometers in 
deuterated solvents and processed using MestreNova software with calibration on 
residual solvent peaks. Chemical shifts (δ) are quoted in ppm. The level of 
palmitoylation was estimated by comparing the ratio of palmitoyl methyl protons (δ ~ 
0.9 ppm) to the sugar protons (δ ~ 3.5 – 4.5 ppm) and the level of quarternisation was 
calculated by comparing the ratio of quaternary ammonium (δ ~ 3.45 ppm) to the 
sugar protons.  
2.3.8    Gel permeation chromatography – multi angled laser light scattering  
The molecular weight of DGC and GCPQ was determined by GCP-MALLS equipped 
with DAWN® EOS™ MALLS (λ = 690 nm), Optilab DSP Interferometric Refractometer 
(λ = 690 nm) and QELS detectors (Wyatt Technology Corporation, USA), using as a 
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mobile phase an acetate buffer (0.3 M CH3COONa/0.2 M CH3COOH, pH 4.5) for DGC 
and a mixture of the acetate buffer:methanol (35:65) for GCPQ. Filtered samples (0.2 
µm, 200 µL) were injected using a Waters 717plus Autosampler into a POLYSEP TM-
GFC-P guard column (35.0 x 7.8 mm, Phenomenex, UK) attached to a POLYSEP 
TM-GFC-P 4000 column (300.0 x 7.8 mm, exclusion limit for PEG =200,000 Da, 
Phenomenex, UK) at a concentration of 5 mg mL-1. The experiments were performed 
at room temperature. The data was processed using ASTRA for Windows version 
4.90.08 software (Wyatt Corporation, USA).  
The specific refractive index increment (dn/dc) of DGC and GCPQ were measured 
with an Optila DSP Interferometric Refractometer (λ=690nm). Filtered samples (0.2 
µm, 33 mm Millex GP syringe driven filter unit, PES membrane for sterilisation of 
aqueous solutions) of 5 concentrations ranging from 0.1-0.5 mg mL-1 were manually 
injected using an Injection System (Wyatt Technology Corporation, USA) at a flow 
rate of 0.3 ml min-1 at room temperature. The data was processed using DNDC for 
Windows version 5.90.03 software (Wyatt Corporation, USA).   
2.3.9    Transmission electron microscopy  
Images were collected using a FEI CM120 BioTwin Transmission Electron 
Microscope (Ex. Philips, Eindhoven, Netherlands). Digital images were captured 
using an AMT digital camera. A drop of the sample was placed on Formvar©/Carbon 
Coated Grid (F196/100 3.05 mm, mesh 300, Tab Labs Ltd, England). Samples were 
stained with 1 % aqueous uranyl acetate where indicated.      
2.3.10    Dynamic light scattering 
Particle size was determined by dynamic light scattering (DLS) on a Malvern 
Zetasizer 3000HS (Malvern Instruments, UK) using a laser wavelength of 633 nm. 
Samples were inverted several times and then left to equilibrate for 10 seconds before 
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particle sizing was carried out. The accuracy of the instrument was assessed 
periodically using latex beads (polystyrene, mean size: 0.2 µm) in a 50 mM sodium 
chloride dispersant phase.      
2.3.11    Manual zeta potential and size – pH titration  
Zeta potential was measured using a Malvern Zetasizer 3000HS (Malvern 
Instruments, UK). Nanoparticles were manually titrated to various pH values using 
0.1 M HCl and 0.1 M NaOH. Measurements were carried out in gold plated disposable 
capillary cells (Malvern Instruments, UK). The accuracy of the instrument was 
assessed periodically using a polystyrene zeta standard (Malvern Instruments, UK).   
2.3.12    Automatic zeta potential and size – pH titration  
Zeta potential was measured using a Malvern Zetasizer 3000HS (Malvern 
Instruments, UK) paired with an MPT-2 automatic titrator (Malvern Instruments, UK). 
Prior to any titration the pH probes were calibrated using pH 4, pH 7 and pH 10 
standards. Nanoparticles were manually titrated to pH 4. The instrument then 
automatically titrated the sample and measured size and zeta potential between pH 
4 and 11. Reservoirs were filled with HCl and NaOH at concentrations of 0.05 M. 
Measurements were carried out in gold plated disposable capillary cells (Malvern 
Instruments, UK). Accuracy of the instrument was assessed periodically using a 
polystyrene zeta standard (Malvern Instruments, UK).   
2.3.13    Magnetic properties  
Magnetization curves were carried out in a Quantum Design hybrid Superconducting 
Quantum Interference Device-Vibrating Sample Magnetometer (SQUID-VSM) at 300 
K, with applied fields up to 7 T. Samples were lyophilised to obtain a dry product. 
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Weighed samples of the dry product were placed into plastic capsules and measured 
in a straw sample holder. 
2.3.14    X-ray diffraction  
X-ray diffraction patterns were collected on an X-ray diffractometer (PanAlytical, UK) 
using CoKα radiation λ = 1.79 Å. Samples were prepared by pressing dried powders 
on a zero background silicon wafer and diffraction patterns were collected within 20–
100 2θ (degrees) range. 
2.3.15    In vitro relaxivity measurements   
Relaxivity measurements for the iron oxide blackberry nanoparticles were performed 
at the ICPMS (Campus de Cronenbourg, Strasbourg, France) on a contrast agent 
analyzer (minispec mq 60, Bruker, Germany) at 1.5T at 37 OC. T2 values were 
collected using a spin-echo sequence. T1 values were obtained using an inversion 
recovery sequence. The relaxivities were plotted against the iron concentration of a 
series of blackberry nanoparticle formulations and the relaxivities was determined 
from the gradient of the slope. Iron concentration was measured using the 1,10-
phenanthroline iron quantification assay.  
2.3.16    MR relaxivity measurements   
MR relaxivities for the raspberry nanoparticles and the DMSA.IONPs were measured 
using a 1T benchtop MRI scanner (ICONTM, Bruker, UK) at 37 OC. For T2 relaxation 
a spin echo sequence was used with the following parameters; TE: 6-100 ms, TR: 
1845 ms. The T2 relaxivities were determined by curve fitting the echo times (TE) 
using MATLAB (Mathworks, UK). The relaxivities were plotted against the iron 
concentration of a series of iron oxide polymeric raspberry nanoparticles samples and 
the T2 was determined from the gradient of the slope. T1 relaxivity was measured 
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using an inversion recovery sequence with the follow parameters; TI: 35-7500 ms, 
TR: 15000. The T1 relaxivities were determined by curve fitting several inversion 
times (TI). The relaxivities were plotted against a series of samples and the T1 was 
determined from the gradient of the slope. 
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2.4 Results 
2.4.1 Amphiphilic polymer synthesis 
 
 
  
Scheme 2.4.1.1. Synthesis of the amphiphilic chitosan based polymer 
(GCPQ).  
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2.4.2 Nuclear magnetic resonance characterisation  
 
 
 
Figure 2.4.2.1. 1H-NMR of degraded glycol chitosan (dGC) in D2O. An acetyl 
group was present in small amounts at position 4. This is an inherited feature 
from chitin, which is the acetylated polymer that glycol chitosan is originally 
derived from. 1H NMR (400 MHz, D2O, 298 K): δ 2.1 (3H, s, H4), δ 3.3 (1H, m, 
H2), δ 3.5-4.5 (9H, m, H1), δ 5.5 (1H, s, H3). 
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Figure 2.4.2.2. 1H-NMR of palmitoylated glycol chitosan (PGC) in 
D2O:MeOD:AcOD (8:4:1). The order of protons found at positions 6 and 7 can 
only be determined by 1H-COESY reported in Figure 2.4.2.4. 1H NMR (400 
MHz, D2O:MeOD:AcOD (8:4:1), 298 K): δ 0.9 (3H, t, H4), δ 1.3 (24H, m, H5), δ 
1.6 (2H, m, H6), δ 2.0 (3H, s, H8), δ 2.3 (2H, m, H7), δ 3.2 (1H, m, H2), δ 3.5-4.5 
(9H, m, H1), δ 4.9 (1H, m, H3). 
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Figure 2.4.2.3. 1H-NMR of N-palmitoyl-N-monomethyl-N,N-dimethyl-N,N,N-
trimethyl-6-O-glycolchitosan (GCPQ) in MeOD. The newly formed quaternary 
ammonium group can be found at position 8. Di and mono substituted 
methylation can be found at position 9. 1H NMR (400 MHz, MeOD, 298 K): δ 0.9 
(3H, t, H4), δ 1.3 (24H, m, H5), δ 1.6 (2H, m, H6), δ 2.0 (3H, s, H10), δ 2.3 (2H, m, 
H7), δ 3.0 (1H, m, H2), δ 3.2 (9H, s, H9), δ 3.4 (9H, s, H8) δ 3.5-4.5 (9H, m, H1), δ 
5.3 (1H, m, H3). 
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Figure 2.4.2.4. COSEY of N-palmitoyl-N-monomethyl-N,N-dimethyl-
N,N,N-trimethyl-6-O-glycolchitosan (GCPQ) in MeOD. A proton-proton 
correlation experiment (COSEY) was used to differentiate between the 
protons found at positions 6 and 7. Solvent coupling between MeOH 
and H2O was observed (circled in red). 
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Table 2.4.2.1. Table summarising the degree of functionalisation of the GCPQ 
polymer between batches determined by NMR giving a palmitoyl 
functionalisation of (13.4 ± 2.9)% and a trimethyl functionalisation of (15.6 ± 
4.7)%. 
115 
 
2.4.3 Gel permeation chromatography  
 
 
  
Figure 2.4.3.1. Gel permeation chromatography coupled to a multi angled 
laser light scatting detector was used to determine the molecular weights 
of the polymers; (a) GPC chromatogram of dGC; 7081 Da; Mw/Mn, 1.011 
(2%). (Inset), the dn/dc; 0.1418 ±0.0016 mL/g; (b) GPC chromatogram of 
GCPQ; 10250 Da; Mw/Mn, 1.032 (3%). (Inset), the dn/dc; 0.1561±0.0039 
mL/g.    
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2.4.4 Formulation 1 using IONPs made via coprecipitation: iron oxide 
“blackberry” nanoparticles  
 
 
 
Scheme 2.4.4.1. The preparation procedure and work up for the polymer stabilised 
iron oxide “blackberry” nanoparticles. This formulation was made using the naked 
IONPs formed from chemical co-precipitation reaction: i, addition of naked IONPs; 
ii, probe sonication.  
117 
 
 
 
  
Figure 2.4.4.2. Blackberry nanoparticles macro images: (a) an image of the 
formulation before processing and (b) the IONP formulation after probe sonication 
with the amphiphilic polymer. Before processing the naked IONPs form a sediment 
on the bottom of the vial however after processing, the IONPs appear to have an 
improved colloidal stability.   
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2.4.5 Formulation 2 using IONPs made via high temperature thermal 
decomposition: iron oxide “raspberry” nanoparticles  
 
 
 
 
Scheme 2.4.5.1. The preparation procedure and work up for the polymer modified 
iron oxide “raspberry” nanoparticles. This formulation was made using the IONPs 
formed from the high temperature thermal decomposition method: i, emulsification 
via probe sonication; ii, separation; iii, extraction; iv, evaporation; v, lyophilisation; 
vi, reconstitution in aqueous medium.   
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Figure 2.4.5.2. Raspberry nanoparticles macro images: (a) an image of the 
formulation before processing. The hydrophobic IONPs sit the upper organic layer 
(hexane), the polymer micelles sit in the lower aqueous layer (water); (b) an image 
of the iron oxide raspberry nanoparticle formulation at a concentration of 0.45 mg 
Fe/mL; (c) an image of the iron oxide raspberry nanoparticle formulation at a 
concentration of 6.5 mg Fe/mL.  
120 
 
2.4.6 Transmission electron microscopy   
 
 
 
 
 
 
Figure 2.4.6.1. (a) TEM image of the amphiphilic polymer (GCPQ) with a 1% uranyl 
acetate stain. The amphiphilic nature of GCPQ allows the polymer to self-
assemble into nano-sized micelles; (b) size distribution of the polymer 
nanoparticles with an average size of (29.6 ± 5.7) nm. Data are means ± s.d., n 
>250. 
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Figure 2.4.6.2. (a) TEM image of the naked IONPs made via chemical co-
precipitation. The high surface energy causes the nanoparticles to cluster into 
large aggregates; (b) size distribution of the naked IONPs with an average size of 
(8.4 ± 2.1) nm. Data are means ± s.d., n >300.  
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Figure 2.4.6.3. (A) TEM image of formulation 1 made using co-precipitation IONPs 
and stabilised using the amphiphilic chitosan based polymer (GCPQ). Nano sized 
“clusters” of IONPs with varying morphology are observed; (a) with a 1% uranyl 
acetate stain; (B) TEM images of the cluster nanoparticles at 180000x 
magnification without a stain and (b) with a 1% uranyl acetate stain. These 
structures will be referred to as ‘blackberry nanoparticles’. 
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Figure 2.4.6.4. (a) Heating profile for a typical IONP reaction. These reactions are 
heated at 10 OC/min and then maintained at 250 OC for 20 mins. Size and 
morphology of the iron oxide crystals have a relationship to the rate of heating and 
reaction temperature they are grown in; (b) TEM image of the resulting 
hydrophobic IONPs; (c) size distribution of IONPs with an average size of (4.8 ± 
0.8) nm. Data are means ± s.d., n >300. 
124 
 
 
 
Figure 2.4.6.5. (A) TEM image of formulation 2 made using high temperature 
thermal decomposition IONPs and encapsulated within a GCPQ polymeric micelle, 
forming “raspberry” like nanostructures without stain and; (a) with a 1% uranyl 
acetate stain; (B) TEM images of the nanoparticles at 330000x magnification 
without a stain and (b) with a 1% uranyl acetate stain. These structures will be 
referred to as ‘raspberry nanoparticles’. 
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Figure 2.4.6.6. TEM image of the commercially available IONP negative MRI 
contrast agent Ferucarbotran® (Resovist®). IONPs are stabilised using a 
carboxymethyl dextran polymer. IONPs (average c.a. 5 nm) are polydisperse in 
size and morphology.     
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2.4.7 Dynamic light scattering  
 
 
 
 
 
 
Figure 2.4.7.1. Macro image of the blackberry nanoparticle formulation and 
stability study. Various concentrations of polymer were used to stabilise 10 mg of 
Naked IONPs. At low polymer concentrations IONP sedimentation was observed, 
however at higher polymer concentrations colloidal stabilisation did appear to 
improve. 
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Figure 2.4.7.2. Dynamic light scattering was used to determine the average size 
of the nanoparticles in the formulation. Measurements of blackberry nanoparticle 
formulations containing different weight ratios of naked IONP:polymer; 1:2, 1:0.4, 
1:0.2 and 1:0.04. IONP:polymer formulations have sizes (and polydispersity 
indexes) of 148 nm (0.19), 183 nm (0.22), 141 nm (0.19) and 152 nm (0.22), 
respectively. Formulations with less polymer than 1:0.04 (IONP:polymer) did not 
stabilise IONPs and gave erroneous results with high polydispersity indexes. The 
size results between formulations are not statistically significant suggesting that 
the ratio of IONP:polymer has no effect on the size of the blackberry nanoparticles 
formed. Data are means ± s.d., n=3, (p <0.05, 1-way ANOVA).  
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Figure 2.4.7.3. Blackberry nanoparticle stability was investigated by dynamic light 
scattering in water over 30-days at 5 OC. Polydispersity values given in labels 
above each column. No significant difference to the formulation on day 1 was 
observed in any of the formulations studied over the time period, suggesting good 
blackberry nanoparticle stability in aqueous conditions. Data are means ± s.d., 
n=3, (p <0.05, 1-way ANOVA, Games-Howell post hoc test). 
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Figure 2.4.7.4. Macro image of the raspberry nanoparticle formulations and stability 
study. Various concentrations of polymer were used to stabilise 8 mg of 
hydrophobic IONPs. At low polymer concentrations no IONP stabilisation was 
observed, however at higher polymer concentrations colloidal stabilisation did 
appear improved.     
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Figure 2.4.7.5. DLS measurements of the raspberry nanoparticle formulations 
containing different weight ratios of IONP:polymer; 1:2.5, 1:0.5 and 1:0.25. 
IONP:polymer formulations have sizes (and polydispersity indexes) of 120 nm 
(0.15), 190 nm (0.14) and 230 nm (0.14), respectively. Formulations with less 
polymer than 1:0.25 (IONP:polymer) did not encapsulate IONPs. There was a 
statistical difference between each formulation suggesting that raspberry 
nanoparticle size can be controlled by manipulation of IONP:polymer ratio. Data 
are means ± s.d., n=3, (p <0.05, 1-way ANOVA, Tukey post hoc test). 
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Figure 2.4.7.6. Raspberry nanoparticle stability was investigated by dynamic light 
scattering in water over 90-days at 5 OC. Polydispersity values given in labels above 
each column. No significant difference to the formulation on day 1 was observed in 
any of the formulations studied over the time period, suggesting good raspberry 
nanoparticle stability in aqueous conditions. Data are means ± s.d., n=3, (p <0.05, 
1-way ANOVA, Games-Howell post hoc test). 
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2.4.8 Zeta surface charge and size - pH titrations    
 
 
Figure 2.4.8.1. Blackberry nanoparticle manual zeta potential pH titration. These 
experiments are conducted to measure the surface charge of a nanoparticle in 
acidic and alkaline environments: Blackberry nanoparticles are shown to be 
positively charged in nature and have a surface zeta potential of (+22.5 6.1) mV 
in neutral conditions (pH 7.1). The surface characteristics of the naked IONPs are 
highly dependent on the pH of its environment and therefore display effectively no 
charge in neutral conditions; (-4.3 5.2) mV at pH 7.1. Data are means ± s.d., n=3. 
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Figure 2.4.8.2. Raspberry nanoparticle automatic zeta potential pH titration. 
Raspberry nanoparticles are positively charged having a (+24.4 1.5) mV in neutral 
conditions (pH 7.0). Data are means ± s.d., n=3. 
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Figure 2.4.8.3. Raspberry nanoparticle automatic dynamic light scattering pH 
titration. Conducted to study the effect of pH on raspberry nanoparticle size. In 
strongly basic conditions (pH >9) large aggregation is observed, indicated by an 
increase in particle size and PdI. These results suggest the raspberry nanoparticles 
are not stable in strongly basic conditions. Data are means ± s.d., n=3.   
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2.4.9 X-ray diffraction     
 
 
 
 
Figure 2.4.9.1. X-ray diffraction patterns of (a) the blackberry nanoparticles and (b) 
the naked IONPs (8 nm). Both patterns indicate the presence of magnetic iron 
oxide. 
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Figure 2.4.9.2. X-ray diffraction patterns of (a) the raspberry nanoparticles and (b) 
the hydrophobic IONPs (5 nm). Both patterns indicate the presence of magnetic 
iron oxide. 
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Figure 2.4.9.3. X-ray diffraction pattern of GCPQ alone. Broad and weak scattering 
observed between 20O- 55O (2θ) with the most intense scattering seen at a 26.9 O. 
This type of scattering is characteristic of an amorphous polymeric material.  
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2.4.10 Magnetic characterisation      
 
 
 
 
Figure 2.4.10.1. M vs H plot at 300 K comparing the blackberry nanoparticles and 
the naked IONPs (8 nm). The blackberry nanoparticles retain their 
superparamagnetic behaviour after formulation with the GCPQ polymer. The 
magnetic saturation of the naked IONP and the blackberry nanoparticles were 
found to be (73.3 ± 1.1) emu/g and (63.5 ± 1.3) emu/g, respectively showing that 
the blackberry nanoparticles are slightly less magnetic per gram of material. Data 
are means ± s.d., n=3, (p <0.05, Student’s t-test). 
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Figure 2.4.10.2. M vs H plot at 300 K comparing raspberry nanoparticles and the 
hydrophobic IONPs (5 nm). Raspberry nanoparticles retain their 
superparamagnetic behaviour after encapsulation within the polymeric GCPQ 
nanoparticle. The magnetic saturation of the hydrophobic IONP and raspberry 
nanoparticles were found to be (13.4 ± 1.9) emu/g and (5.5 ± 0.3) emu/g, 
respectively, showing that the raspberry nanoparticles are less magnetic per gram 
of material. Data are means ± s.d., n=3, (p <0.05, Student’s t-test). 
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Figure 2.4.10.3. M vs H plot at 300 K comparing the magnetic iron content of the 
raspberry nanoparticles and the hydrophobic IONPs. Samples of hydrophobic 
IONPs and raspberry nanoparticles were measured for iron content and then 
plotted against their magnetisation profile. This yielded a magnetic saturation value 
of (29.6 ± 3.7) emu/g Fe and (33.8 ± 1.8) emu/g Fe for the hydrophobic IONPs and 
raspberry nanoparticles, respectively. There is no significant change in 
magnetisation between the two curves, showing that modification using the 
polymer has little to no effect on the IONPs magnetisation. Data are means ± s.d., 
n=3, (p <0.05, Student’s t-test).  
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2.4.11 Relaxometry  
 
 
 
 
Figure 2.4.11.1 Relaxivity plot of the blackberry nanoparticles conducted on a 
Bruker Mq 60 Minispectrometer (Bruker, Germany). Plot of 1/T1 S-1 and 1/T2 S-1 
against the concentration of a series of blackberry nanoparticles in [Fe]. The 
relaxivities (r1 and r2) can be determined from the slope of the plots. 
Figure 2.4.11.2. (a) Phantom T1 and T2 maps of raspberry nanoparticles 
conducted on a 1T benchtop MRI scanner (ICONTM, Bruker, UK) and (b), Plot of 
1/T1 S-1 and 1/T2 S-1 against the concentration of a series of raspberry nanoparticles 
in [Fe].  
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Figure 2.4.11.3 To investigate the effects of clustering on relaxivity a single crystal 
IONP was made using dimercaptosuccinic acid (DMSA): (a), molecular structure of 
DMSA; (b), schematic of the resulting DMSA.IONP produced via ligand exchange; 
(c), TEM of the DMSA.IONP; (d), DLS of the DMSA.IONP with an average 
hydrodynamic size by volume of 9 nm.    
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Figure 2.4.11.4 (a) Phantom T1 and T2 maps of DMSA.IONPs conducted on the 
1T benchtop MRI scanner (ICONTM, Bruker, UK)and (b), Plot of 1/T1 S-1 and 1/T2 S-
1 against the concentration of a series of DMSA.IONP in [Fe].  
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2.5 Discussion  
2.5.1    Synthesis of the modified chitosan amphiphilic polymer (GCPQ) 
The synthesis of GCPQ began with a commercially available derivative of chitin 
named glycol chitosan (GC). The commercially available polymer is far too large 
(120,000 Da) to be of use, as using the final polymer at this size would often lead to 
gelation in the formulation, as a result its size had to be reduced. This is achieved via 
acid hydrolysis in the presence of 4M HCl to yield a polymer with an average mass of 
7,000 Da measured by gel permeation chromatography coupled to a multi angled 
laser light scatting detector (GPC-MALLS) (Figure 2.4.2.1 and 2.4.3.1.a). The 
polymers amphiphilic nature was added by introducing a long chained hydrophobic 
alkyl chain to the amine position in the sugar backbone using palmitic acid N-
hydroxysuccinimide (Figure 2.4.2.2). The palmitoylated GC was only sparingly 
soluble in aqueous environments and so a quaternary ammonium cation was 
introduced to increase it aqueous solubility in a process known as methylation using 
methyl iodide as the main reagent (Figure 2.4.2.3). The final polymer (GCPQ) was 
obtained as a white fibrous solid with a total synthetic yield of 30%. Only a number of 
the sugar units in the polymer backbone were functionalised and the degree of 
palmitoylation was estimated via 1H NMR (Figure 2.4.2.3). This was done by 
comparing the integration values of the methyl peak (from the alkyl chain) found at δ 
0.9 ppm and that of the sugar unit peak found at δ 3.5-4.5 ppm and placing them into 
Equation 2.5.1.1.  
 
%                =
                                   / 
                                  / 
× 100  (2.5.1.1) 
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The degree of quarternisation was again calculated using 1H NMR (Figure 2.4.2.3). 
This was done by comparing the integration values of the trimethyl protons from the 
quaternary amine found at 3.4 ppm and that of the sugar unit peak and placing them 
into Equation 2.5.1.2.     
 
%                =
                                      / 
                                  / 
× 100 (2.5.1.2) 
 
 
From the 1H NMR data the average degree of palmitoylation and the average degree 
of quarternisation between batches is summarised in Table 2.4.2.1. Palmitoylation 
gave an average functionalisation of (13.4 ± 2.9)%, while quarternisation gave an 
average functionalisation of (15.6 ± 4.7)%. Synthesising GCPQ polymers with highly 
reproducible functionalisation was difficult, to minimise variation large batches were 
produced. The average molecular weight of the final GCPQ polymer was often found 
to be approximately 10,000 Da as determined by GPC-MALLS (Figure 2.4.3.1.b). The 
amphiphilic nature of GCPQ allows the polymer to self-assemble into nano-sized 
micelles of around 32 nm in diameter which could be seen via electron microscopy 
(TEM), these nanoparticles were stable at low polymer concentrations without the 
need for further crosslinking (Figure 2.4.6.1.a and b). 
2.5.2    Formulation and nanoparticle morphology   
The naked IONPs were prepared via the chemical co-precipitation of FeCl3.6H2O and 
FeCl2.4H2O (Fe3+:Fe2+, 2:1) using 25% NH4OH. To minimise oxidation of the resulting 
nanoparticles the reaction was carried out in oxygen free conditions by purging all 
aqueous reagents with N2 (g) for several hours. After the addition of NH4OH a black 
precipitate was immediately formed which could be isolated with a strong magnet and 
washed with de-oxygenated water until a neutral pH was obtained. Electron 
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microscopy (TEM) confirmed the presence of nanoparticles which where spherical in 
nature and had an average diameter of (8.4 ± 2.1) nm (Figure 2.4.6.2.a and b). TEM 
images also show that these IONPs formed irregular size and shaped agglomerates 
which can largely be attributed to the IONPs clustering together to minimise their high 
surface energies.4 The prepared naked IONPs had a tendency to sediment in 
aqueous conditions making them unsuitable for biological applications. In order to 
stabilise the nanoparticles in aqueous conditions the naked IONP aggregates and the 
modified chitosan polymer (GCPQ) were formulated together with the aid of probe-
sonication (Scheme 2.4.4.1). This method yielded a formulation which was observed 
to have improved colloidal properties compared to the naked IONPs alone (Figure 
2.4.4.2.a and b). Electron microscopy revealed that the polymer modified formulation 
was composed of irregular size and shaped agglomerates and a 1% uranyl acetate 
stain provided evidence that these structures were coated by a hydrophilic layer as, 
by its nature, this stain likes to accumulate in regions of hydrophilicity (Figure 2.4.6.3). 
A reasonable hypothesis for the structures observed is that the energy provided by 
sonication was enough to fragment the large naked IONP agglomerates into much 
smaller clusters, their high surface energies could then be stabilised by the GCPQ 
polymer and in doing so reduce their tendency to re-aggregate. These structures will 
now be referred to as ‘blackberry nanoparticles’.        
 
Uniform iron oxide nanocrystals were synthesised via high temperature thermal 
decomposition of an iron-oleate complex in the presence of oleic acid, oleyl alcohol 
and diphenyl ether in a method reported by kim et al.13 Diphenyl ether turned out to 
be the most suitable high temperature solvent tested (b.p. 258 OC) as the 
nanoparticles were easily purified by washing with acetone. Octadecene was also 
investigated as a potential solvent, however purification of these nanoparticles from 
the solvent was troublesome. The reaction was heated at a rate of approximately 10 
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OC/min and then kept at the desired temperature for 20 min (Figure 2.4.6.4.a). 
Electron microscopy (TEM) confirmed the presence of nanoparticles which had an 
average diameter of (4.8 ± 0.8) nm and were spherical in nature (Figure 2.4.6.4.b and 
c). Compared to the IONPs prepared by aqueous co-precipitation these were 
considerably more uniform and would easily disperse in organic solvents (hexane and 
chloroform). The prepared nanoparticles were coated in a layer of oleic acid making 
them extremely hydrophobic and not suitable for biological applications. In order to 
stabilise these nanoparticles in aqueous conditions the modified amphiphilic chitosan 
based polymer (GCPQ) was used. The hydrophobic oleic acid coated nanoparticles 
can be incorporated into the micelle core by a system of emulsification with the aid of 
ultra-sonication and then removal of the solvent (Scheme 2.4.5.1). Dry nanoparticles 
could then be reconstituted into aqueous based solvents at the desired concentration. 
This method yielded impressive ‘raspberry’ like nanostructures which can be seen via 
TEM. Interestingly, the hydrophobic nanoparticles seem to situate themselves inside 
the hydrophobic core of the polymer micelle which can be seen via electron 
microscopy (Figure 2.4.6.5). It is predicted that the driving force behind this structure 
formation is from the hydrophobic IONPs trying to avoid high energy interactions with 
the aqueous media.15 These structures will now be referred to as ‘raspberry 
nanoparticles’.  
2.5.3    Nanoparticle size and aqueous stability  
Several blackberry nanoparticle formulations, containing different weight ratios of 
IONP:polymer; 1:2, 1:0.4, 1:0.2 and 1:0.04 were formulated and monitored via 
dynamic light scattering (DLS) over a 30-day period in water.16 Formulations made 
with less polymer than 1:0.04 (IONP:polymer) showed ineffective stabilisation from 
day 1 (Figure 2.4.7.1). DLS is a technique used to measure the size of nanoparticles 
in a collodial suspension. DLS is a light scattering technique that measures 
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fluctuations in scattered light from nanoparticles undgergoing bownian motion. The 
fluctuations are directly related to the movement of a nanoparticle through the solvent, 
which in turn, is related to the particles' hydrodynamic size. The various blackberry 
nanoparticle formulations have sizes (and polydispersity indexes) of 148 nm (0.19), 
183 nm (0.22), 141 nm (0.19) and 152 nm (0.22), respectively. (Figure 2.4.7.2). A 
monodisperse sample will have polydispersity index (PdI) values around 0.05 
whereas, a polydisperse sample has values close to 1.0 (values over 0.5 are usually 
considered polydisperse). The formulations remained colloidally stable and did not 
display any significant change in size over the time period (Figure 2.4.7.3). This data 
suggests that at least an IONP:polymer ratio of 1:0.04 is needed to create a colloidally 
stable formulation and that manipulating the IONP:polymer ratio has no significant 
effect on the overall size of the blackberry nanoparticles formed.  
Several raspberry nanoparticle formulations, containing different weight ratios of 
IONP:polymer; 1:2.5, 1:0.5 and 1:0.25 were formulated and monitored via DLS over 
a 90-day period in water. Formulations made with less polymer showed ineffective 
stabilisation (Figure 2.4.7.4). A reasonable hypothesis for this observation is that 
polymer concentrations lower than the ones used for the IONP:polymer; 1:2.5 
formulation are below the critical micelle concentration (CMC) of the polymer. One 
can see that the IONP:polymer formulations have sizes (and polydispersity indexes) 
of 120 nm (0.15), 190 nm (0.14) and 230 nm (0.14), respectively (Figure 2.4.7.5). This 
result remains relatively unchanged throughout the 90-day period indicating that the 
raspberry nanoparticles have good aqueous colloidal stability and that the size can 
be controlled by varying polymer concentrations (Figure 2.4.7.6). It is worth 
mentioning that nanoparticles did settle over prolonged periods of time, it is thought 
that this effect was probably caused by the large density of the raspberry 
nanoparticles however, these would easily re-disperse with gentle agitation with no 
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effect on the nanoparticle size. This effect was also observed by Lin et al with their 
chitosan-IONP.17  
2.5.4    Nanoparticle pH titrations      
The surface chemistry of a nanoparticle system is an important feature to understand 
as it is at this solid-liquid interface where the nanoparticle will interact with its 
environment. Surface charge is considered one of the most important features and 
many believe it plays an important role in colloidal stability and many biological 
mechanisms.18,19 It is very difficult to measure the exact surface charge of a 
nanoparticle in solution, however it is possible to measure the electrostatic charge at 
the particle’s slipping plane. The slipping plane is a term used to describe the point at 
which counter ions strongly adsorbed to the nanoparticles surface meet with loosely 
bound counter ions in the bulk phase.20 The electrostatic charge at the point is called 
the zeta potential and it can be measured via electrophoretic light scattering. 
Nanoparticle surface charge usually has a direct correlation with environmental pH 
and so it is important to investigate the zeta potential in a range of acidic and basic 
conditions.21 The zeta potential of the blackberry nanoparticle was monitored over a 
pH range in a manual titration experiment and then compared to the naked IONPs 
(Figure 2.4.8.1). Distinctive sigmoidal curves are observed for both nanoparticle 
systems where, the blackberry nanoparticles are shown to be positively charged and 
have a surface zeta potential of (+22.5 6.1) mV in neutral conditions (pH 7.1). The 
surface characteristics of the naked IONPs are highly dependent on the pH of its 
environment and therefore display effectively no charge in neutral conditions; (-4.3 
5.2) mV at pH 7.1. The positively charged zeta potential of the blackberry 
nanoparticle can be attributed to the quaternary ammonium cationic functional group 
found on the polymer which has a pKa of 5.99 0.15.22 This is a good indication that 
the polymer is bound to the surface of the IONPs. The zeta potential of the polymer 
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alone was difficult to measure and usually resulted in damage to the cell most likely 
due to its high ionic strength.  
 
The zeta potential of the raspberry nanoparticle was measured whilst varying the pH 
in an automatic titration experiment (Figure 2.4.8.2). It was found, like many other 
nanoparticles of this nature, the zeta potential of the raspberry nanoparticles 
displayed a strong dependence with pH. Typically, the raspberry nanoparticles are 
positively charged having a positive zeta potential of (+24.4 ± 1.5) mV in neutral 
conditions (pH 7.1). Again, the positively charged nature of the nanoparticle can be 
attributed quaternary ammonium cationic functional group found on the polymer. 
Hydrophobic IONPs made via high temperature thermal decomposition could not be 
measured as they were not dispersible in aqueous media. From recent studies it has 
become clear that surface charge plays a key role in the adsorption of surface 
proteins, a process known as opsonisation, and it is often these surface bound agents 
that will dictate how a nanoparticle will behave in a biological environment.23,24 An 
additional advantage is that positively charged nanoparticles appear to have 
enhanced penetration in tumour tissue than their neutral or negatively charged 
equivalents, this is most likely a result of the slight negative charge of the cell 
membrane.25,26 A few examples include Jiang et al who have comprehensively 
investigating the effects of polystyrene nanoparticle surface charge on mesenchymal 
stem cells and have found that cationic nanoparticles (>100 nm) show much greater 
cellular internalization. Additionally, Angeles et al found that positively charged IONPs 
showed significantly better internalisation within human cervical carcinoma cell lines 
(HeLa) than their neutral or negatively charged counterparts.27-29 Although positively 
charged nanoparticles may be preferred for their greater tissue penetration a number 
of studies have shown that positively charged nanoparticles could actually reduce 
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systemic blood circulation times and so may actually hinder the nanoparticle from 
getting to the diseased site.30,31  
The size of the raspberry nanoparticles was also monitored with pH (Figure 2.4.8.3).  
It was found that the size of the raspberry nanoparticles displayed a slight reduction 
in size from acid to neutral pH however, once the nanoparticles were placed in a basic 
environment (pH >9) a large increase in particle size was observed, which is a strong 
indication of aggregation and instability. 
2.5.5    X-ray diffraction 
X-ray diffraction (XRD) is a technique used to measure the crystallinity of a material. 
Arrays of atoms are able to scatter x-rays primarily through their electronic 
configuration. Regular arrays of atoms produce regular arrays of scattering that result 
in a diffraction pattern. A typical XRD pattern from a crystalline material provides a 
unique “fingerprint” of the crystals present in the sample. When properly interpreted 
this fingerprint allows for identification of the crystalline material present. X-ray 
diffraction patterns were collected from the naked IONPs and the blackberry 
nanoparticles which confirm the presence of magnetic iron oxide (Figure 2.4.9.1). The 
addition of polymer to the formulation has little effect on the crystallinity of the IONPs. 
The average crystal size of the naked IONPs calculated by the Scherrer equation 
(Equation 2.5.5.1) was (8.8 ± 0.2) nm which is a very similar to the value obtained 
from TEM (8.4 ± 2.1) nm. 
   =
 .   
  /     
    (2.5.5.1) 
 
Where: Dp, average crystallite size; β, line broadening in radians; θ, bragg angle; 
λ, X-ray wavelength 
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X-ray diffraction (XRD) patterns from the raspberry nanoparticles and the 
hydrophobic IONPs (Figure 2.4.9.2) correspond to the patterns previously reported 
for super paramagnetic IONPs made via the high temperature thermal decomposition 
method.8,32,33 One noticeable difference observed is that some of the peaks are 
weaker in intensity resulting in some of the smaller peaks being lost in the 
background, most likely indicating the XRD is measuring a less crystalline material 
caused by the increase in oleic acid and polymer content which is amorphous is 
nature. The average crystal size of the hydrophobic IONPs calculated by the Scherrer 
equation was (3.6 ± 0.1) nm. The small decrease in measured size compared to TEM 
(4.8 ± 0.8) nm and could be due to the spin canting effect. The spin canting effect is 
the term given to a small, non-crystalline layer of iron oxide often found at the surface 
of IONPs.34 
2.5.6    Magnetic characterisation 
A super quantum interference device (SQUID) is an instrument used to measure 
small variations in magnetic field flux. A SQUID device usually comprises of a 
superconducting loop separated by a number of non-superconducting junctions 
called Josephson Junctions or weak links. As the temperature of the device is cooled 
to below the material’s Curie Temperature (Tc) all the material’s magnetic flux is 
expelled. When a current is delivered through the device the measured voltage 
oscillates, this oscillation is extremely sensitive to the magnetic flux passing through 
the loop. Consequently, any material that has an effect on the loop’s magnetic flux 
can be measured. A SQUID can be used to conduct a number of experiments but in 
this project it has been used to construct M-H curves or hysteresis loops. The 
magnetic behaviour of the newly created nanoparticles was investigated by collecting 
field dependant magnetization plots (M vs H plots). The magnetic characteristics of 
the nanoparticles is an important feature to understand as it is the magnetic 
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interaction with a proton relaxing back to the ground state that will fundamentally give 
contrast in an MRI procedure. Both the naked IONPs and the blackberry 
nanoparticles display superparamagnetic behaviour with no observable remnant 
magnetisation (Figure 2.4.10.1). This superparamagnetic behaviour means the 
nanoparticles will only become magnetised in the presence on an external magnetic 
field. The magnetic saturation of the naked IONP and the blackberry nanoparticles 
were found to be (73.3 ± 1.1) emu/g and (63.5 ± 1.3) emu/g, respectively. The small 
reduction in magnetisation is most likely due to the increase of the non-magnetic 
polymer within the sample which will contribute to the overall mass but not the 
magnetisation of the material.  
Both the hydrophobic IONPs and the raspberry nanoparticles display 
superparamagnetic behaviour with no observable remnant magnetisation (Figure 
2.4.10.2). The magnetic saturation of the hydrophobic IONPs was found to be (13.4 
± 1.9) emu/g. When comparing this result to the naked IONPs the hydrophobic IONPs 
have a much lower magnetic saturation which is most likely due to their smaller core 
size (5 nm compared to 8 nm for hydrophobic IONPs and naked IONPs, respectively) 
and the fact that the hydrophobic IONPs also contain a layer of non-magnetic oleic 
acid. The magnetic saturation of the raspberry IONPs were found to be (5.5 ± 0.3) 
emu/g. The reduction in magnetisation is most likely due to the increase in the non-
magnetic polymer within the sample. To get a direct comparison between the 
magnetic component of the nanoparticle systems, the amount of iron in the samples 
was measured and plotted against the magnetisation which yielded a magnetic 
saturation value of (29.6 ± 3.7) emu/g Fe and (33.8 ± 1.8) emu/g Fe for the 
hydrophobic IONPs and raspberry nanoparticles, respectively (Figure 2.4.10.3). The 
polymer modified raspberry nanoparticles do exhibit a small increase in magnetic 
saturation, however this result was not statistically significant (p >0.05) suggesting 
that encapsulation within the polymer micelle has little to no effect on the magnetic 
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behaviour of the IONPs. Overall both nanoparticle systems display 
superparamagnetic characteristics. The larger magnetic saturation observed for the 
blackberry nanoparticles over the raspberry nanoparticles is likely to be a result of the 
increased crystallinity of the IONPs (as shown in the X-ray diffraction data). Both 
nanoparticle formulations are appropriately magnetic making them potentially suitably 
candidates for MRI contrast applications.  
2.5.7    Relaxometry 
A fundamental property of any MRI contrast agent will be its ability to alter the spin-
lattice relaxation (r1) and their spin-spin relaxation (r2) of protons in their vicinity. To 
investigate the MRI contrast ability of the blackberry nanoparticles their r1 and their r2 
was measured as a function of iron concentration using a contrast agent analyser 
(minispec mq 60, Bruker, Germany) at 1.5T at 37 OC (Figure 2.4.11.1). Overall, there 
was good correlation between concentration and relaxivity resulting in an r1 value of 
13.9 µM-1 S-1 and an r2 value of 294.8 µM-1 S-1 hence, giving an r2/r1 of 21.1. Values 
of r2/r1 < 10 are generally considered to be positive contrast agents and r2/r1 >10 are 
typically considered to be negative contrast agents.35,36 This high r2/r1 value indicates 
that the blackberry nanoparticles are an effective negative contrast agent. When 
compared to commercially available negative contrast agents the blackberry 
nanoparticles have comparable relaxivity ratios and so could be considered to be just 
as effective for MRI contrast applications.  
To investigate the MRI contrast ability of the raspberry nanoparticles their r1 and their 
r2 was measured as a function of iron concentration using a 1T bench top MRI 
scanner (ICONTM, Bruker, UK) (Figure 2.4.11.2). Overall, there was good correlation 
between concentration and relaxivity resulting in an r1 value of 0.66 µM-1 S-1 and an 
r2 value of 51.8 µM-1 S-1 hence, giving an r2/r1 of 79.1. This high r2/r1 value indicates 
that an effective negative contrast agent has been created and is much larger than 
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any other commercially available negative contrast agent. As this was a unique result 
it was deemed necessary to investigate the effect of encapsulating the IONPs within 
a micelle further by measuring the IONPs in their single crystal form. This was 
achieved by coating the surface of the hydrophobic IONPs with dimercaptosuccinic 
acid (DMSA) via a ligand exchange procedure outlined by Palma et al.14 The 
DMSA.IONPs were colloidally stable in aqueous conditions and gave an average 
hydrodynamic size of 9 nm by DLS (Figure 2.4.11.3). When measured in the MRI 
scanner they gave an r1 value of 1.33 µM-1 S-1 and an r2 value of 3.99 µM-1 S-1 
therefore, giving an r2/r1 of 3.0 (Figure 2.4.11.4). This large reduction in the r2/r1 value 
suggests that the DMSA.IONPs are a much weaker negative contrast agent and 
possibly a more favourable positive contrast agent.13,35 The data suggests that by 
encapsulating the IONPs within a micellar architecture one is able to reduce the spin-
lattice relaxation and greatly improve the spin-spin relaxation. The reasoning behind 
these observations can be explained as follows; particles encapsulated within the 
polymeric micelle undergo the clustering effect, a well-documented phenomenon in 
which large clusters of packed IONPs are much more effective at generating magnetic 
field inhomogeneities and therefore, increase the spin-spin relaxation of the 
neighbouring water protons.37-39 The IONP’s ability to affect the spin-lattice relaxation 
is a less well understood mechanism although a compelling hypothesis is that 
encapsulation within the hydrophobic core of the micelle inhibits the water’s dipolar 
interactions with the paramagnetic iron ions, a key interaction in the mechanism of 
spin-lattice relaxation, overall reducing its effect.40,41 The data collected here shows 
that encapsulation within the polymeric micelle can greatly enhance the IONPs ability 
to act as a potent negative contrast agent.  
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2.6 Conclusions  
In conclusion, the chitosan based amphiphilic polymer N-palmitoyl-N-monomethyl-
N,N-dimethyl-N,N,N-trimethyl-6-O-glycolchitosan (GCPQ) has successfully been 
synthesized and characterised via NMR and GPC-MALLS. The amphiphilic nature of 
the polymer has caused it to form micelles of around 32 nm confirmed by TEM. Highly 
crystalline IONPs were successfully formed via chemical co-precipitation (c.a. 8 nm) 
and via high temperature thermal decomposition (c.a. 5 nm) which have given IONP 
products with very different properties. The naked IONPs made via chemical co 
precipitation were made colloidally stable in aqueous conditions by coating their 
surface with the GCPQ polymer, reducing their tendency to aggregate and sediment. 
These structures were dubbed ‘blackberry’ nanoparticles. The blackberry 
nanoparticles had an average size of 156 nm by DLS and were found to be positively 
charged in neutral conditions. XRD confirmed the presence of crystalline magnetic 
iron oxide and magnetometer experimentation found that the IONPs were still 
superparamagnetic even after modifying their surface with the polymer. Relaxometry 
found that the blackberry nanoparticles had a high r2 value of 294.8 µM-1 S-1 and an 
r2/r1 of 21.1 giving it a comparable relaxivity profile to a number of known commercially 
available IONP based negative MRI contrast agents.  
 
The hydrophobic IONPs were made colloidally stable in aqueous conditions by 
encapsulating them within a polymeric micelle (GCPQ) via a process of 
emulsification-evaporation that yielded highly ordered spherical nanostructures that 
were dubbed ‘raspberry’ nanoparticles. The size of the raspberry nanoparticle could 
be controlled by adjusting the ratio of IONP:polymer and had averages sizes between 
120 – 230 nm by dynamic light scattering. The polymer modified raspberry 
nanoparticles were found to be positively charged and displayed instability in highly 
157 
 
basic conditions. XRD confirmed that the raspberry nanoparticles contained 
crystalline magnetic iron oxide and from magnetometer experimentation it was found 
that the IONPs retained their superparamagnetism even after encapsulation within 
the polymeric micelle. MR experimentation has shown that encapsulating IONPs 
within this polymeric nanoparticle greatly enhances the r2 relaxivity and decreases 
the r1 relaxivity compared to the single crystals alone overall, giving an effective 
negative contrast agent (r2, 51.8 µM-1 S-1 and r2/r1, 79.1). The data presented in this 
chapter has shown that IONPs and GCPQ have been formulated into a stable 
polymeric nanoparticles using two distinctive strategies yielding very different 
nanoparticle structures. Both the blackberry nanoparticles and the raspberry 
nanoparticles have shown to be affective as a negative contrast agent for MR imaging 
applications. This said however, the only way to truly evaluate their suitability as an 
MRI contrast agent for biological applications will be through tougher in vivo 
investigations.     
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Chapter 3 
The In vivo Evaluation of Micellar Iron 
Oxide ‘Raspberry’ Nanoparticles for use 
as a Negative MRI Contrast Agent for 
Specific Cancer Diagnostics     
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3.1 Introduction  
Animal research has long been key to the development of new medicines and is 
widely considered a prerequisite before clinical studies may be performed in 
humans.1 In recent years, in vitro methods have become increasingly more 
sophisticated, but to get a complete understanding of complex interactions between 
chemical species in biological systems, an intact biological organism is often needed. 
This chapter explores a number of key biomedical questions that arise from using the 
iron oxide raspberry nanoparticles, as described in chapter 2, as a negative MRI 
contrast agent for in vivo applications by using animal tissues and fluids as a 
surrogate for their human counterparts. This chapter specifically evaluates the iron 
oxide raspberry nanoparticles and does not cover the blackberry nanoparticles. As 
covered in previous chapters, other attempts to encapsulate IONPs within a polymeric 
micelle have been attempted. Previous studies have often yielded impressive in vitro 
results but many have limited or no information regarding their biological stability or 
in vivo pharmacokinetic/pharmacodynamic characteristics.2-8 These kinds of studies 
can often be challenging as polymeric surfactant nanoparticles can be highly sensitive 
to pH, salts and protein adsorption leading to instability in biological environments.9 
In vitro stability testing in bio-relevant environments should be evaluated before 
animal work is conducted and these types of investigations will be covered in this 
chapter. 
 
Animal models can largely be divided into two categories; pharmacokinetics and 
pharmacodynamics.1 Pharmacokinetics is often conducted in animals to observe the 
absorption, distribution, metabolism, and excretion of medicines in the body 
(ADME).10 Through studying these processes one can gather information with 
regards to the raspberry nanoparticle’s regions of potential imaging interest and 
toxicity. Pharmacodynamic animal models can further be divided into the primary 
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effects of the medicine/diagnostic, which in this project will focus on the ability of the 
raspberry nanoparticles to act as a contrast agent and, the secondary effects or side 
effects of which, are usually the undesired toxic effects of the agent. This chapter will 
focus on evaluating the pharmacokinetics and the primary pharmacodynamics effects 
(MR imaging capability) of the raspberry nanoparticles.    
       
To fully evaluate their biomedical potential the iron oxide raspberry nanoparticles will 
also be tested against a cancer model. In vivo tumour models have been key to 
evaluating chemotherapeutic entities and over the years they have become 
increasingly advanced.11 In vitro testing allows one to understand the mechanisms 
and the specific nature of a new chemical entity and is preferred where possible but, 
as of yet, these in vitro experiments are an over simplification of the chemical biology 
of a tumour environment and do not act as an effective surrogate for a human 
response to a treatment. Flank tumour models are a widely used cancer model.12 A 
small amount of cancerous tissue is transplanted subcutaneously into a specific 
region, usually the flank, of a rodent. With the correct technique and the appropriate 
conditions the cancer cells will grow into full tumours within days or weeks. Flank 
tumours protrude from the surface of the host and so can easily be monitored 
throughout the experiment. Compared to alternative cancer models, flank tumour 
models are also relatively inexpensive and so are widely considered a good model to 
initially test the effectiveness of a cancer treatment.       
 
A tumour is typically characterised by the defective architecture of its vasculature, 
primarily to meet the nutrient and oxygen demands of the rapidly growing cells. This 
defective vasculature is comprised of irregularly shaped, poorly aligned epithelial cells 
that form ‘leaky’ fenestrations in the newly formed blood vessels.13 As a consequence 
it was soon discovered that macromolecules of appreciable size displayed 
preferential accumulation at tumour sites that exhibited this leaky vasculature.14 This 
167 
 
phenomenon was termed the enhanced permeation and retention (EPR) effect and 
since its discovery nanomedicines have aimed to exploit this feature to favourably 
deliver nanoparticles to the sites of malignant growth. Maeda et al, amongst others, 
conducted many of the early studies using this principle to preferentially deliver 
chemotherapeutic agents and over the years this theory has become a gold standard 
in cancer research with a number of widely used clinically available non-targeted nano 
drug products, Doxil® and DaunoXome®, rationalising their mechanism of action using 
the EPR effect.15-17 It is hypothesised in this project that the iron oxide raspberry 
nanoparticles will also display preferential tumour distribution and accumulation 
because of their nanosized nature. In this chapter a murine 4T1 breast cancer cell 
line was selected as they are widely regarded as an effective model to produce fast 
growing reproducible tumours on immunocompetent BALB/c mice.18  
 
This chapter will aim to evaluate a number of key areas concerned with the biomedical 
investigation of the iron oxide raspberry nanoparticles. In vitro stability experiments 
will continue on from chapter 2 and will now be studied in biologically relevant 
solutions. Pharmacokinetics will be investigated in a number of major organs 
including; blood, liver, spleen, brain, lungs, heart and kidneys. In vivo MRI imaging 
will be conducted and will be compared with a commercially available product in order 
to assess the raspberry nanoparticle’s imaging capability. Finally, in vivo 
investigations will be performed in a 4T1 sub-cutaneous flank tumour model in order 
to monitor their distribution, accumulation and imaging potential.  
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3.2 Materials  
Chemical  Purity  Supplier  
1,10-phenanthroline  >99.5% Sigma-Aldrich 
4T1 ATCC CRL-2539 cells   ATTC 
BALB/c mice Female Harlem/ Charles River 
Dextrose 20% Martindale  
EDTA microtainer   BD 
Ferucarbotran® (Resovist®) 52.2 mg/mL Meito Sangyo Co 
Fetal bovine serum  Gibco 
Hydrochloric acid 32% Fisher 
Hydroxylamine hydrochloride >99% Sigma-Aldrich 
Iron standard for ICP 1000 ppm Sigma-Aldrich 
FeCl2.4H2O 98% Sigma-Aldrich 
Isoflurane  Vetone  
PentojectTM (pentobarbitone)  20% w/v Animalcare 
Phosphate buffer saline  10X Gibco 
RPMI 1640 medium  Gibco 
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Chemical  Purity  Supplier  
Sodium acetate >99% Sigma-Aldrich 
Sodium chloride  >99.8% Fisher 
Sodium hydroxide >99% Sigma-Aldrich 
Trypan blue 0.4% Gibco 
Trypsin-EDTA 0.25% Sigma-Aldrich  
Wister rats Male Harlem 
Yttrium standard for ICP 1000 ppm Sigma-Aldrich 
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3.3 Methods 
3.3.1   Stability in biologically relevant solutions  
The iron oxide raspberry nanoparticle’s obtained from methods described in section 
2.3.5 were investigated for stability in; H2O, 0.9% NaCl, 1X PBS and 5% dextrose. 
Iron oxide raspberry nanoparticles were frozen and lyophilised to obtain a dry product 
and then dispersed in MilliQ water. Following this, the raspberry nanoparticles (2.5 
mL) were added to; H2O (2.5 mL), 1.8% NaCl (2.5 mL), 2X PBS (2.5 mL), 10% 
dextrose (2.5 mL), diluting each of the buffers by a factor of 2, and were incubated at 
37 OC. At various time points aliquots were removed, centrifuged (224 rcf, 10 min) 
and then the supernatant was analysed for iron content via the 1,10-phenanthroline 
iron quantification assay. Briefly; The supernatant (200 µL) was added to 4 M HCl 
(200 µL) and digested at 70 OC. In a sample vial; sodium acetate (450 µL, 125 mg/mL) 
and hydroxylamine hydrochloride (50 µL, 10 mg/mL) were added to the supernatant 
(200 µL) followed by the 1,10-phenanthroline (300 µL, 10 mg/mL) turning the sample 
bright red if iron was present. Sample vials were protect from light for 1 h and then 
measured using UV/VIS at 510 nm. The iron concentrations were determined based 
on a calibration curve made from iron(II) chloride tetrahydrate.   
3.3.2   Plasma stability  
Plasma stability was monitored by ICP-AES (Varian 720-ES, Agilent, UK) paired with 
an automatic sample preparation system (Varian SPS 3, Agilent, UK). Blood was 
obtained from male Wister rats (400-450 g, Harlem, UK), collected into microtainer 
tubes coated in EDTA (K3E Vacutainer, BD Biosciences, UK) and maintained on ice. 
Plasma was obtained as the supernatant after centrifugation of blood samples (252 
rcf, 10 min, 4 OC) and stored at -20 OC until used. Raspberry nanoparticles (2.5 mL) 
were added to rat plasma (2.5 mL), diluting the plasma by a factor of 2, and were 
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incubated at 37 OC. At various time points, aliquots were removed, centrifuged (224 
rcf, 10 min) and then the supernatant was analysed for iron content via ICP-AES. 
Briefly; the supernatant (300 µL) was added to 70 % HNO3 (300 µL) digested at 70 
OC. The digestant was diluted by a factor of 35 and then measured on an ICP-AES. 
The iron concentrations were determined based on a calibration curve made from an 
iron standard for ICP (TraceCERT, Fluka). 
3.3.3   Pharmacokinetics and biodistribution   
Female BALB/c mice were used (20-25 g, Harlem, UK). All experiments were 
performed under a UK Home Office Animal License and in accordance with local 
ethics committee rules. A suspension of the iron oxide polymeric raspberry 
nanoparticles (6.5 mg Fe/mL) were prepared in 5% dextrose, titrated to pH 6 using 
0.1 M NaOH and filtered through a 0.22 µm filter. The formulation was intravenously 
administrated via the tail vein (32.5 mg Fe/kg). At various time points animals were 
euthanized with PentojectTM (pentobarbitone sodium 20% w/v, 150 mg/kg) via 
intraperitoneal injection. Blood was immediately collected via cardiac puncture and 
collected into microtainer tubes coated in EDTA (K2E Vacutainer, BD Biosciences, 
UK). Various tissues were collected (liver, spleen, brain, heart, lungs and kidneys) 
and were thoroughly rinsed in 0.9% NaCl (50 mL) and then stored at -80 OC until they 
could be further analysed. The tissues were lyophilised, the dry weight was 
determined and an yttrium standard for ICP was added (50 µL, 1000 ppm, 
TraceCERT, Fluka). Dry tissue samples were degraded in HNO3 (70 %, 250 µL) for 1 
h at 70 OC, this was followed by the addition of H2O2 (200 µL) and the tissues were 
degraded for a further 1 h at 70 OC. The digestant was cooled, diluted 35 times and 
centrifuged (4032 rcf, 10 min) to remove any fatty residue. Samples were analysed 
using ICP-AES (Varian 720, Agilent, UK). The iron concentrations were determined 
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based on a calibration curve made from an iron standard for ICP (TraceCERT, Fluka) 
in 2% HNO3. 
3.3.4 In vivo MRI measurements  
T2 weighted MR images were collected using a 1T benchtop MRI scanner (ICONTM, 
Bruker, UK) at 37 OC. Iron oxide raspberry nanoparticles (5 mg Fe/kg) were 
administered via the tail vein and images were collected pre-treatment and 1 h post 
administration of the contrast agent. A multi-slice spin-echo pulse sequence with the 
following parameters; TE: 6-100 ms, TR: 1845 ms was used to collect axial and 
coronal images. Animals were anesthetised using isoflurane while the animal’s 
temperature was controlled via a heated bed and its respiration was monitored. All 
experiments were non-recovery and animals were euthanized via an overdose of 
isoflurane and death was confirmed via neck dislocation. The T2 relaxation was 
determined by curve fitting the echo times (TE) of each pixel in the image using 
MATLAB (Mathworks, UK). Commercially available Ferucarbotran (Resovist®) was 
also administrated and measured under the same conditions.   
3.3.5   4T1 cell culture   
4T1 (ATCC® CRL-2539TM) were maintained in RPMI 1640 medium (GlutaMAXTM, 
Gibco), supplemented with 10% fetal bovine serum incubated in a 5% CO2 
atmosphere at 37.5 OC. Fresh media was added every other day and cells were 
passaged (1/10) when they had reached 80-90% confluency using 0.25% trypsin-
EDTA (sigma, UK) as the dissociation reagent. A 4T1 cell growth curve was 
conducted as follows; once the cells had reached 80% confluency, they were 
detached and counted using a haemocytometer and trypan blue dye (Gibco, UK). The 
cells were then seeded into wells with a total surface area of 9.6 cm2 at a density of 
20,000 cells per well. At various time points the cells would be detached and counted 
using a haemocytometer.  
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3.3.6   4T1 flank tumour model    
4T1 cells were cultured in RPMI 1640 medium (GlutaMAXTM, Gibco), supplemented 
with 10% fetal bovine serum (FBS). 3-4 h before harvesting, the cell medium was 
replaced to remove any dead cells. To harvest the cells the medium was removed 
and the cells washed with 1X PBS before adding 0.25% trypsin-EDTA (Sigma, UK) 
to dissociate the cells from then plate. After incubating the cells for 4 min at 37 OC the 
cell suspension was diluted 10:1 with complete medium and the cells counted using 
a haemocytometer. The cells were then placed in a centrifuge (214 rcf, 4 min) to pellet 
the cells, the medium was discarded and the cells were washed twice with PBS (214 
rcf, 4 min). The cells were then suspended in FBS free medium at a density of 10 
x106 cells/mL and kept on ice. Female BALB/c mice were used (20-25 g, Charles 
River, UK). All experiments were performed under a UK Home Office Animal License 
and in accordance with local ethics committee rules. The animals were shaved using 
hair clippers around the site of injection. Tumour cells were allowed to warm to room 
temperature and injected (1 x 106 cells, 100 µL) into the lower flank of the mouse. 
Tumour size and mouse weight was continually monitored through-out the duration 
of the experiment. Experiments were conducted when the tumour had reached at 
least 100 mm3 which was measured using digital callipers and calculated using the 
formula; volume = (width)2 x length/2.  
3.3.7   Pharmacokinetic tumour study  
For the pharmacokinetic study A suspension of the iron oxide polymeric raspberry 
nanoparticles (6.5 mg Fe/mL) were prepared in 5% dextrose, titrated to pH 6 using 
0.1 M NaOH and filtered through a 0.22 µm filter. The formulation was intravenously 
administrated via the tail vein (32.5 mg Fe/kg). At various time points animals were 
euthanized with PentojectTM (pentobarbitone sodium 20% w/v, 150 mg/kg) via 
intraperitoneal injection. The tumour tissue and tissue from the opposite flank was 
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removed, thoroughly rinsed in 0.9% NaCl (50 mL) and then stored at -80 OC until 
further analysed via ICP-AES as described previously.  
3.3.8   In vivo MRI tumour study 
T2 weighted MR images were collected using a 1T benchtop MRI scanner (ICONTM, 
Bruker, UK) at 37 OC. Iron oxide raspberry nanoparticles (5 mg Fe/kg) were 
administered via the tail vein, images were collected pre-treatment and at various 
time points post administration of the contrast agent. A commercially available 
Ferucarbotran® was also administrated and measured under the same conditions.   
3.3.9   Statistical analysis  
Statistical analysis was performed via a one-way ANOVA test using IBM SPSS 
Statistics (IBM corp, Released 2016. IBM SPSS Statistics for Windows, Version 24.0) 
followed by an appropriate post-hoc test where necessary.  
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3.4 Results 
3.4.1   Stability in biologically relevant solutions   
 
 
  
Figure 3.4.1.1. Raspberry nanoparticle stability was investigated in various 
biologically relevant solutions at 37 OC (H2O, 1X PBS, 5% Dextrose, 0.9% NaCl). 
The iron content was monitored using the 1,10-iron phenanthroline assay. No 
significant difference to the controls was observed in any of the media tested 
suggesting good raspberry nanoparticle stability over the time period. Data are 
means ± s.d., n=3, (p <0.05, 1-way ANOVA, Tukey post hoc test).  
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3.4.2   Plasma stability  
 
 
  
Figure 3.4.2.2. Raspberry nanoparticle stability was investigated in 50% rat plasma 
at 37 OC. The iron content was monitored using ICP-AES. A significant change in 
iron content was observed over the time period indicating a slight nanoparticle 
instability in plasma. Results suggest that while the raspberry nanoparticles are 
not fully stable in plasma, retaining a colloidal stability of 66% over a 48 h period 
should be satisfactory for most biomedical applications. Data are means ± s.d., 
n=3, (p <0.05, 1-way ANOVA, Tukey post hoc test). 
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3.4.3   Pharmacokinetics and biodistribution 
 
 
 
 
 
Figure 3.4.3.1. Total iron concentration in the blood following the i.v. administration 
of iron oxide raspberry nanoparticles (32.5 mg/kg) via the tail vein in female 
BALB/c mice. Background levels of iron are indicated via the dashed line. Plasma 
half-life (t1/2) was 28.3 min. Data are means ± s.d., n=5.  
 
Figure 3.4.3.2. Total iron levels in the liver at various time points following the i.v. 
administration of iron oxide raspberry nanoparticles (32.5 mg/kg) via the tail vein 
in female BALB/c mice. Background levels of iron are indicated via the dashed 
line. Data are means ± s.d., n=5.  
 
178 
 
 
 
 
 
 
Figure 3.4.3.3. Total iron levels in the spleen at various time points following the 
i.v. administration of iron oxide raspberry nanoparticles (32.5 mg/kg) via the tail 
vein in female BALB/c mice. Background levels of iron are indicated via the dashed 
line. Data are means ± s.d., n=5.  
 
Figure 3.4.3.4. Total iron levels in the brain at various time points following the i.v. 
administration of iron oxide raspberry nanoparticles (32.5 mg/kg) via the tail vein 
in female BALB/c mice. Background levels of iron are indicated via the dashed 
line. Data are means ± s.d., n=5. 
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Figure 3.4.3.5. Total iron levels in the lung at various time points following the i.v. 
administration of iron oxide raspberry nanoparticles (32.5 mg/kg) via the tail vein 
in female BALB/c mice. Background levels of iron are indicated via the dashed 
line. Data are means ± s.d., n=5. 
 
Figure 3.4.3.6. Total iron levels in the heart at various time points following the i.v. 
administration of iron oxide raspberry nanoparticles (32.5 mg/kg) via the tail vein 
in female BALB/c mice. Background levels of iron are indicated via the dashed 
line. Data are means ± s.d., n=5. 
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Figure 3.4.3.7. Total iron levels in the kidney at various time points following the 
i.v. administration of iron oxide raspberry nanoparticles (32.5 mg/kg) via the tail 
vein in female BALB/c mice. Background levels of iron are indicated via the dashed 
line. Data are means ± s.d., n=5. 
 
Figure 3.4.3.8. A summary comparing 1 h and 24 h iron levels to control levels in 
various organs following the i.v. administration of iron oxide raspberry 
nanoparticles (32.5 mg/kg) via the tail vein in female BALB/c mice. Data are means 
± s.d., n=5 (significance = p <0.05, 1-way ANOVA, Tukey post hoc test).  
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3.4.4   In vivo MRI  
 
 
 
Figure 3.4.4.1. T2 weighted axial and coronal MRI images using the raspberry 
nanoparticles taken pre administration of the contrast agent (A and B) and 1 h after 
the administration of the contrast agent (a and b). Raspberry nanoparticles show 
distinct hypocontrast in the liver. Fine tissue structure of the liver, as well as, 
greater definition of the surrounding organs can be seen in the post contrast 
images using the raspberry nanoparticles.  
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Figure 3.4.4.2. T2 weighted axial and coronal MRI images using the commercially 
available Ferucarbotran® (Resovist®, Meito Sangyo Co) taken pre administration 
of the contrast agent (A and B) and 1 h after the administration of the contrast 
agent (a and b). Distinct hypocontrast effect is observed in the liver, spleen and 
the lungs. 
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Figure 3.4.4.3. A collection of T2 weighted MRI axial images comparing the 
contrast effect of the raspberry nanoparticles to the commercially available 
Ferucarbotran® in the chest, upper abdomen and the lower abdomen regions. 
Organs of interest are highlighted as follows; heart (red), lungs (blue), liver 
(yellow), spleen (green) and kidneys (pink). The raspberry nanoparticles and 
Ferucarbotran® gave hypointense contrast in the liver (b and II) and spleen (c and 
III) while, signal darkening was only intensely observed in the lungs with the 
Ferucarbotran® (I).  
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Figure 3.4.4.4. Comparison of the T2 weighted axial MRI images of the liver cross 
section using; (a), the raspberry nanoparticles and; (b), the commercially available 
Ferucarbotran®. Images were collected 1 h after the administration of the contrast 
agent. Both contrast agents display considerable darkening of the liver however, 
hepatic liver vessels can be seen in the post contrast images using the raspberry 
nanoparticles (arrowed).  
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Figure 3.4.4.5. T2 relaxation maps of; no contrast agent (A-C), raspberry 
nanoparticles (a-c) and Ferucarbotran® (I-III) in the chest, upper abdomen and the 
lower abdomen regions. Maps were collected 1 hour post administration with the 
contrast agent. The T2 relaxation was determined by curve fitting the echo times 
(TE) of each pixel in the image using MATLAB (Mathworks, UK). T2 mapping 
allows one to visualise and quantify the effect a contrast agent has on the 
relaxation of the protons in an MR experiment.  
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Figure 3.4.4.6. A summary of the effect on T2 relaxation times in various organs 
when using the raspberry nanoparticles compared to no contrast agent and the 
commercially available product Ferucarbotran®. Maps were collected 1 hour post 
administration with the contrast agents. The heart was unable to be mapped most 
likely due to movement from the beating heart during the experiment. Respiration 
was accounted for by gating the experimental procedure and as a result, show that 
the raspberry nanoparticles had no significant effect on the lungs unlike 
Ferucarbotran®, which did display a significant contrast effect in the region, the 
same relationship was observed in the kidneys. Both the raspberry nanoparticles 
and Ferucarbotran® gave significant signal reduction in the liver and spleen to a 
similar extent. Data are means ± s.d., (significance = p <0.05, 1-way ANOVA, 
Games-Howell post hoc test). 
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3.4.5   4T1 flank tumour model  
 
 
 
 
 
Figure 3.4.5.1. 4T1 growth dynamics, a typical sigmoidal curve is observed, which 
is composed of latency phase, exponential growth phase and a stationary phase. 
4T1 cells have a doubling time of 1.8 days.   
 
 
Figure 3.4.5.2. Pilot study for 4T1 flank tumour. Female BALB/c mice were injected 
with cancer cells in the right lower flank via a subcutaneous injection. The size of the 
tumour was monitored over the duration of experiment. Fully grown tumours (100 
mm3) could be grown within 7 days. The tumour associated with n=1 failed to take. 
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Figure 3.4.5.3. Pilot study for 4T1 flank tumour. Weight was monitored over the 
experiment as an indication of health.   
 
 
Figure 3.4.5.4. Pilot study for 4T1 flank tumour. Macro images of excised tumours. 
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3.4.6   In vivo tumour biodistribution 
 
 
  
Figure 3.4.6.1. In vivo 4T1 flank tumour distribution for the raspberry nanoparticles. 
Total iron levels in the tumour were measured by ICP-AES at various time points 
following the i.v. administration of iron oxide raspberry nanoparticles (32.5 mg/kg) 
via the tail vein in female BALB/c mice. Background levels of iron are indicated via 
the dashed line. No significant increase in iron levels was observed over the time 
period, indicating that no raspberry nanoparticles were being distributed or 
accumulated in the tumour tissue. Data are means ± s.d., n=5 (p <0.05, 1-way 
ANOVA). 
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Figure 3.4.6.2. Total iron levels were measured in muscle tissue from the opposing 
flank as a negative control. A small trend increase in iron concentration was 
observed in the early time points however, this small increase was not statistically 
significant. Data are means ± s.d., n=5 (p <0.05, 1-way ANOVA). 
Figure 3.4.6.3. Summary of the iron distribution levels in a flank tumour and the 
surrounding muscle tissue compared to their control levels following the i.v. 
administration of iron oxide raspberry nanoparticles (32.5 mg/kg) via the tail vein 
in female BALB/c mice. No significant amounts of raspberry nanoparticles entered 
the tumour tissue. Data are means ± s.d., n=5 (significance = p <0.05, 1-way 
ANOVA, Tukey post hoc test). 
 
191 
 
3.4.7   In vivo MRI tumour study  
 
 
 
Figure 3.4.7.1. T2 weighted MR images of a flank tumour over a 2 hour period after i.v. administration of the Ferucarbotran® (Resovist®, 5 
mg Fe/kg); (a), pre-contrast image; (b), 30 min; (c), 1 h and (d), 2 h. No distinctive hypointense contrast was observed in the tumour tissue 
at any time during the experiment.  
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Figure 3.4.7.2. T2 weighted MR images of a flank tumour over a 2 hour period following the i.v. administration of the raspberry nanoparticles 
(5 mg Fe/kg); (a), pre-contrast image; (b), 30 min; (c), 1 h and (d), 2 h. As with the commercially available Ferucarbotran®, the raspberry 
nanoparticles gave no distinct hypointense contrast in the tumour tissue over the time period suggesting the raspberry nanoparticles do 
not act as an effective MRI contrast agent for this type of disease model.   
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Figure 3.4.7.3. T2 relaxation maps of a flank tumour over a 2 hour period following the i.v. administration of the raspberry nanoparticles (5 
mg Fe/kg); (a), pre-contrast image; (b), 30 min; (c), 1 h and (d), 2 h. The T2 relaxation was determined by curve fitting the echo times (TE) 
of each pixel in the image using MATLAB (Mathworks, UK).  
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Figure 3.4.7.4. (a), A summary of the effect on T2 relaxation times in a flank tumour 
over a 2 hour period following an i.v. administration of the raspberry nanoparticles 
and (b), increased scale to highlight the significant change in relaxation time over 
the time period. A significant change in relaxation time was observed between the 
pre-contrast and post-contrast maps. This could be evidence for small levels of 
raspberry nanoparticles accumulating in the tumour tissue, however this difference 
was so small it had no effect on the overall contrast in an MR image to a human 
observer. Data are means ± s.d. (significance = p <0.05, 1-way ANOVA, Tukey 
post hoc test). 
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3.5 Discussion  
3.5.1   Stability in biologically relevant solutions 
Colloidal stability remains a critical parameter for nanoparticle systems that are to be 
used within a biological environment. In the previous chapter it was established that 
the iron oxide raspberry nanoparticles did have suitable colloidal properties in pure 
water conditions over 90 days, however the chemical environment of the human body 
is far more complex than merely a pure water system.19 Where possible, in vitro 
stability testing should be performed to establish the suitability of a nanoparticle under 
more specific conditions. Unfortunately, studies like these can be challenging as 
polymeric surfactant based nanoparticles can often be highly sensitive to pH, salts 
and protein adsorption leading to stability issues within biological environments.9,20 
Not only could stability issues diminish the quality and effectiveness of the product, it 
could also lead to unexpected side effects; for example intravenously administered 
suspensions that contain particles >5 μm could lead to capillary blockage, reduced 
blood flow and result in embolism.21,22 Colloidal stability was monitored in various 
biological relevant solutions at 37 OC and analysed by measuring the iron 
concentrations in the formulations using the 1,10-phenanthroline iron quantification 
assay (Figure 3.4.1.1). The 1,10-phenanthroline iron quantification assay is a method 
used to determine iron concentration. In the presence of iron in its +2 oxidation state, 
the 1,10-phenanthroline ligand is able to form the complex [Fe(phen)3]2+, more 
commonly known as ferroin, and upon complexation a bright red colour is observed 
that can easily be measured using UV/VIS spectroscopy.23 Formation of ferroin is 
highly dependent on its chemical environment especially, oxidation state, pH and 
competitive binding ligands. The 1,10-phenanthroline ligand does not form the 
brightly coloured ferroin complex with iron in the commonly found +3 oxidation state 
and so a reducing agent such as hydroxylamine hydrochloride is used to confirm that 
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iron is only present in its reduced form. All assays were performed using a sodium 
acetate buffer in order to control pH. One must appreciate that measuring iron present 
in the supernatant does not directly indicate the presence of intact iron oxide 
raspberry nanoparticles, however when evaluating colloidal stability, it is widely 
considered that nanoparticles that are not stable have a strong tendency to flocculate 
increasing their mass considerably and in turn, causing sedimentation or creaming.22 
This understood, measuring iron concentration in the supernatant (after a 
centrifugation process) is a good indication that the nanoparticles are colloidally 
stable in their environment. Water was selected as a positive control, physiological 
concentration of isotonic saline (0.9% NaCl (w/v), 5% dextrose and phosphate buffer 
saline (1X PBS, pH 7.4) were believed to be a good selection of media to test the 
effects of salt screening, pH and osmotic pressures on the stability of the 
nanoparticles. It can be seen form Figure 3.4.1.1 that the raspberry nanoparticle 
formulations retain their colloidal stability over the 48 h period in all solutions. This 
strongly indicates that the raspberry nanoparticles should be suitably robust under 
physiological conditions.  
3.5.2   Plasma stability 
Although the biologically relevant solutions can give a good indication to the stability 
of the raspberry nanoparticles in biological environments, they are an over 
simplification and do not fully represent the complexity of biological fluids. The blood 
and blood vasculature is important for the delivery of drugs and diagnostic contrast 
agents and as the raspberry nanoparticles will most likely be intravenously 
administrated, it was thought necessary to measure their stability in blood plasma. 
Blood plasma is the liquid component of the blood which makes up about half of the 
blood volume. Plasma is devoid of the red and white cellular material and contains an 
array of proteins and electrolytes that are critical for healthy human function. Plasma 
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protein adsorption and charge screening from electrolytes pose considerable stability 
challenges when formulating a polymeric nanoparticle for biomedical purposes.24 In 
this study the stability of the raspberry nanoparticles was investigated in 50% rat 
plasma via inductively coupled plasma – atomic emission spectroscopy (ICP-AES) as 
the 1,10-phenanthroline iron quantification assay did not work with biological samples 
(Figure 3.4.2.2.). A reasonable hypothesise is that ions or proteins within the blood 
samples may have competitively bound with the iron(II) or 1,10-phenanthroline 
ligands rendering the assay completely useless. ICP-AES is an analytical technique 
used for the detection of trace elements. A superheated gas cloud of charged 
particles is used to dissociate the sample into its constituent atoms or ions, exciting 
them to a higher energy level. As they return to their ground state they emit photons 
of a characteristic wavelength depending on the element present. This technique was 
found to be the most appropriate method for measuring iron content in the biological 
samples. Naturally, plasma samples do contain endogenous levels of iron and so 
background levels were always carefully monitored and subtracted from any data 
collected. The iron oxide raspberry nanoparticles had satisfactory plasma stability 
retaining stabilities of; 92%, 70% and 66% after 1 h, 24 h and 48 h, respectively. 
Overall, this was an extremely favourable result for a polymeric nanoparticle system 
in plasma and should be suitable for most biomedical applications.  
3.5.3   Pharmacokinetics and biodistribution 
To determine the in vivo biodistribution of the raspberry nanoparticles, various tissues 
(blood, liver, spleen, brain, lung, kidney and heart) were collected at various time 
points and the iron content measured using ICP-AES following tail vein injection into 
female BALB/c mice. A large dose at 32.5 mg Fe/kg was administrated in order to 
distinguish IONP iron levels from endogenous iron levels found in the blood and 
organs. By taking the average blood volume in a 20 g mouse to be 2 mL it can be 
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calculated that by the first 15 min time point 61% of the injected dose was present in 
the blood (Figure 3.4.3.1). After this point iron levels continued to decay and by the 1 
h time point 43% of the injected dose was present in the blood. By the 8 h time point 
iron levels had reached background concentrations. Overall, the raspberry 
nanoparticles have a blood half-life (t1/2) of 28.3 min. Literature findings report 
considerably varied IONP blood half-lives, typically ranging from several minutes to 
several hours, although some have been detected in the blood for longer.25 This high 
variation in IONP half-life is often attributed to the engineered parameters of size, 
charge and surface coating of each IONP system under examination. As expected, 
the longer half-lives are often observed for PEGylated systems (t1/2, 61–91 min in 
mice species), however the raspberry nanoparticles seem to compare quite 
favourable to a number of the dextran IONPs (t1/2, 5–60 min in mice species).26,27 The 
large dose administrated must also be considered, this was carried out in order to 
distinguish between endogenous levels of iron and the iron from the IONPs. However 
one study by Levy et al concluded that they may have observed IONP saturation 
within the spleen and, if this is the case, then one might expect to see longer blood 
circulation times of the nanoparticles under investigation.28 A comprehensive 
summary of IONP blood half-lives can be found in a review by Arami et al.25  
Over time, the data suggests that raspberry nanoparticles accumulate in the liver and 
spleen (Figure 3.4.3.2 and 3.4.3.3). By taking the average dry liver weight in a 20 g 
mouse to be 0.2 g and its dry spleen to be 30 mg it can be calculated that by the first 
15 min time point, 23% of the injected dose is present in the liver and 11% of the 
injected dose is present in the spleen. By the 1 h time point this increases to; 41% in 
the liver and 15% in the spleen. Accumulation in the liver and spleen is widely 
considered the most common elimination pathway for IONP systems and is most 
likely as a result of the first pass effect in which the nanoparticles accumulate in the 
macrophage rich filter like tissues of these organs. The liver is comprised of sinusoidal 
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endothelial cells which have a sieve like nature and contain fenestrations that range 
between 100-200 nm.29 This fenestrated tissue can easily filter out macromolecules 
of appreciable size and is a major challenge when designing long circulating 
nanoparticles. As the raspberry nanoparticles have an average hydrodynamic 
diameter of 190 nm many of these particles could simply be mechanically filtered out 
by the liver organ. The tissue of the liver is also lined with kupffer cells. These cells 
are highly effective at quickly phagocytizing the nearby IONPs from the blood.30,31 
Due to the high rate of IONP accumulation in the liver, past research has focused on 
using IONP as a negative MRI contrast agent for the detection of liver diseases with 
the majority of early clinical trials and commercially available products focusing in this 
area. The spleen can be divided into three key tissue types: The white pulp which, is 
responsible for the production of B and T lymphocytes; the red pulp which, is 
comprised of highly porous sinusoids which mechanically filter the blood as it enters 
the spleen and, the marginal zone which is lined with macrophage rich tissue.32 Not 
surprisingly, studies have reported that IONPs often rapidly accumulate in the red 
pulp and the marginal zones of the spleen as the nanoparticles are filtered out by 
fenestrated venules and collected by the macrophages.33,34 Several animal and 
clinical experiments have been performed predominantly focusing on the detection of 
spleen lesions using IONP contrast agents.35 The iron oxide raspberry nanoparticles 
appear to adhere to the standard model and quickly accumulate in the liver and 
spleen reaching saturation in these organs by the 30 min time point. The iron 
concentrations stay at elevated levels throughout the duration of the 48 h experiment 
which is consistent with other studies that have reported increased levels of iron up 
to several days to weeks after treatment.28,36-38     
There was no increase in iron concentration in the brain (Figure 3.4.3.4). This is most 
likely due to the highly effective blood brain barrier (BBB), a naturally occurring 
defence system which is made up of tightly packed endothelial cells that form highly 
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restrictive tight junctions designed to keep macromolecular toxins from entering the 
brain.39 Studies showing IONPs reaching the brain tissue via parenteral 
administration do exist for example some recent studies include: Kim et al who found 
their silica coated nanoparticles were distributed to the brain while keeping the BBB 
intact and Raut et al learnt that by placing a magnetic field near the brain they could 
obtain preferential accumulation at the site.40,41 Furthermore, Veiseh et al managed 
to deliver their protein targeted polyethylene glycol–grafted chitosan copolymer IONP 
to brain tumours while also keeping the BBB intact.42 Although these seem like 
promising examples of IONP brain delivery, these discoveries are not common and 
their mechanism of transport through the BBB still needs to be investigated. A key 
advantage of IONPs not accumulating in the brain is that in recent years, scientists 
have found links between increased deposits of iron in the brain and 
neurodegenerative diseases such as Alzheimer’s.43,44 The causative link still needs 
investigating, however the case could be made that there is very little risk of these 
types of adverse effect with the raspberry nanoparticles.          
A considerable iron increase was detected in the lungs however this was cleared after 
4 h (Figure 3.4.3.5). In this case the increase in iron is most likely due to the raspberry 
nanoparticles being present in the blood at these moments. In other studies, IONPs 
have been found in the lungs and this is often attributed to the lung’s large vasculature 
combined with the presence of macrophage rich tissue in the alveoli.45,46 Although 
there is a severe need to treat and identify chronic obstructive pulmonary diseases, 
their detection using a T2 weighted IONP enhanced MRI images does pose a 
challenge due to lungs often being characterised by their distinct lack of an MRI 
signal. This said, it would still be an effective route for therapeutic intervention if drug 
loaded IONPs did display preferential accumulation in the lung tissue.47    
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The heart did exhibit an increase in iron in the early time points and this is probably 
due to the raspberry nanoparticles being present in the blood at these moments 
(Figure 3.4.3.6). Creating agents that target the heart is of high importance as 
myocardial infarction remains a leading cause of death and disability. In a study by 
Chapon et al they found that their dextran-IONPs did show higher contrast between 
healthy and ischemic myocardium and since then, two clinical studies have also 
shown Ferumoxytol® (Feraheme®) to produce hypo-enhancement in infarcted left 
ventricular walls.48,49 Mechanistically, it is understood that ischemic injury in the heart 
triggers a release of macrophages to aid with the wound healing process and it is 
these extra macrophages that are responsible for the accumulation of IONPs in the 
damaged heart tissue.25   
The kidneys also revealed a small increase in iron concentration in the early time 
points and this is also probably due to the raspberry nanoparticles being present in 
the blood at these time points (Figure 3.4.3.7). Like the liver and spleen, the kidneys 
are also reported to have filter like properties however, its filtering capacity is usually 
reserved for particles that are much smaller (<10 nm), as a result the raspberry 
nanoparticles are probably too big to demonstrate any renal filtration.50 No adverse 
effects were observed in any of the animals in this experiment, even, when the 
administered dose was several fold higher than that needed for MR imaging. Overall 
from the findings presented here, one could speculate that shorter MRI scan times 
using this contrast agent would best serve to image whole body pathological 
conditions, whereas longer scan times would be preferential for imaging organs of 
the reticuloendothelial system such as the liver and spleen. 
3.5.4   In vivo MRI 
To evaluate the imaging potential of the raspberry nanoparticles, in vivo MR imaging 
was conducted using a 1T bench top MRI scanner (ICONTM, Bruker, UK). Raspberry 
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nanoparticles (5 mg Fe/kg) were injected into the tail vein of female BALB/c mice. 
Pre-treatment and 1 hour post injection T2 weighted coronal and axial maps were 
collected (Figure 3.4.4.1). Noticeable hypointense contrast was observed in the liver 
to the extent where hepatic liver vessels became apparent.51 The portal vein also was 
clearly visible in post contrast images. The benefit of having large contrast in the liver 
region is that many of the surrounding organs became easy to identify, most notably 
the kidneys which were often hard to distinguish from the liver in the pre-treatment 
images. Negative contrast was also observed in the spleen region. The data 
presented here corresponds nicely to the data collected from the pharmacokinetic 
data with most of the image darkening being observed in the liver and spleen. To 
assess the raspberry nanoparticle’s clinical relevance, a commercially available IONP 
negative contrast agent Ferucarbotran® (Resovist®) was also measured (Figure 
3.4.4.2). As predicted, darkening of the liver was also observed, however many of the 
hepatic liver vessels witnessed with the raspberry nanoparticles were not seen with 
Ferucarbotran®. Additionally, Ferucarbotran® displayed considerably more image 
darkening in the lungs which was not observed with the raspberry nanoparticles 
(Figure 3.4.4.3). Overall, the data presented here shows that the raspberry 
nanoparticles are more effective at highlighting fine vessel structure of the liver when 
compared to the commercial system (Figure 3.4.4.4). The reason why these hepatic 
liver veins are visualised with the raspberry nanoparticles and not the commercially 
available Ferucarbotran® could be associated with the size of the nanoparticle under 
investigation. The raspberry nanoparticles and Ferucarbotran® have average 
hydrodynamic sizes of 190 nm and 50 nm, respectively. After injection into the blood 
vasculature system, smaller sized Ferucarbotran® nanoparticles have the ability to 
penetrate and infiltrate the fenestrated sieve like tissue of the liver to a greater extent 
than the larger raspberry nanoparticles. The leaves areas surrounded by densely 
packed endothelial cells protected from the raspberry nanoparticles and therefore do 
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not appear hypointense in the resulting MR image, unlike Ferucarbotran® which is 
small enough to penetrate these areas.  
To be able to quantify the effect the raspberry nanoparticles had on the T2 relaxivity 
in the various tissues, T2 relaxivity maps were collected and compared to 
experiments using no contrast agent and Ferucarbotran® (Figure 3.4.4.5). Maps were 
collected 1 hour post administration with the contrast agent. The T2 relaxation was 
determined by curve fitting the echo times (TE) of each pixel in the image using 
MATLAB (Mathworks, UK). A summary of the T2 relaxation times of specific regions 
of interest (lungs, liver, kidney and spleen) can be seen in Figure 3.4.4.6. The heart 
could not be mapped accurately as it gave a large variation in the results collected, 
this was most likely due to movement from the beating heart during the experiment 
which would have taken several seconds to acquire for each slice. Respiration was 
accounted for by gating the experimental procedure and as a result, show that the 
raspberry nanoparticles had no significant effect on the lungs unlike Ferucarbotran®, 
which did display a significant effect on relaxation time in the region. The same 
relationship was observed in the kidneys. Both the raspberry nanoparticles and 
Ferucarbotran® gave significant effects on relaxivity in the liver and spleen to a similar 
extent. Overall this data signifies an overall difference between the raspberry 
nanoparticles and the commercially available Ferucarbotran®; at the 1 hour time point 
both species can be used to give hypointense MRI contrast in healthy liver and spleen 
tissue, however the raspberry nanoparticles do not affect other organs such as the 
lungs and kidneys making them somewhat more selective in their organ imaging. 
IONPs have been used to image organs of the reticuloendothelial system for a 
number of years, however their popularity has decreased considerable with many of 
the original IONP MRI liver imaging contrast agents having been withdrawn from the 
market. This has largely been attributed to their lack of specificity to a disease target. 
The work presented here shows that the iron oxide raspberry nanoparticles can be 
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used for imaging in biological environments, especially in the liver and spleen without 
any of the other regions or organs being involved. However their true success will be 
measured upon their specificity towards a disease target and the extent to which they 
are useful for the diagnosis of liver and spleen diseases, such as liver cirrhosis, 
splenic rupture and cancer.      
3.5.5   Tumour modelling  
In this project a tumour study was established to investigate the iron oxide raspberry 
nanoparticles’ ability to distribute and accumulate into tumour tissue. The 
experimental hypothesis was that distribution and accumulation of non-targeted 
nanoparticles would be driven by the enhanced permeability and retention (EPR) 
effect. This is a well-documented effect where particles of appreciable size display 
preferential accumulation in tumour tissue by exploiting the leaky vasculature of the 
rapidly growing mass of cells. In this study a murine 4T1 breast cancer cell line was 
selected as it is widely regarded as one of the best models to produce fast growing 
reproducible breast tissue tumours in immunocompetent BALB/c mice.52 When 
inoculated into breast tissue, 4T1 cells are known to rapidly progress into a lethal 
disease quickly spreading to the liver, lungs, bone and brain, making this cell line a 
good model for late stage metastatic breast cancer.53 Unlike many other flank tumour 
models, 4T1 cells can be implemented into non-immunocompromised BALB/c mice. 
Finding cells lines that can be used on immunocompetent species is considered 
significant as the immune system is often a key defence mechanism in the body’s 
fight against a foreign species like a drug or imaging agent. Most tumour models are 
conducted in immune deficient nude mice in order to allow human tissues to be 
grown, however removing the immune system may introduce a significant 
discrepancy into the model that does not translate to typical cancer patients who often 
will have immune function. In this project it was found that 4T1 cell cultures grew 
rapidly and aggressively giving a doubling time of 1.8 days (Figure 3.4.5.1). 4T1 
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growth dynamics followed a typical sigmoidal curve, which is composed of latency 
phase, exponential growth phase and a stationary phase. In vivo pilot studies were 
conducted in order to establish a reasonable protocol and understand the growth 
progress of the 4T1 tumour cells. Female BALB/c mice were injected with cancer cells 
in the right lower flank via a subcutaneous injection. The size of the tumour was 
monitored over the duration of the experiment using digital callipers (Figure 3.4.5.2).54 
Fully grown tumours (100 mm3) could be grown within 7 days. Injecting 2 x106 cells 
displayed more variation than injecting 1 x106 cells as, n=1 failed to take in the same 
manner. There appears to be little difference between the growth rate of injecting 2 
x106 cells and 1 x106 cells (excluding n=1). Weight was monitored over the 
experiment as an indication of health (Figure 3.4.5.3). n=1 in the group that was 
inoculated with 2 x106 cells was the only animal to lose weight over the experiment 
however, it was still within the 15% deviation from initial weight. All other animals 
gained weight over the experiment indicating satisfactory health. Tumours were 
excised at the end of the pilot experiment revealing that solid tumours had developed 
at the site of injection that were spherical and homogenous in nature (Figure 3.4.5.4). 
In conclusion to the pilot study, 1 x106 cells were used to inoculate mice in further 
studies as this produced good tumours and had a higher take rate than using 2 x106 
cells.  
3.5.6   In vivo tumour biodistribution and MRI  
The raspberry nanoparticles were evaluated for their specificity towards a disease 
target by performing an in vivo biodistribution experiment. 4T1 flank tumours were 
developed by subcutaneously injecting 1 x106 cells into the lower right flank of BALB/c 
female mice. All the mice developed homogenous tumours as expected confirming 
the robustness of the 4T1 model. As previously used, a large dose at 32.5 mg Fe/kg 
was administrated and at various time points tissues were collected and analysed via 
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ICP-AES (Figure 3.4.6.1). Tissue was collected from muscle in the left flank to act as 
a negative control (Figure 3.4.6.2). It was found that no increase in iron levels was 
observed in the tumour tissue at any time point. Although a disappointing result it was 
thought that investigating this result further could be beneficial.  
In vivo MRI tumour investigations were conducted on the raspberry nanoparticles 
using Ferucarbotran® as a control. As predicted Ferucarbotran® did not accumulate 
in the tumour over a 2 h duration (Figure 3.4.7.1). Resovist® has been used to 
diagnose liver carcinoma, however it does so by accumulating in healthy liver tissue 
consequently, reducing its signal and highlighting the regions of disease. Using the 
Molecular Envelope Technology (GCPQ) to create a positively charged nanoparticle 
it was predicted that the raspberry nanoparticles would overcome the challenges 
faced by the mononuclear phagocyte system (predominantly the liver and spleen) 
and accumulate in the tumour tissue as a result of the EPR effect. Raspberry 
nanoparticles were injected into BALB/c mice at a concentration of 5 mg Fe/kg and 
monitored over 2 h via MRI (Figure 3.4.7.2). Results show that no signal darkening 
was observed in the flank tumour over the 2 h period. These results correlate well 
with the ICP-AES tumour biodistribution data. T2 relaxation maps of a flank tumour 
were also collected over a 2 hour period (Figure 3.4.7.3 and Figure 3.4.7.4). The 
results indicate there was a small significant reduction in relaxation time between the 
pre-contrast and post-contrast experiments. This could be evidence that small 
amounts of raspberry nanoparticles are accumulating in the tumour tissue and overall 
slightly reducing its relaxation time, however in conclusion, this effect is so small it 
has no effect on the overall MR image to a human observer. These results suggest 
that in this 4T1 flank tumour model the raspberry nanoparticles do not act as a good 
diagnostic agent for the detection of tumour tissue.        
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When considering results such as the ones above, evaluating the limitations of these 
complex experiments should be discussed. The Alliance for Nanotechnology in 
Cancer recently published that to evaluate the EPR effect, sub-cutaneous flank 
tumour xenografts were thought to offer limited value as these types of tumours did 
not often translate well into human diseases.55 In addition to this, the National Cancer 
Institute (NCI) screening programme has stated, the activity of an agent in vitro did 
not predict the activity in subcutaneous flank xenograft models, which in turn did not 
predict for the activity against clinical cancer.56,57 The use of flank tumour animal 
models as a predictive tool for the performance of cancer treatments in patients has 
been extensively debated in recent years. Defining the optimal cancer model to 
evaluate the activity of a drug or imaging agent still remains an elusive goal for 
oncologists to this day. This said, it is still widely considered that the flank tumour 
model is a useful experiment and its success can be significantly increased by 
selecting and culturing a tumour with similar factors that resemble the disease that 
one aims to mimic. Factors that have considerable effects on the tumour model 
include: tumour volume, type of tumour, location, nature of the vasculature and the 
surrounding stroma and macrophage infiltration. The 4T1 cell line may model the 
effect of late stage breast cancer very well however, its microenvironment may not be 
suitable to study the EPR effect with this type of nanoparticle. In future it would be 
wise to understand the micro environment of the 4T1 flank tumour; physically, using 
microscopy, histochemical procedures and size exclusion experimentation using high 
molecular weight dyes and; chemically, by evaluating and quantifying the 
biochemistry at the tumour site. When considering the above result one should also 
reflect on the blood half-life (t1/2). In the seminal work of Matsumura and Maeda they 
claimed that a nanoparticle must be in systemic circulation for several hours before 
nanoparticle can be influenced by the EPR effect.14,15 Upon reflection the raspberry 
nanoparticle’s t1/2 of 28.3 min may not be long enough for it to take advantage of the 
EPR effect and hence, provides evidence to support the standard theory.  
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On all accounts a number of passively targeted IONP entities have been shown to 
accumulate in tumour tissues for example; Moore et al was successfully able to obtain 
contrast in their gliosarcoma rodent model using a dextran-IONP.58 Laresen et al 
showed tumour uptake in their silane anchored PEGylated IONP in a flank tumour 
model while Park et al have had success delivering their non-targeted dextran based 
IONP nanoworms.59,60 A number of other examples exist however, relative to the 
magnitude of IONP research, the author believes that evidence of passively targeted 
tumour nanoparticles is not overly abundant with the majority relying on dextran and 
PEGylated systems to provide the stealth surface coating needed to evade the 
reticuloendothelial system.61,62 In recent years, one strategy used to increase the 
specificity and delivery of a nanoparticle to a diseased site is by a practise known as 
active targeting. It is widely known that cancers often display an overexpression of 
biological markers and receptors and so by anchoring a targeting ligand to the outer 
sphere of the nanoparticle one may improve its affinity to a specific target.63,64 Many 
innovative methods have been used to target IONPs to disease sites including the 
surface modification using; folate like molecules, peptides, proteins, antibodies and 
aptamers. A comprehensive summary of active targeted IONPs can be found in a 
recent review by Rosen et al.65 This said however, one cannot simply rely on active 
targeting as there are a number of examples in the literature where active targeting 
has had little to no effect on IONP tumour accumulation. NDong et al found their 
monoclonal antibody targeted IONP showed great promise through extensive in vitro 
testing, however failed to display any significant tumour uptake in their animal 
models.66 This is because the biological environment of an animal is incredibly 
complex and nanoparticles are often subjected to a range of biochemical processes.  
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3.6 Conclusions  
In conclusion, this chapter has conducted a number of pre-clinical experiments to 
evaluate the effectiveness of the iron oxide raspberry nanoparticles as an MRI 
contrast agent. Results demonstrate that the iron oxide raspberry nanoparticles have 
good colloidal stability in a range of biologically relevant solutions (H2O, 0.9% NaCl, 
5% dextrose and 1X PBS) and display adequate stability in blood plasma. 
Pharmacokinetic studies have shown that the nanoparticles have a blood half-life of 
28.3 min and quickly accumulate in the liver and spleen. The raspberry nanoparticles 
are also distributed to the lungs, heart and kidneys, however they do not accumulate 
in these organ tissues, no nanoparticle distribution or accumulation was observed in 
the brain. In vivo MRI studies show that these nanoparticles do act as effective MRI 
contrast agent in the liver and spleen and when compared to the commercially 
available product, they appear to make it easier to visualise the fine vesical structure 
of the liver and its surrounding organs. To evaluate the iron oxide raspberry’s 
specificity towards a disease target an in vivo tumour model was conducted. A murine 
4T1 breast cancer cell line was cultured and subcutaneously injected into the lower 
flank of BALB/c mice at a concentration of 1 x106 cells per animal. Fully grown flank 
tumours (100 mm3) could be grown on healthy mice within 7 days. Iron oxide 
raspberry nanoparticles were injected into tumour bearing mice, however a 
pharmacokinetic study showed no nanoparticle accumulation at the tumour site. This 
result was later confirmed by conducting in vivo MRI experiments which also gave no 
observable hypointense contrast at the tumour site. T2 relaxation maps may have 
indicated a small change in relaxivity after contrast agent administration however, it 
was not large enough to produce any meaningful contrast effect in an MR image. 
Using a 4T1 sub-cutaneous flank tumour, the raspberry nanoparticles do not appear 
to be a good candidate for MRI tumour diagnostics. Future work would be to evaluate 
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the raspberry nanoparticles on alternative tumour models to validate these results 
and in addition to this, consider strategies to PEGylate or anchor an active targeting 
ligand to the outer sphere of the nanoparticle to improved tumour distribution and 
penetration. Overall, the iron oxide raspberry nanoparticles proved to give good 
contrast in the liver but their true success will rely on their specificity towards a disease 
target.   
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Chapter 4 
Encapsulation Strategies for Poorly 
Soluble Anticancer Drugs within Micellar 
Iron Oxide Nanoparticles          
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4.1 Introduction  
A key challenge in this project was to design a theranostic nanoparticle platform to 
investigate if the simultaneous visualisation and treatment of a medicine would 
improve the effectiveness of a cancer treatment. The previous chapters have focused 
on the imaging element of the nanoparticle platform. This chapter outlines the efforts 
to investigate the therapeutic element. Chemotherapy using small molecule drugs 
has been considered a front line strategy for the treatment of cancer since the 1950s.1 
These small molecule entities are highly effective at providing a lethal package to 
cancer cells, however they are often limited by; poor solubility in aqueous 
environments, low bioavailability and a lack of disease specificity usually leading to 
off target side effects.2,3 Scientists have attempted to overcome many of these 
challenges by incorporating anticancer drugs within a polymer matrix. It was 
envisaged from the conception of this project that the GCPQ technology would 
provide a good strategy for encapsulation of IONPs and a hydrophobic drug. By 
adding a magnetic component to an anticancer drug one can open the therapeutic to 
several pathways that may prove to be advantageous in the treatment of cancer: 
Firstly, one now has the ability to visualise the drug in vivo using the non-invasive 
technique of MRI, a strategy extensively studied in this body of work. Secondly, an 
element of specificity may be added, as the drug may now be magnetically guided to 
the site of disease by an external magnetic field and lastly, local heating may be 
induced by applying an alternating magnetic field. This chapter will explore methods 
for small molecule drug encapsulation within the magnetic iron oxide raspberry 
nanoparticles.               
In this chapter three drugs were investigated: 
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Lomustine is a highly hydrophobic nitrosourea alkylating agent (<0.5 mg/mL at 25 OC) 
which has traditionally been used to treat glioblastoma.4 Under physiological 
conditions lomustine decomposes into several intermediates, the most significant 
being a 2-chloroethyl carbonium ion, a highly reactive species that readily undergoes 
DNA alkylation and crosslinking, a lethal process that inevitably results in cell death.5-
7 Lomustine is sold under the tradename CeeNU® and has been approved for use to 
treat glioblastoma since 1976.  
 
 
Paclitaxel is a diterpenoid first isolated from the bark of the Pacific Yew (Taxus 
brevifolia) and was found to stabilise microtubule assemblies within the cell, in turn 
inhibiting mitosis and triggering an apoptotic cell death pathway.8 Paclitaxel is sold 
under the tradenames TaxolTM and AbraxaneTM and has been found to have 
anticancer effects against a wide variety of cancers including, breast, colon, ovarian, 
neck and lung.9 Paclitaxel is however a hydrophobic drug and is limited by its poor 
aqueous solubility (<0.3 µg/mL at 25 OC).10 In the commercially available TaxolTM 
formulation, paclitaxel is administrated as an infusion formulated with ethanol and 
polyethoxylated caster oil (Cremphor EL®) (1:1, v/v). Cremphor EL® is not an inert 
excipient and has been associated with a number of adverse effects.11,12 Paclitaxel is 
also available in a Cremphor EL® free formulation in the form of an albumin-paclitaxel 
nanoparticle suspension sold under the name of AbraxaneTM.  
Figure 4.1.1. Chemical structure of lomustine: Mw, 233.7 g/mol 
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Methotrexate is classified as an antifolate chemotherapeutic which acts by 
suppressing the activity of the dihydrofolate reductase enzyme, in turn, interrupting 
the folate cycle which is a key mechanism needed for cell proliferation.13 Methotrexate 
was one of the earliest small molecule anti-cancer drugs to be approved and has 
been used to treat a wide variety of cancers including; acute lymphocytic leukemia, 
non-Hodgkin's lymphoma, osteosarcoma, choriocarcinoma, head and neck cancer, 
and breast cancer.14 Although methotrexate has been at the forefront of cancer 
treatment for decades it is limited by its poor water soluble at physiological pH (<0.01 
mg/mL at 20 OC) and has a low bioavailability leading patients to require high doses 
or frequent administrations.15 This kind of regime leads to off target side effects in the 
bone marrow, liver, kidney and gastrointestinal tract and drug resistance.16,17 To 
overcome these challenges a number of publications have conjugated methotrexate 
to larger macromolecules, including PEG and albumin, to increase the plasma half-
life and provide some targeting as a result of the EPR effect.18,19    
 
Figure 4.1.2. Chemical structure of paclitaxel: Mw, 853.9 g/mol 
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Figure 4.1.2. Chemical structure of methotrexate: Mw, 454.4 g/mol 
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4.2 Materials 
Chemical  Purity  Supplier  
Acetonitrile >99.9% Fisher 
Chloroform >99.9% Sigma-Aldrich 
Dimethyl sulfoxide >99.7% Sigma-Aldrich 
Hexane >99.5% Sigma-Aldrich 
Lomustine >98% Sigma-Aldrich 
Methanol >99.9% Fisher 
Methotrexate >98% Sigma-Aldrich 
Nitrogen >99.99% BOC 
Disodium phosphate 
(Na2HPO4) 
>99% Sigma-Aldrich 
Monosodium phosphate 
(NaH2PO4) 
>99% Sigma-Aldrich 
Paclitaxel 99.5% LC Laboratories  
Toluene >99.5% Fisher 
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4.3 Methods 
4.3.1 Lomustine HPLC procedure  
High performance liquid chromatography (HPLC) was conducted using an Agilent 
Technologies 1200 series HPLC system, which comprised of a vacuum degasser, 
quaternary pump, auto-sampler, column compartment with thermostat and a variable 
wavelength UV detector.  
Lomustine analysis was measured using in a procedure outlined by Fisusi et al.20 
Chromatograms were acquired using a C18 reverse phase monolithic column (Onyx, 
5 µm, 100 x 4.6 mm, Phenomenex, UK) fitted with a guard column (Onyx monolithic 
C18 guard cartridge, 5 x 4.6 mm, Phenomenex, UK). The mobile phase consisted of 
methanol:water (50:50) and a flow rate of 1.5 mL/min. The column temperature was 
maintained at 40 OC and the detection wavelength was set at 230 nm. Formulations 
were diluted in methanol (1:10) and centrifuged (224 rcf, 5 min) before analysis.     
4.3.2 Lomustine encapsulation via the emulsification-evaporation method  
In a vial, iron oxide nanoparticles (20 mg/mL) prepared as described in section 2.3.4 
and Lomustine (5 mg/mL) were suspended in hexane (0.8 mL) and were added to a 
GCPQ solution (2 mL, 15 mg/mL). The solution was sonicated using probe sonication 
(2 x 5 min, 7 micron amplitude, Soni Prep 150, MSE, UK) at the interface between 
the organic and aqueous phases, creating a brown emulsion. This emulsion was left 
to separate over 48 h. The aqueous layer was then extracted and any residual hexane 
was allowed to evaporate overnight. The product was frozen and lyophilised to obtain 
a dry product which was then reconstituted in water (2 mL).  
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4.3.3 Lomustine encapsulation via the solvent free method  
In a vial, 4 mg of powdered lomustine was added to a solution of raspberry 
nanoparticles (2 mL), prepared as described in section 2.3.5, with an iron content of 
10 mg Fe/mL and a GCPQ content of 15 mg/mL. The solution was sonicated in an 
ice bath using probe sonication (2 x 5 min, Soni Prep 150, MSE, UK). 
4.3.4 Lomustine encapsulation via the ethanoic co-solvent method  
An ethanoic solution of lomustine (0.2 mL, 20 mg/mL) was added to an aqueous 
solution raspberry nanoparticles (1.8 mL) with an iron content of 11 mg Fe/mL and a 
GCPQ content of 16.5 mg/mL and immediately sonicated in an ice bath using probe 
sonication (2 x 5 min). The addition of the ethanoic solution diluted the formulation by 
a factor of 1.1 overall giving a final formulation with a drug concentration of 2 mg/mL, 
iron content of 10 mg Fe/mL and a GCPQ content of 15 mg/mL.  
4.3.5 Lomustine encapsulation via the thin-film method 
Raspberry nanoparticles were suspended in methanol (2 mL) with a resulting iron 
content of 10 mg Fe/mL and a GCPQ content of 15 mg/mL. This solution was then 
added to 4 mg of lomustine and vortexed until fully dissolved. The methanol was 
evaporated under a gentle stream of N2 and then suspended in 2 mL of water. 
4.3.6 Paclitaxel HPLC procedure 
Paclitaxel chromatograms were acquired using a C18 reverse phase monolithic 
column (Onyx, 5 µm, 100 x 4.6 mm, Phenomenex, UK) fitted with a guard column 
(Onyx monolithic C18 guard cartridge, 5 x 4.6 mm, Phenomenex, UK). The mobile 
phase consisted of acetonitrile:water (50:50) and a flow rate of 1.0 mL/min. The 
column temperature was maintained at 40 OC and the detection wavelength was set 
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at 227 nm. Formulations were diluted in methanol (1:10) and centrifuged (2000 rpm, 
5 min) before analysis.     
4.3.7 Paclitaxel encapsulation via the emulsification-evaporation method  
In a vial, iron oxide nanoparticles (20 mg/mL) prepared as described in section 2.3.4  
and paclitaxel (3 mg/mL) were suspended in chloroform (2 mL) and were added to a 
GCPQ solution (5 mL, 15 mg/mL). The solution was then sonicated using probe 
sonication (2 x 5 min, Soni Prep 150, MSE, UK) at the interface between the organic 
and aqueous phases, creating a brown emulsion. This emulsion was left to separate 
over 48 h. The aqueous layer was then extracted and any residual chloroform was 
allowed to evaporate overnight. The product was frozen and lyophilised to obtain a 
dry product which was then reconstituted in water (5 mL).  
4.3.8 Paclitaxel encapsulation ethanoic co-solvent method 
An ethanoic solution of paclitaxel (0.25 mL, 12 mg/mL) was added to an aqueous 
solution of pre-prepared raspberry nanoparticles (2.25 mL), prepared as described in 
section 2.3.5, with an iron content of 11 mg Fe/mL and a GCPQ content of 16.5 
mg/mL and immediately sonicated in an ice bath using probe sonication (2 x 5 min). 
The addition of the ethanoic solution diluted the formulation by a factor of 1.1 overall 
giving a final formulation with a drug concentration of 2 mg/mL, iron content of 10 mg 
Fe/mL and a GCPQ content of 15 mg/mL. This formulation was then measured for 
drug content via HPLC. 
4.3.9 Methotrexate HPLC procedure 
Methotrexate chromatograms were acquired using a C18 reverse phase monolithic 
column (Onyx, 5 µm, 100 x 4.6 mm, Phenomenex, UK) fitted with a guard column 
(Onyx monolithic C18 guard cartridge, 5 x 4.6 mm, Phenomenex, UK). The mobile 
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phase consisted of sodium phosphate buffer pH 8:acetonitrile (92:8) and a flow rate 
of 1.0 mL/min. The column temperature was maintained at 30 OC and the detection 
wavelength was set at 305 nm. Formulations were diluted in mobile phase (1:10).  
4.3.10 Ligand exchange of hydrophobic iron oxide nanoparticles with 
methotrexate   
Briefly, iron oxide nanoparticles (20 mg) were precipitated from hexane (1 mL) by the 
addition of ethanol and were collected via centrifugation (5436 rcf, 10 min), the 
supernatant was discarded and replaced with ethanol and this procedure was 
repeated twice. The final precipitate was re-dispersed in toluene. MTX (36 mg) in 
DMSO (2 mL) was added to the toluene mixture and the reaction was bath sonicated 
(10 min) and left to stir at room temperature for 48 h. After 48 h a sediment was 
observed, this was collected via centrifugation (5436 rcf, 10 min), the supernatant 
was discarded and replaced with ethanol and this procedure was repeated twice and 
then dried under vacuum. The final precipitate was collected as a red solid.  
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4.4 Results 
4.4.1 Method 1: In situ emulsification-evaporation method  
 
 
 
Scheme 4.4.1.1. The preparation of drug loaded iron oxide raspberry nanoparticles 
via the in situ emulsification and evaporation method. The drug and iron oxide 
nanoparticles are suspended in the organic layer (hexane or dichloromethane) 
while the polymer micelles are in an aqueous layer (water). The formulation then 
undergoes: i, emulsification via probe sonication; ii, separation; iii, extraction; iv, 
evaporation; v, lyophilisation; vi, reconstitution in aqueous medium.   
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4.4.2 Method 2: Solvent free method 
 
 
 
 
 
 
  
Scheme 4.4.2.1. The preparation of drug loaded iron oxide raspberry nanoparticles 
via the solvent free method. The drug was added in powder form to an aqueous 
solution of pre-prepared raspberry nanoparticles. The procedure involves: i, probe 
sonication.  
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4.4.3 Method 3: Ethanoic co-solvent method   
 
 
 
  
Scheme 4.4.3.1. The preparation of drug loaded iron oxide raspberry nanoparticles 
via the ethanoic co-solvent method. The drug was dissolved in an ethanoic solution 
and then added to an aqueous solution of pre-prepared raspberry nanoparticles. 
The procedure involves: i, addition of drug in ethanoic solution; ii, probe 
sonication.  
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4.4.4 Method 4: Thin-film method   
 
 
 
  
Scheme 4.4.4.1. The preparation of drug loaded iron oxide raspberry nanoparticles 
via the thin film method. The procedure involves; mixing the drug and pre-prepared 
iron oxide raspberry nanoparticles in methanol and then i, evaporation of solvent 
followed by ii, reconstitution in aqueous medium. 
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4.4.5 Lomustine encapsulation  
 
 
 
 
Figure 4.4.5.1. HPLC chromatogram of lomustine (Lom) using an isocratic 
procedure of H2O: MeOH (1:1) at 40 OC, UV/Vis wavelength = 230 nm. Lomustine 
had a retention time of 4.6 min and a LOD of 0.00781 mg/mL.    
Figure 4.4.5.2. Lomustine calibration curve: y = 6816x +45.6, r2 = 0.9998.   
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Table 4.4.5.1. HPLC Summary of various raspberry nanoparticle 
encapsulation methods for lomustine. Target drug content was 2 mg/mL. The 
results suggest that no method gave suitable encapsulation efficiencies. The 
emulsification-evaporation method 1 gave the highest drug encapsulation, 
however this was still <10% and cannot be considered an efficient strategy. 
Data are means ± s.d., n =3.       
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4.4.6 Paclitaxel encapsulation  
 
 
 
 
Figure 4.4.6.1. HPLC chromatogram of paclitaxel (Taxol) using an isocratic 
procedure of [H2O: ACN (1:1)] at 40 OC, UV/Vis wavelength = 227 nm. Paclitaxel 
had a retention time of 2.7 min and a LOD of 0.0039 mg/mL.    
Figure 4.4.6.2. Paclitaxel calibration curve: y = 11524x +17.3, r2 = 0.9999.   
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Table 4.4.6.1. HPLC Summary of various raspberry nanoparticle encapsulation 
methods for Paclitaxel. Target drug content was 1.2 mg/mL. The HPLC data 
confirmed that the ethanoic co-solvent method 3 produced a formulation that 
contained a suitable drug content and encapsulation efficiency. Data are means ± 
s.d., n =3. 
Figure 4.4.6.3. (a), DLS measurement of the paclitaxel iron oxide raspberry 
nanoparticle formulation. Average size by Intensity was 256 nm, PdI; 0.22 and gave 
an encapsulation efficiency of (96.4 ± 1.9)% measured by HPLC. A second peak 
several microns in size can also be seen. This could be caused by a small amount 
of unencapsulated drug. (b), These larger particulates were removed via filtration 
(1.2 µM). The filtered formulation gave an average size by Intensity of 143.0 nm, 
PdI; 0.14. n=3. EE% (101.5 ± 3.6). Data are means ± s.d., n=3. 
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Figure 4.4.6.4. TEM of the paclitaxel iron oxide raspberry nanoparticle formulation; 
(a), no stain and (b), with a 1% uranyl acetate stain. TEM images with no stain 
clearly show the typical iron oxide raspberry nanoparticles, however when the stain 
is added nanocrystals of paclitaxel can be visualised as large nano-rods (700 nm 
x 200 nm). This result could be evidence that paclitaxel has been stabilised in the 
formulation in a nanocrystal form, however it has not been encapsulated within the 
micellar raspberry nanoparticle.  
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4.4.7 Methotrexate encapsulation    
 
 
 
 
Figure 4.4.7.1. HPLC chromatogram of methotrexate (MTX) using an isocratic 
procedure of [sodium phosphate buffer pH 8: ACN (92:8)] at 30 OC, UV/Vis 
wavelength = 305 nm. Methotrexate had a retention time of 3.2 min and a LOD of 
0.0039 mg/mL.    
Figure 4.4.7.2. Methotrexate calibration curve: y = 14540x -1.0, r2 = 1.   
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Figure 4.4.7.3. Schematic of the resulting MTX.IONP produced via ligand 
exchange.   
Figure 4.4.7.4. Macro image of the resulting MTX.IONP produced via ligand 
exchange in water. The resulting material was insoluble in a range of organic and 
polar solvents making it unsuitable for downstream applications.    
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4.5 Discussion  
The thermodynamic equilibrium between the drug and polymer is often not sufficient 
enough to overcome the activation energy needed for spontaneous drug 
encapsulated micellisation.21 A preparation method is usually required to facilitate 
high drug loading within the polymeric nanoparticle. The encapsulation of lomustine 
within the GCPQ polymeric nanoparticle was first investigated via an in situ 
emulsification-evaporation method, where the lomustine and the hydrophobic IONPs 
were suspended in a hexane layer while the GCPQ nanoparticles were suspended in 
an aqueous layer. Probe sonication was used to provide the energy needed to 
emulsify the formulation. The resulting emulsion was allowed to separate over 48 h 
and the aqueous layer was extracted, frozen and then lyophilised to obtain a dry 
product that could then be reconstituted in water at the desired concentration. This 
technique was deemed the most suitable as the drug could be loaded together with 
the hydrophobic IONPs in a one-step procedure. The lomustine content of the 
formulation was measured via HPLC and gave a drug content of (0.18 ± 0.010) mg/mL 
and an EE% of (7.79 ± 0.29) %. Overall this was not considered an efficient method 
for drug loading. Following this, a solvent-free method was investigated for lomustine 
encapsulation. Lomustine in powder form was added to a suspension of raspberry 
nanoparticles and sonicated. This type of procedure is classified as a top-down 
strategy where large crystals of the drug, several microns in size, are subjected to a 
high energy environment via sonication in an attempt to break the drug crystals into 
nano-sized particulates that could then be incorporated within the nano-sized 
micelles. Analysis via HPLC gave a drug content of (0.07 ± 0.002) mg/mL and an 
EE% of (3.65 ± 0.11) % concluding that this was not a suitable method for drug 
encapsulation. A bottom-up strategy was investigated and this came in the form of an 
ethanoic co-solvent method. The miscibility of ethanol and water allows for this 
formulation to exist as a singly phase while according to EMA and FDA guidelines 
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ethanol may be present in an injectable formulation up to 20% v/v. Lomustine readily 
dissolves in ethanol (47 mg/mL at 25 OC) and therefore an ethanoic solution of 
lomustine was added to a solution of raspberry nanoparticles under sonication. It was 
hypothesised that the GCPQ polymer would control the precipitation of lomustine in 
the aqueous environment in order to facilitate micelle encapsulation. HPLC analysis 
gave a drug content of (0.04 ± 0.001) mg/mL and an EE% of (2.43 ± 0.45) %, overall 
concluding that this was a poor strategy for drug encapsulation. The thin-film or 
solution casting technique is a widely known technique often used for drug 
encapsulation within liposomes. The method involved suspending both the raspberry 
nanoparticles and lomustine in methanol. Once thoroughly dispersed the methanol 
was removed via a stream of N2 and gentle heating in order to obtain a thin-film on 
the surface of the vessel. The thin-film was then hydrated with water to obtain the 
formulation at the desired concentration. HPLC analysis gave a drug content of (0.13 
± 0.001) mg/mL and an EE% of (4.50 ± 0.11) %, suggesting this was not a good 
lomustine encapsulation procedure. In conclusion, several method for lomustine 
encapsulation within the raspberry nanoparticles were investigated resulting in the 
identification of no effective drug loading methods. When considering a result such 
as this, it should be considered that a lomustine loaded raspberry nanoparticle may 
not be a thermodynamically favoured structure. The Flory-Huggins theory attempts to 
describe the interaction between a drug and a polymeric matrix thermodynamically 
through an entropy component and an enthalpy component. The theory is based on 
the principle that chemical entities that are similar in nature interact favourably. It can 
therefore be hypothesised that the hydrophobic core of the polymeric GCPQ micelle 
and the lomustine molecule are not similar enough in nature to undergo a favourable 
interaction. Future experiments could involve measuring the Flory-Huggins parameter 
to see if the palmitic core of the GCPQ micelle and lomustine have a favourable 
thermodynamic interaction. The difficulty with loading lomustine into a nanoparticle 
may be reflected by the limited number of attempts to encapsulate this drug within a 
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nanoparticle. To the authors knowledge, only two lomustine encapsulated 
nanoparticles exist: Mehrotra et al adopted an emulsion-evaporation procedure using 
chitosan as their nanoparticle forming polymer.22 To produce a stable nanoparticle 
they had to use a crosslinking agent to chemically entrap the drug within the 
nanoparticle. The second method published was by our own group Fisusi et al, where 
lomustine was encapsulated by producing a stable oil-in-water emulsion.20 Although 
both strategies were effective at loading lomustine into a polymeric nanoparticle, in 
this project they were considered undesirable strategies as it was believed that the 
oil-in-water emulsion would have a significant effect on the contrast ability of the 
raspberry nanoparticle and the crosslinking may produce a nanoparticle that does not 
effectively release the drug pay load. Lomustine is still a promising candidate 
however, a suitable method for simple drug loading into the raspberry nanoparticles 
was not identified in this body of work.     
 
Paclitaxel was chosen as the next drug candidate to be investigated as the 
theranostic therapeutic. Paclitaxel is a widely used chemotherapeutic drug and it is 
active against a broad range of cancers. The use of paclitaxel is limited by its poor 
aqueous solubility and is often formulated in a mixture of Cremophor® 
(polyoxyethylated castor oil) and ethanol (c.a. 50:50 v/v). To increase the efficiency 
of paclitaxel many nanoparticle formulations have been developed which has even 
lead to a commercially available product in the form of Abraxane®, approved by the 
FDA in 2005 for the treatment of breast cancer. In this project the preferred in situ 
emulsion and evaporation method was initially investigated. In this circumstance, 
paclitaxel was not soluble in hexane and so the organic solvent was substituted for 
chloroform. Both the paclitaxel and hydrophobic IONPs were suspended in a 
chloroform layer and the GCPQ polymer was suspended in a water layer. Sonication 
was used to provide the energy for emulsification and the resulting product was 
worked up as previously described. HPLC analysis gave a drug content of (0.03 ± 
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0.01) mg/mL and an EE% of (2.31 ± 1.0) %, indicating this is a poor method for 
encapsulation. It was predicted that an ethanoic co-solvent may provide improved 
encapsulation results as paclitaxel has good solubility in ethanol (40 mg/mL at 25 OC) 
and ethanol is a major excipient in the Taxol® formulation. Paclitaxel was suspended 
in ethanol and was added to the raspberry nanoparticles under sonication. The 
formulation was measured for drug content by HPLC and gave a loading of (1.06 ± 
0.04) mg/mL and an EE% of (96.6 ± 4.8) % which was a particularly good result. The 
formulation was measured for size by DLS resulting in a distribution with two distinct 
peaks and an average size by intensity of 256 nm, PDI; 0.22 (Figure 4.4.6.3.a). The 
larger peak measured several microns in size and is most likely a result of a small 
number of drug aggregates in the formulation. These aggregates were removed via 
filtration through a 1.2 µm syringe filter. Upon removal of the paclitaxel aggregates 
the DLS distribution gave a single peak with an average size by intensity of 143.0 nm, 
PDI; 0.14 and HPLC confirmed that there was no significant change in drug 
concentration after filtration. Electron microscopy was used to investigate the 
morphology of the paclitaxel-raspberry nanoparticle formulation. Typical iron oxide 
raspberry nanoparticles were imaged however, when a 1% uranyl acetate stain was 
used, large rod like nanocrystals were observed (c.a. 700 nm x 200 nm). This could 
be evidence that paclitaxel had not been encapsulated within the polymer micelle but 
instead, small nanocrystals of paclitaxel have been stabilised within the conditions of 
the formulation. A control formulation with just paclitaxel and no raspberry 
nanoparticles was prepared in the same manner and when measured by HPLC gave 
no drug encapsulation, suggesting that the polymeric raspberry nanoparticles are 
having an effect on the paclitaxel. A reasonable hypothesis for the structures 
observed is that the energy provided by sonication was enough to disintegrate large 
micron sized crystals into much smaller nano crystals, their high surface energies 
could then be stabilised by free GCPQ polymer and in doing so reduce their tendency 
to re-aggregate. Although the formation of paclitaxel nanocrystals is quite interesting, 
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it nevertheless, does not meet the criteria for a theranostic nanoparticle. One could 
imagine when administered into the body the paclitaxel nanocrystals and the 
raspberry nanoparticles could undergo mechanisms completely independently of 
each other and would therefore not make for a useful duel functional nanoparticle. An 
alternative hypothesis is that the uranyl acetate stain may have a competitive 
interaction with the paclitaxel in the drug-GCPQ complex, causing the paclitaxel to 
crystallise out of the aqueous formulation to form the observed nano-rods. It is also, 
possible that the nano-rod crystals observed are formed from the crystallisation of the 
uranyl acetate salt itself, however this premise is unlikely, as uranyl acetate 
crystallisation was never observed in previous imaging experiments conducted under 
similar conditions (use of the uranyl acetate stain at concentration of 1% w/w in water, 
pH 4-5). The correct hypothesis was determined by a simple magnetic separation 
procedure. A strong magnet was used to collect the raspberry nanoparticles from the 
formulation which were then dispersed into fresh media. HPLC gave a drug 
encapsulation of (0.01 ± 0.002) mg/mL and an EE% of (0.66 ± 0.23) % concluding 
that the paclitaxel was not bound to the magnetic raspberry nanoparticles. Overall, 
with the techniques employed here it can be concluded that paclitaxel was not 
encapsulated within the raspberry nanoparticles.  
Interestingly, the conditions from the ethanoic co-solvent method did yield rod like 
nanocrystals of paclitaxel which could have some significance. Nanocrystals are 
considered sub-micron particles of the pure compound in its crystalline form. These 
formulations require no carrier nanoparticle but frequently need some stabilising 
agents to prevent agglomeration. Nanocrystals have gained considerable attention 
for the oral administration of drugs as they often have significantly improved 
dissolution profiles compared to their micron sized counterparts.23 Their success has 
led to a number of chemotherapeutic compounds now available as a nanocrystal 
formulation including; Rapamune®, Emend®, TriCor®, Megace® ES, Triglide®, 
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Avinza®, Focalin® XR, Ritalin® LA and Zanaflex Capsules.24 Alternatively, high 
concentrations of hydrophobic drug nanocrystals can be injected intravenously as 
there is little risk of capillary blockage and embolism. Both strategies discussed would 
overcome the toxic effects of administering paclitaxel with Cremophor EL® in the 
Taxol formulation® and the expense associated with the albumin nanoparticle carrier 
in Abraxane®. Currently there are 12 published studies where paclitaxel nanocrystals 
have been reported. The first was by Lui et al in 2010, using D-α-tocopheryl 
polyethylene glycol 1000 succinate (TPGS) as the stabilising agent.25 Comparable to 
GCPQ, TPGS is a long chained amphiphilic polymer and may account for the similar 
structures seen. The methods reported for paclitaxel nanocrystal synthesis can 
largely be divided into two strategies; the use of a co-solvent (bottom up strategy)26-
31 and the mechanical disintegration (top down strategy)24,32-34 with many of the 
studies using a variety of stabilizers and excipients to achieve the desired 
nanoparticles. A number of relevant studies include; Wei et al,26 Hollis et al,28 Gao et 
al,29 and Zhao et al,31 who all used an ethanoic co-solvent to produce their paclitaxel 
nanocrystals and Lv et al, who used a chitosan and a quaternized chitosan as the 
stabilising agent for their paclitaxel nanocrystals which when administered as a 
treatment to tumour bearing mice gave a significant increase in mean survival rates.30 
Paclitaxel still remains a promising drug and so other methods could still be 
investigated in order to achieve appreciable drug loading. Alternatively as discussed 
previously, perhaps the hydrophobic core of the GCPQ nanoparticle is not a suitable 
environment to stabilise the paclitaxel molecules.  
The third drug investigated was Methotrexate. An attempt was made to encapsulate 
methotrexate by anchoring the drug to the surface of the IONPs, via a ligand 
exchange procedure, prior to encapsulation within the GCPQ polymeric micelle. 
Methotrexate is classified as an antifolate chemotherapeutic and is characterised by 
its structural similarity to folic acid. The structure of methotrexate is comprised of a 
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multi-ring pteridine group linked to para-aminobenzoic acid, which in turn connects 
with a terminal glutamic acid residue.13 This molecular structure presents itself with 
two carboxylic acid groups and it was predicted that, via a ligand exchange procedure, 
methotrexate could be anchored to the surface of the iron oxide via these two electron 
dense groups. A HPLC procedure was developed for the detection of methotrexate 
using a C-18 reverse phase column with a mobile phase of sodium phosphate buffer, 
pH 8:aceonitrile (92:8). The ligand exchange procedure was conducted in a similar 
manner to that described by the DMSA ligand exchange procedure performed in 
Chapter 2. Methotrexate was solubilised in DMSO and was added to a dispersion of 
hydrophobic IONPs in toluene and vigorously mixed. After 48 h a precipitate had 
formed indicating a change in composition, however the resulting product was not 
soluble in a range of polar and non-polar solvents rendering, the newly formed 
species difficult to use in downstream applications. There have been 12 reported 
attempts to formulate methotrexate with IONPs: 7 of the studies involve methotrexate 
being chemically conjugated to the surface of an IONP via an anchoring group.18,35-40 
4 studies use emulsification41-44 and one study uses electrostatic interactions45. There 
are no reported studies where methotrexate have been bound to the surface of iron 
oxide via a ligand exchange procedure. This is a surprise as co-ordinating 
methotrexate to the surface of an IONP via its carboxylic acid groups appears to be 
an obvious strategy, however with the lack of published data supporting this, perhaps 
it is not actually possible obtain a product that can be used for biological applications. 
Overall one attempt was made to load methotrexate into the iron oxide raspberry 
nanoparticle and so future work could seek to explore several other strategies.    
 
 
 
248 
 
4.6 Conclusion  
In conclusion, this chapter aimed to encapsulate three chemotherapeutic drugs into 
the iron oxide raspberry nanoparticles in order to act as the therapeutic element in 
the proposed theranostic nano-platform. The drug loading of lomustine was 
attempted via four individual methods; emulsion-evaporation, solvent-free, ethanoic 
co-solvent and thin-film, yielding encapsulation efficiencies of (7.79 ± 0.29) %, (3.65 
± 0.11) %, (2.43 ± 0.45) % and (4.50 ± 0.11) %, respectively. No method yielded an 
effective or efficient encapsulation method for lomustine within the formulation.  
The loading of paclitaxel was attempted via two individual methods; emulsion-
evaporation and ethanoic co-solvent, yielding encapsulation efficiencies of (2.31 ± 
1.0) % and (96.6 ± 4.8) %, respectively. The ethanoic co-solvent method gave 
apparently good encapsulation results, however when further analysed via TEM, it 
was revealed that the paclitaxel had not been encapsulated within the raspberry 
nanoparticles, but instead had formed stabilised nanocrystals of the drug in the 
formulation. Although an interesting result, this type of formulation did not meet the 
criteria for a theranostic platform.  
The loading of methotrexate directly onto the IONPs was attempted via a ligand 
exchange procedure taking advantage of the free carboxylic acid groups within 
methotrexates’ chemical structure. Although there was an indication that a new 
species had formed it did not disperse in a range of polar and non-polar solvents 
making downstream characterisation and formulation difficult.  
Overall, no drug was encapsulated within the raspberry nanoparticles effectively or 
efficiently. Future work could focus on measuring the Flory-Huggins parameter of the 
hydrophobic core of the micelle in order to narrow the selection of drug candidates 
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down to molecules that might have thermodynamically favourable interactions. 
Secondly, other strategies for drug encapsulation within a polymeric nanoparticle do 
exist including acid-base titrations and oil-in-water emulsions. Alternatively, one could 
chemically conjugate the drug to the nanoparticle through a suitable linker.      
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5.1 Thesis Overview 
This project has introduced an amphiphilic chitosan based polymer, named GCPQ, 
as a potential biocompatible vector for the simultaneous delivery of a diagnostic probe 
and a chemotherapeutic agent. The GCPQ polymer was successfully synthesised via 
a three-step reaction from the starting material, glycol chitosan. Acid hydrolysis was 
used to reduce the molecular weight of the glycol chitosan from c.a. 120 kDa to c.a. 
7 kDa measured by GPC-MALLS. Hydrophobic alkyl pendent chains were introduced 
via a palmitoylation step using palmitic acid N-hydrosuccinimide (PNS). Palmitoylated 
glycol chitosan (PGC) was further functionalised with trimethyl, dimethyl and 
monomethyl amine groups using methyl iodide, overall yielding N-palmitoyl-N-
monomethyl-N,N-dimethyl-N,N,N-trimethyl-6-O-glycolchitosan (GCPQ). Polymer 
structures were confirmed by NMR and gave a palmitoyl functionalisation of (13.4 ± 
2.9)% and a trimethyl functionalisation of (15.6 ± 4.7)%.  
The co-precipitation method using iron(II/III) chloride salts and ammonium hydroxide 
was used to make naked IONPs. Purification was performed via a magnetic 
separation and wash procedure. The naked IONPs had an average diameter of (8.4 
± 2.1) nm, but would agglomerate into micron sized particles causing sedimentation 
in aqueous conditions. The naked IONPs were made colloidally stable via 
sonochemical treatment in the presence of GCPQ, only when the IONP:polymer ratio 
was >1:0.04. The structures formed were termed blackberry nanoparticles. The 
blackberry nanoparticles had an average size of 156 nm by DLS and remained 
colloidally stable in water for at least 30 days at 5 OC. The blackberry nanoparticles 
had a positive surface charge of (+22.5 ± 6.1) mV in neutral conditions (pH 7.1) 
confirmed by electrophoretic light scattering. XRD confirmed the presence of 
magnetic iron oxide while SQUID experimentation confirmed that the blackberry 
nanoparticles were superparamagnetic making them a suitable candidate for MRI 
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contrast applications. Relaxometry found that the blackberry nanoparticles had a high 
r2 value of 294.8 µM-1 S-1 and an r2/r1 of 21.1 giving it a comparable relaxivity profile 
to a number of known commercially available IONP based negative MRI contrast 
agents.  
Hydrophobic IONPs were synthesised via the high temperature thermal 
decomposition of an iron-oleate complex. The hydrophobic IONPs had an average 
diameter of (4.8 ± 0.8) nm and would only disperse in organic solvents such as 
hexane, chloroform and THF. The hydrophobic IONPs could be made colloidally 
stable in aqueous environments by incorporating them within a GCPQ micelle using 
an emulsification-evaporation procedure. The resulting nanoparticles formed ordered 
nanostructures and were termed raspberry nanoparticles. Colloidal stability was only 
achieved when the IONP:polymer ratio was >1:0.25 and the raspberry nanoparticles 
were found to be colloidally stable in water for at least 90 days at 5 OC. Raspberry 
nanoparticle size could also be controlled (120-230 nm by DLS) by varying the 
IONP:polymer ratio. Raspberry nanoparticles had a positive charge of (+24.4 ± 1.5) 
mV in neutral conditions (pH 7.1) and were not stable in strongly alkaline conditions 
(pH >8). XRD confirmed the presence of magnetic iron oxide and SQUID 
experimentation confirmed that the raspberry nanoparticles were superparamagnetic 
and that IONP encapsulation within the micelle did not diminish their magnetic 
properties. Relaxometry experimentation found that the raspberry nanoparticles had 
an r2 value of 51.8 µM-1 S-1 and an r2/r1 of 79.1, giving it a relaxivity profile unlike any 
other commercially available product. Essentially, the same materials were used in 
both GCPQ IONP formulations, however differences in synthesis methods and 
formulation procedures produced two nanoparticle species with different magnetic 
and MRI contrast properties.     
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Preclinical animal studies were performed using the raspberry nanoparticles. The 
raspberry nanoparticle had favourable colloidal stabilities in a range of biologically 
relevant solutions (H2O, 0.9% NaCl, 5% dextrose, 1X PBS and 50% rat plasma). 
Raspberry nanoparticle pharmacokinetics were evaluated in female BALB/c mice by 
ICP-AES following intravenous administration. The raspberry nanoparticles had a 
blood half-life of 28.3 min and accumulated in the liver and spleen over time. The 
raspberry nanoparticles were also distributed to the heart, lungs and kidneys, 
however no accumulation in these tissues was observed. No raspberry nanoparticles 
were observed in the brain at any time point. The in vivo MRI properties of the 
raspberry nanoparticles were evaluated using a 1T bench top MRI scanner (ICONTM, 
Bruker, UK). Significant contrast was observed in the liver and spleen. Liver contrast 
produced clear visualisation of hepatic liver veins, which were not observed when 
compared to the commercially available product. For a conclusive comparison this 
result should be replicated several more times, however it could indicate a significant 
clinical advantage for using the raspberry nanoparticles as an MRI probe. The 
raspberry nanoparticles were evaluated in a cancer disease model. 4T1 tumours were 
successfully established on female BALB/c mice. A pharmacokinetic study indicated 
no significant amounts of raspberry nanoparticles were accumulating in the tumour 
tissue. MRI studies indicate a small reduction in signal, however this was not large 
enough to create a contrast effect for a human observer. Overall, the raspberry 
nanoparticles did provide good in vivo contrast in the liver and spleen, however using 
a 4T1 tumour model no contrast was observed in the diseased site. This result could 
be a result of an unsuitable tumour model, or alternatively, the blood half-life of the 
raspberry nanoparticles may not have been long enough to take advantage of the 
EPR effect. Future work should validate this result in an alternative tumour model. 
Addition of a therapeutic component was investigated using several drug molecules 
and several encapsulation procedures. Lomustine was made available in the 
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formulation at a drug concentration of (0.18 ± 0.010) mg/mL and an EE% of (7.79 ± 
0.29)%. Paclitaxel was made available in the formulation at a drug concentration of 
(1.06 ± 0.04) mg/mL and an EE% of (96.6 ± 4.8)%, however upon further investigation 
it was found that the paclitaxel was not encapsulated within the raspberry 
nanoparticles, but was in fact present as nanocrystals. An interesting result, but 
cannot be considered a nanotheranostic. Methotrexate was briefly investigated, as it 
was predicted that the drug would have an affinity to the IONPs via its terminal 
carboxylic acid groups. An MTX.IONP complex may have been produced via a ligand 
exchange procedure, however the product was insoluble in a range of solvents 
making it challenging to characterise and difficult to use for downstream formulations. 
In all, no effective drug encapsulation was discovered in this body of work within the 
given time. 
5.2 Future work 
A major challenge to address was that no effective drug encapsulation was 
discovered within the project. A number of chemotherapeutic agents were 
investigated, however satisfactory conditions for drug encapsulation were not met. 
Methotrexate was only briefly investigated and so alternative encapsulation strategies 
could be used. At physiological pH, methotrexate has a poor aqueous solubility (<1 
mg/mL at 19 OC), however its solubility increases significantly when placed in weakly 
alkaline conditions (~ pH 8.5). As a result an interesting strategy could be to titrate a 
weakly basic solution of methotrexate with a weakly acid solution of the raspberry 
nanoparticles. Alternatively, a hydrophilic drug could be considered, for example 
doxorubicin or cisplatin, although their mechanism of drug loading would be unknown 
and as it is unlikely that they would be compatible within the hydrophobic core of the 
GCPQ micelle. An interesting strategy may be to use the raspberry nanoparticle as a 
delivery vector for gene therapies, most notably small interfering RNA (siRNA).1 
siRNA is a class of small double stranded RNA that is used to inhibit upstream 
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mechanisms used for protein synthesis. Specific types of siRNA molecules can be 
used to suppress the expression of disease promoting proteins and therefore have 
wide applications as a therapeutic agent. Although promising, siRNA has to overcome 
several biological barriers, most notably the blood, which rapidly degrades naked 
siRNA before it reaches its therapeutic target.2 The delivery of siRNA may be 
promoted by using vectors such as polymers, liposomes and viruses.3,4 As siRNA has 
a negative charge and the raspberry nanoparticles have a positive charge, it could 
therefore be hypothesised that an electrostatic complex may be formed. This could 
help protect the siRNA and provide the therapeutic element to the nanotheranostic.    
Another crucial aspect was that the raspberry nanoparticle did not accumulate at the 
site of the 4T1 tumour. To be considered a good delivery vector the raspberry 
nanoparticles must accumulate at the diseased site. Future work should investigate 
their distribution in alternative tumour models, preferably ones that have been 
validated for the EPR effect. Cell lines that have been used to demonstrate the EPR 
effect include; B16F10 melanoma, Sarcoma 180 (S-180), Meth-A sarcoma and Colon 
38 in mice. Walker 256 and Yoshida AH136B in rats and VX-II in rabbits.5 Alternative 
tumours can be used, however their microenvironment should be validated for 
nanoparticle permeation. This can be performed using the Evan's blue-albumin 
complex. This large macromolecular dye should accumulate in tumour tissue that has 
poor architecture and leaky fenestrations.  
Accumulation may also be improved by exploiting the magnetic nature of the 
raspberry nanoparticles. The raspberry nanoparticles are superparamagnetic in 
nature and will become magnetised in the presence of an external magnetic field, 
however will be rendered inactive when the field is removed. Medicine can exploit this 
feature, as when the superparamagnetic delivery vector is administrated into 
systemic absorption it is free to circulate, depicted by its pharmacokinetic profile, 
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however it may be separated from the blood by passing through a magnetic field. As 
long as the magnetic forces overcome the drag forces of the blood, then it can allow 
for the accumulation of superparamagnetic species at the site of the external 
magnetic field.6 Increasing the accumulation of the drug at the site using magnetic 
guidance would reduce the amount of drug in systemic distribution and reduce the 
amount of drug required in each dose. Overall, leading to a more efficient treatment 
with less off target side effects. Very quickly it can be seen how magnetic targeting 
can be used to improve the specificity of a treatment, this topic has been discussed 
in section 1.4.3 where a number of studies have investigated the clinical relevance of 
this strategy. It is not hard to imagine that the raspberry nanoparticle could be used 
in this manner.  
Additionally another strategy that could improve the accumulation of the raspberry 
nanoparticles at the tumour site is a practise known as active targeting.7 To be an 
effective delivery vector the raspberry nanoparticles must accumulate in the tumour 
tissue and avoid healthy tissue. Cancers cells often display an overexpression of 
biological markers and receptors associated with their rapid growth. Decorating the 
nanoparticle with ligands that have an affinity with these overexpressed receptors can 
provide the nanoparticle with an enhanced disposition for a cancer target. This 
process has been adopted for drug delivery with varying degrees of success using; 
folate like molecules, peptides, proteins, antibodies, antibody fragments and 
aptamers. Active targeting alone is not a solution to nanoparticle accumulation in a 
cancer target, as distribution to the tumour must first occur. However, when 
nanoparticle distribution is observed at the diseased site, active targeting may be 
used to increase the efficiency of the treatment.  
It is also worth discussing how the nanotheranostic could be evaluated for its clinical 
relevance. It is of the author’s opinion that the clinical relevance of a nanotheranostic 
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has not yet clearly been demonstrated in the literature. As reviewed, tumour efficiency 
studies of drug loaded IONPs have been conducted with reasonably successful 
outcomes at reducing tumour volume and growth rate (section 1.4.2). This however, 
does not indicate a tangible clinical benefit as these tumour efficiency studies do not 
take advantage of the diagnostic probe. However, using a drug filled nanotheranostic 
as a diagnostic probe would not be appropriate either, as this could lead to the drug 
dosing of potentially healthy patients. When considering the nature of a diagnostic 
and the nature of a therapeutic an interesting discussion emerges. The key point 
being made is that diagnostics and therapeutics often have very different 
requirements. For example, a diagnostic should be reasonably non-toxic and should 
have a short half-life in a patient, whereas, a drug may be toxic and should have 
maximum residence time at the site of disease. These points have been largely 
unaddressed in the nanotheranostic community and pose considerable challenges 
when trying to determine clinical relevance.   
The main advantage of a nanotheranostic is that via a simple diagnostic procedure 
one can map the therapeutic distribution within a patient. The benefit being, that one 
now has the ability to determine if the drug is being delivered to the diseased site. 
This kind of advantage is difficult to model in an in vivo experiment. One possible 
experiment that could highlight this advantage would be to have a large subject 
population with a large variation in disease type. In one half of the population you 
would blanket dose the group with the nanotheranostic (therapeutic group). In the 
second population you would perform a diagnostic procedure following administration 
of the nanotheranostic (nanotheranostic group). If the nanotheranostic was found to 
accumulate at the diseased site, then the treatment could be continued in that 
individual. Of course, treating patients in this manner would actually lead to the same 
number of successful treatment cases in both groups, however the efficiency of 
treatment would be much higher in the nanotheranostic group due to the initial 
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screening procedure. Attempting to find clinical significance using smaller sample 
groups may seem counter intuitive but, it could lead to increased treatment 
efficiencies. This ultimately leads to an interesting situation, where, as the specificity 
of a treatment increases, the number of patients in a trial would ultimately have to 
decrease. Designing studies which show the relevance of nanotheranostics is 
challenging and is worth some considerable thought.            
The author also believes it would be worth investigating the effect that IONP core size 
has on the properties of the raspberry nanoparticles. Increasing the IONP core size 
should increase the magnetic properties of the raspberry nanoparticles. Increased 
magnetic properties would lead to the development of a more potent T2 contrast 
agent and would increase the raspberry nanoparticle’s applicability in magnetic 
targeting and hyperthermia applications. High temperature thermal decomposition 
methods to yield larger crystal sizes (~10 nm) were investigated in the early stages 
of this project. TEM confirmed that they had been successfully synthesised, but their 
purification from the reaction solvent was troublesome making them unsuitable for 
downstream applications. Organic phase dialysis using polycarbonate membranes is 
a purification method that was not investigated and could perhaps be used to 
separate the high b.p. organic solvents from the nanoparticles.  
As mentioned, a superparamagnetic nanoparticle can also be used to provide 
localised magnetic heating by placing them in the vicinity of an alternating magnetic 
field (section 1.4.3).8 Hyperthermia treatment using IONPs is perhaps one of the most 
exciting new areas for magnetic nanoparticle research. Cancer cells are more 
sensitive to heat than healthy cells and if the localised magnetic heating is controlled 
between 42-46 OC for between 10-30 mins then the cancer cells can be killed with 
minimal damage to the healthy tissue.8 Additionally, a number of studies have also 
reported that the hyperthermia tumour kill efficiency can be greatly enhanced while 
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the patient is undergoing a chemotherapeutic regime.9 It can therefore be 
hypothesised that a chemotherapeutic IONP could provide the same effects but in a 
localised packet, reducing off target side effects caused by the drug being in systemic 
distribution. This area is relatively new and a drug encapsulation raspberry 
nanoparticle has all the components to qualify as a candidate for this type of 
treatment. 
5.3 Scientific impact  
Nanotheranostics allow for disease visualisation, treatment and real time monitoring 
in a single package. In theory, they have the ability to vastly increase the efficiency of 
a treatment, however in practice their clinical relevance has yet to be demonstrated. 
Nanotheranostic success lies with engineering particles that are specific in design 
and function. In this project it was hoped that micelle technology could be used to 
simultaneously encapsulate an IONP imaging probe and a chemotherapeutic drug. 
Overall, the formulation of a nanotheranostic was not discovered in this body of work 
within the given time frame, however the experimentation leading up to its formation 
have led to some interesting scientific results that may have some impact on the 
scientific community. Firstly, IONPs themselves are not biocompatible. Naked IONPs 
agglomerate to reduce their high surface energies, while IONPs made from organic 
solvent reactions are highly hydrophobic. New strategies to make biocompatible 
IONPs are important and this project addressed these issues by using the amphiphilic 
GCPQ polymer. In the project two new colloidally stable IONP products were created; 
the blackberry nanoparticles and the raspberry nanoparticles. Comprehensive 
characterisation and analysis was performed on both nanostructures leading to a set 
of experiments that any researcher could follow for their own engineered IONPs. The 
most unique structure created was the raspberry nanoparticle. By comparing these 
structures to single crystal DMSA.IONPs it was found that the raspberry nanoparticles 
266 
 
enhanced r2 relaxivity, while supressing r1 relaxivity, ultimately leading to a technology 
that can provide improved T2 "negative" contrast agents. This project also described 
the stability of IONPs in biorelevant solutions using DLS, the iron phenanthroline 
quantification assay and ICP-AES. These studies are often overlooked in the 
literature and hopefully the stability studies conducted here will provide a template 
that can be followed by scientists in the field. One of the most impressive results was 
the development of the ICP-AES protocol for the analysis of in vivo tissue samples 
used to evaluate the pharmacokinetics and biodistribution of the raspberry 
nanoparticles. In the past, the pharmacokinetics and biodistribution were usually 
performed using radioactive isotopes, however these studies have become 
unfashionable due to the considerable risks to the researchers involved. Alternatively, 
MRI can be used to monitor the biodistribution of the IONPs, however these studies 
do not give quantitative data in relation to IONP accumulation. The ICP-AES is a 
relatively straight forward procedure, which gave quantitative data at minimum risk to 
the user. To the author’s knowledge the pharmacokinetic studies performed in this 
body of work, are the first to evaluate a positively charged micellar IONP in vivo. In 
vivo MRI studies were also performed which actually validated the pharmacokinetic 
and biodistribution data. Raspberry nanoparticles accumulated in the spleen and liver 
and so validating the standard model for IONP clearance in a biological system. 
Raspberry nanoparticle did not show a significant effect on the lungs or kidneys, 
unlike the commercially available product Ferucarbotran® (Resovist®) possibly 
indicating a more organ specific contrast agent. In an addition to this, the raspberry 
nanoparticles highlighted the hepatic veins to a much larger extent than the 
commercially available product. This could give the raspberry nanoparticle a 
significant clinical advantage for their use as a diagnostic device for liver imaging. The 
raspberry nanoparticles were also evaluated for their tumour accumulation in a 4T1 
BALB/c model. Tumour studies suggested that the raspberry nanoparticles had a 
small effect in the tumour site, however this was not large enough to produce any 
267 
 
meaningful contrast to a human observer. This project has highlighted that the 4T1 
model is simple to establish, however may not be appropriate for the investigation of 
nanoparticle accumulation and other researchers should use it with caution. This body 
of work has also investigated the drug loading capacity of the micellar raspberry 
nanoparticles. It has shown that simply being hydrophobic is often not enough of a 
driving force to yield drug encapsulation within micelle nanoparticles and great care 
should be taken when selecting a drug candidate. Lastly this project has openly 
discussed the clinical relevance of a nanotheranostic and strategies that demonstrate 
their advantage to a patient. Although multifunctional nanotheranostics are 
impressive constructions of nanoengineering, their application for improving patient 
health is largely not discussed in the nanoscale community. Importantly, this thesis 
has led to an open discussion with regards to the application of nanotheranostics in 
disease treatment. 
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